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Abstract
Childhood nephrotic syndrome results from massive leakage of protein into the urine, a 
low plasma albumin and oedema. Disease may be kidney-specific, occur as part of a 
malformation syndrome, or may complicate systemic diseases such as diabetes mellitus. 
Despite the apparent heterogeneity, the underlying defect is loss of the normal 
permselective characteristics of the glomerular filtration barrier (GFB). Clues for a 
molecular basis came from observation of occasional autosomal dominant or recessive 
inheritance, and the detection of WT1 mutations in Denys Drash syndrome (DDS), a 
triad of intersex, nephrotic syndrome and Wilms’ tumour (Pelletier et al, 1991).
The role of three glomerular genes WT1, NPHS1 and NPHS2 in the pathogenesis of 
glomerular protein leak was investigated. WT1 mutations were not detected in non- 
syndromic diffuse mesangial sclerosis (DMS) and focal segmental glomerulosclerosis 
(FSGS), despite their association with DDS. However, subsequent analysis established 
that WT1 mutations cause Frasier syndrome, a triad of FSGS, intersex and 
gonadoblastoma, by reversing the normal +(KTS)/-(KTS) WT1 isoform ratio. 
Unfortunately, yeast 2-hybrid screens failed to ascertain any WT1 protein binding 
partners with clear roles in glomerular function, and through which the effects of 
mutations might be mediated.
A wide range of NPHS1 mutations was detected in Finnish type congenital nephrotic 
syndrome (CNF) in non-Finns, and a novel mild CNF phenotype described. NPHS2 
mutations affected some CNF cases, and an overlap in the NPHS1/NPHS2 mutation 
spectrum was confirmed by the discovery of a unique di-genic inheritance of mutations. 
This modified the phenotype from CNF to congenital FSGS, providing the first evidence 
for a functional inter-relationship between these genes. Finally, disrupted protein-DNA 
binding to an area of the NPHS1 promoter containing a G—»C base substitution was 
identified, suggesting the location of a transcription factor binding site and underscoring 
the importance of appropriate transcriptional control of NPHS1 for correct gene 
function.
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CHAPTER Is INTRODUCTION
1.1 Kidney Structure and Function
The two kidneys are anatomically complex organs located in the retroperitoneal space 
and composed of a large number of specialised cells arranged in a highly organised 
three-dimensional pattern. The length and weight of each kidney ranges from 
approximately 6  cm and 24g in the full term newborn to 11-12 cm in length and about 
115 to 170g in the adult (Tisher and Madsen, 1991). The structural and functional unit 
of the kidney is the nephron, and each kidney contains approximately one million of 
these. Nephrons are composed of a renal corpuscle consisting of a glomerulus, 
Bowman’s capsule and the juxtaglomerular apparatus leading into a long tube made of a 
single layer of epithelial cells segmented into distinct parts, a proximal tubule, Loop of 
Henle, distal tubule and collecting duct. Each area has a typical cellular appearance and 
specific functional characteristics.
Macroscopically, the kidney consists of an outer fibrous capsule and the renal 
parenchyma, which predominately consists of tightly packed nephrons and can be 
divided into two distinct regions: an outer cortex, and central medulla (Figures 1.1 and 
1.2). The cortex contains glomeruli, much of the proximal tubules and some of the distal 
portions whereas the medulla consists of parallel arrays of the loops of Henle and the 
collecting ducts. The medulla is arranged into cone shaped regions called pyramids, 
which extend into the renal pelvis (Briggs et al, 1998). The process of urine formation 
begins at the glomerular capillary tuft, where an ultra-filtrate of plasma is formed. The 
filtered fluid collects in Bowman’s capsule and enters the renal tubule where it is 
successively modified by exposure to a sequence of specialised tubular epithelial 
segments with differing transport functions. Most of the glomerular filtrate is absorbed, 
with some additional substances secreted. The proximal convoluted tubule is located 
entirely within the renal cortex and absorbs approximately two-thirds of the glomerular 
filtrate. Remaining fluid enters the Loop of Henle which dips in a hairpin configuration 
into the medulla, is processed further, and returns to the cortex passing close to its
18
Figure 1.1 Gross morphology of the kidney (adapted with permission from
http:t/www. kumc. edu!instruction! medicine/pathology /ed/ch_l 6/cl6_skid_xsect. html)
AFFERENT ARTERIOLE
COLLECTING
GLOMERULUS
ARCUATE ARTERY 
AND VEIN
PROXIMAL CONVOLUTED
VASA
RECTA
TUBULE
LOOP OF HENLE
Figure 1.2 Schematic representation of the nephron (adapted with permission from  
http://www.Kumc.edu/instruction/medicine/pathology/ed/ch_16/cl6_skid_xsect.html)
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parent glomerulus at the juxta-glomerular apparatus. It then enters the distal convoluted 
tubule and finally the collecting duct, which courses back through the medulla to empty 
at the renal pelvis at the tip of the medulla. Since the extracellular fluid in this region of 
the kidney has a much higher solute concentration than plasma, with the highest solute 
concentration reached at the tips of the medullary pyramids, the primary function of 
medullary structures is the concentration of urine. The final product enters the renal 
pelvis and then the bladder and is excreted from the body.
Since cellular functions only proceed normally when body fluid composition and 
volume are maintained within an appropriate range, the principle function of the kidneys 
is to correct the variations in these that occur as a consequence of food intake, 
metabolism, environmental factors and exercise. Consequently, the main functions of 
the kidneys can be categorised as follows:
1) Maintenance of body composition; i.e. volume, osmolarity, electrolyte 
concentration and acid base balance.
2) Excretion of metabolic end products principally urea, and foreign substances 
such as toxins and drugs.
3) Production and secretion of enzymes and hormones, such as renin (salt balance 
and blood pressure regulation), erythropoietin (maturation of erythrocytes) and 
1,25 di-hydroxy vitamin D3 (calcium and phosphate balance).
In the normal situation, these regulatory processes are tightly controlled to the extent 
that the body fluid volume and concentration of most ions do not deviate to any great 
extent from normal set points. In disease states, however, this regulation is disturbed 
resulting in persistent deviations in fluid volumes or ionic concentrations and cellular 
malfunction.
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1.2 Renal Blood Supply
The blood supply to each kidney comes through a single renal artery arising from the 
descending aorta. This enters the kidney at the renal hilum and carries about one-fifth of 
the cardiac output, representing the highest tissue-specific flow of all larger organs in 
the body (approximately 350 ml/min/lOOg tissue). The renal artery branches into the 
arcuate arteries, and then into interlobular arteries. The afferent arterioles supplying 
glomeruli in turn branch off the interlobular vessels (Tisher and Madsen 1991). The 
renal circulation is unusual in that it breaks into separate glomerular and the peri-tubular 
capillary beds arranged in series so that all the renal blood flow passes through both. 
Approximately 25% of the plasma arriving at the glomerulus becomes glomerular 
filtrate, whereas blood cells, most proteins and about 75% of the fluid and small solutes 
stay in the capillary and leave the glomerulus via the efferent arteriole into the peri­
tubular network. The high concentration of protein and red blood cells in the post- 
glomerular blood results in a high oncotic pressure within the peri-tubular capillaries, 
facilitating return of the tubular reabsorbate to the circulation (Kanwar et al 1991). The 
peritubular capillaries coalesce to form venules and eventually leave the kidney as the 
renal vein.
1.3 The Glomerulus
The normal glomerulus is the primary ultrafiltration unit of the kidney and consists of a 
capillary tuft supported on a basement membrane lined by highly specialised epithelial 
cells called podocytes on the urine-space aspect. These form an array of lace-like foot 
processes over the outer layer of the capillaries. To facilitate glomerular filtration, the 
hydrostatic pressure within this glomerular capillary bed is considerably higher than 
normal, ranging between 40 to 50 mmHg as opposed to between 5 and 10 mmHg. A 
Bowman’s capsule forms an outer epithelial layer around the glomerulus and acts as a 
pouch to capture the filtrate and direct it to the proximal tubule (Tisher and Madsen 
1991). The glomerulus is also associated with specialised cells known as mesangial 
cells, and which have both structural and regulatory functions. These glomerular 
structures are represented in Figures 1.3 to 1.5.
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Urinary pole
Figure 1.3 Schematic representation of the glomerulus (adapted from  
http://www.utmck.edu/surgery/KidneyTransplant2.asp)
Figure 1.4 Scanning electron micrograph of the normal glomerulus. A) Complete 
glomerulus with afferent arteriole. B) Freeze fractured renal glomerulus 
surrounded by renal tubules. (reproduced with permission from  
http://www.sghms.ac. uk/  em!galleries/0 _gallery _mainlgall_ frameset, html)
Figure 1.5 Normal renal glomerulus (H and E stain) viewed under light microscopy 
to show distribution of cellular components.
Key: AA- afferent arteriole , EA- efferent arteriole, BC- Bowman’s capsule; US -  
urinary space; PT - first part of the proximal tubule; P -  podocytes; M -  mesangial 
cells.
Glomerular mesangial cells have multiple physiological roles in maintaining structure 
and function of the glomerular capillary ultrafiltration apparatus, and are thus able to 
affect glomerular hydrostatic pressure, ultrafiltration surface area and the glomerular 
filtration rate. This predominantly occurs through the provision of structural stability to 
the glomerular filtration barrier, synthesis of the extracellular matrix and secretion of a 
wide variety of hormones and growth factors that coordinate the activities of a variety of 
target cells such as podocytes and invading macrophages within the glomerulus. 
Mesangial cell processes attach to glomerular capillaries and complete the partial 
covering of the capillary by the basement membrane. The direct contact between some 
endothelial cells and the mesangial extracellular matrix equalises the hydrostatic 
pressure between the capillary and mesangium, allowing it to play a key role in 
regulating glomerular volume and countering the glomerular microaneurysms that result 
from increased capillary pressure (Blantz et al, 1993; Kriz et al, 1996). In addition, 
mesangial cells also form loops that regulate blood flow to the capillaries that they
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surround (Inkyo-Hayasaka et al 1996) and extraglomerular mesangial cells provide 
structural support to the glomerular tuft (reviewed in Kriz et al, 1996). Although their 
morphology is very similar to vascular smooth muscle cells and marker expression 
supports a common origin for mesangial cells and the smooth muscle cells of glomerular 
afferent and efferent arterioles (Lindahl et al, 1998), their lineage remains unknown.
1.4 The Glomerular Filtration Barrier
Filtration of blood within the glomerular capillaries takes place at the glomerular 
filtration barrier (GFB). This consists of three key components: a fenestrated 
endothelium, an extracellular glomerular basement membrane (GBM) and glomerular 
visceral epithelial cells or podocytes, with distal foot processes and interposed slit 
diaphragms which bridge the filtration slits between adjacent podocyte foot processes 
(Figures 1.6 and 1.7). The flow of glomerular filtrate from the capillary lumen to the 
urinary space follows a strictly extracellular route, passing across the fenestrated 
endothelium and GBM, across the slit diaphragms and finally through the filtration slit 
into the urinary space where it enters the proximal tubular lumen. In essence, the GFB is 
a size and charge selective molecular sieve highly permeable to water, small solutes and 
ions, but in the normal situation restricting the passage of plasma proteins and other 
large macromolecules based on their size, three dimensional structure and charge (Seiler 
et al, 1975; Brenner et al, 1978; Venkatachalam et al, 1978; Kanwar et al, 1991). The 
filtration of macromolecules is generally inversely related to molecular weight. 
Consequently, substances of increasing size are retained with increasing efficiency and 
molecules with a molecular weight above 60-70 kDa are normally unable to traverse the 
barrier. However, ionic charge also affects filtration, so that negatively charged 
molecules are filtered in smaller amounts in comparison to neutrally charged molecules 
of comparable size, and the passage of positively charged molecules appears facilitated. 
Although the exact locations of the filtration functions within the barrier remain a matter 
of much debate, traditionally the fenestrated endothelium and GBM are thought to be 
the primary contributors to charge selection, whereas the GBM, podocytes and slit 
diaphragms appear primarily responsible for size selection. In addition, large plasma 
proteins appear restricted by the GBM, but the ultimate barrier for smaller proteins is 
thought to reside in the slit diaphragm (Kamovsky and Ainsworth, 1972; Latta 1970).
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Podocyte primary processes
Endothelial fenestration
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Capillary endothelium
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Filtration slits
Figure 1.6 Schematic representation of the glomerular filtration barrier (adapted 
from http://www. utmck. edu!surgery/Kidney/Transplant!.asp)
Figure 1.7 Ultrastructure of the glomerular filtration barrier. A) endothelial cells 
lining the capillary lumen B) glomerular basement membrane and C) podocyte 
layer lining the urinary space (Photo courtesy o f Professor Risdon)
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1.4.1 Endothelial cells
The first component of the GFB is the fenestrated endothelial cell layer. These are 
flattened attenuated cells containing numerous fenestrae approximately 40-70nm in 
diameter (Briggs et al, 1998; Kanwar et al, 1991; Smoyer and Mundel, 1998), which 
allow the intercellular passage of water and solutes. The endothelial surface layer is 
covered in glycocalyx rich in anionic molecules such as heparan sulphate and sialic acid, 
which confer a highly negative surface charge to the luminal surface of the glomerular 
capillary wall.
1.4.2 The Glomerular basement membrane (GBM)
The GBM lies directly beneath the endothelial cells and their fenestrae. It is 
approximately 300nm wide and consists of a central electron-dense layer, the lamina 
densa, flanked by electron lucent regions, the lamina rara interna and externa (Figure
1.7) and is thought to contain pores 10 nm wide. Structural integrity is conferred by a 
hetero-polymeric network of type IV collagen, laminin, fibronectin, entactin and 
heparan sulphate proteoglycans (Maddox et al, 1974; Laurie et al, 1984). Collagen IV, a 
triple helical polypeptide is thought to form an interconnected network of fibres within 
the GBM to which the other matrix components are attached. Laminin, an asymmetrical 
four-armed structure, is also thought to play an important role in the structural integrity 
of the GBM and its interactions with the cellular layers of the capillary wall. The 
sulphated glycoprotein entactin, and fibronectin, a 500 kDa glycoprotein, both bind 
collagen IV, heparan sulphate proteoglycans and laminin cross-link the GBM 
components to each other. The predominant GBM proteoglycan is made up of a 400- 
kDa core protein called perlecan which has four to five heparan sulphate chains bound 
to one end of the core protein. (Kanwar et al, 1980; Kanwar et al, 1984) This results in 
an overall negative charge and contributes further to the anionic charge selectivity of the 
GFB.
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1.4.3 Glomerular podocytes
Glomerular podocytes form the outer component of the GFB, and play a major role in 
glomerular permselectivity. In common with extra-glomerular mesangial cells, an 
additional role is the provision of structural support to the glomerular tuft. Podocytes are 
highly specialised, terminally differentiated cells with a complex cellular organisation. 
Their function is critically based on complex cytoskeletal machinery which regulates 
adhesion to the GBM, motility of the foot processes on the GBM, and the function of 
intervening filtration slits. The cell cycle of podocytes is under tight control, and there is 
mounting evidence that cell cycle quiescence is required for the apparent terminal 
differentiation of mature cells. This may be mediated by the CDK inhibitors such as p27 
and p57 (Coombs et al, 1998; Nagata et al, 1998; Nagata et al, 1999) and even when 
they are diseased, it is unusual for podocytes to undergo cell division (Nagata et al, 
1995; Kriz et al, 1996). Exceptions are proliferative glomerulopathies such as HIV 
nephropathy, associated with decreased levels of CDK inhibitors and where podocytes 
regain their ability to divide (Barisoni et al, 2000, Shankland et al, 2000). It is possible 
that this apparent terminal differentiation of podocytes is a prerequisite for the 
development of their highly specialised cellular architecture and ability to attach to the 
GBM, although by the same token this greatly enhances their vulnerability to damage.
Podocytes are organised in a polarized fashion with apical and basolateral membrane 
domains and consist of three different segments: a cell body, major processes and foot 
processes. The basolateral domain includes the sole plates of the foot processes, which 
are completely embedded in the GBM and is separated from the apical domain by a 
structure known as the slit diaphragm. In general, the cell bodies and major processes 
are not directly connected to the GBM but hang freely in the urinary space fixed to the 
underlying capillaries only via attachment of their foot processes to the GBM (Figure
1.8), leaving a sub-cell body space between the cell body and the foot processes. The 
major processes arise from the cell body and split directly, or after additional branching 
into the more distal foot processes. These decorate the outer aspect of the GBM, and 
establish a typical interdigitating pattern with foot processes of neighbouring cells 
(Figure 1.9). Foot processes originating from a single podocyte are never adjacent to 
each other along the GBM, but are separated by foot processes from a neighbouring cell.
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Figure 1.8. Scanning electron micrograph of a podocyte viewed from the urinary 
space. The major processes can be seen extending out from the cell body and 
branching into the more distal foot processes. The resulting spaces between the foot 
processes are the filtration slits. (Photo reproduced with permission from  
http://www.nephcure. org/mechanism. html).
Figure 1.9 (a) Scanning electron micrograph of a human glomerulus showing the 
spherical tuft formed by glomerular capillaries (C), visible after removal of the 
covering Bowman's capsule, (b) On higher magnification of the capillary surface, 
filtration slits (S) are seen between interdigitating podocyte foot processes (FP).
(reproduced with permission, from Tryggvason and Wartiovaara, 2001).
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Segmentation of podocytes into cell body, major foot processes and foot processes can 
also been seen at the level of the cytoskeleton. The gaps between them form filtration 
slits bridged by a structure known as the slit diaphragm described in detail in the next 
section (1.4.4). The intermediate filament proteins vimentin (Holthofer et al, 1984; 
Oosterwijk et al, 1990; Bachmann et al, 1983; Drenckhahn and Franke, 1988) and 
desmin (Yaoita et al, 1990), typical of mesenchymal cells, are found in the cell body. 
The major processes contain mainly microtubules of mixed polarity, which appear 
essential for process formation (Kobayashi et al, 2001). In contrast, the foot processes 
contain an actin-based cytoskeleton, which is composed of actin, myosin-H, a-actinin, 
talin and vinculin (Drenckhahn and Franke, 1988) which functions as a microfilament 
based contractile apparatus. This apparatus is anchored to focal contacts at the basal cell 
membrane (sole plate) of the foot processes via an (X3P1- integrin complex (Adler, 1992; 
Kerjaschki et al, 1989; Korhonen et al, 1990) and a dystrophoglycans complex, (Raats et 
al, 2000; Regele et al, 2000) which in turn anchor the entire foot process to the GBM. 
The actin bundles are also linked to the slit diaphragm by adaptor proteins ZO-1 and 
catenins (Reiser et al, 2000) and CD2AP (Yuan et al, 2002). From a structural 
viewpoint, cell matrix contacts in podocyte foot processes are probably crucially 
involved in the maintenance of GBM substructure and hence GFB function. In addition, 
the apical membrane of the foot processes has a negatively charged surface primarily 
made up of podocalyxin, a CD34 related membrane glycoprotein which contacts the 
actin cytoskeleton through an interaction with ezrin, a member of the ERM family of 
actin binding proteins (Orlando et al, 2001). Enzymatic modification of podocalyxin 
causes collapse of normal foot process structure, suggesting it plays an essential role in 
maintaining this domain and thus GFB integrity (Gelberg et al, 1996). Further evidence 
that podocalyxin contributes to foot process stability comes from the knockout mouse, 
which has immature glomeruli with flattened embryonic podocytes (Doyonnas et al, 
2 0 0 1 ), although it is not known whether this occurs as a result of loss of negative 
surface charge, or through disruption of the connection with the actin cytoskeleton. In 
addition to the structural and charge selective contributions podocytes make to barrier 
integrity, an ancillary influence on glomerular permselectivity is likely to come from 
outside-in signalling which regulates the podocyte cytoskeleton and thus podocyte 
function. However, the mechanisms involved are yet to be identified.
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1.4.4 The Slit Diaphragm
Although it is generally acknowledged that the GBM can restrict the passage of large 
plasma proteins, there is evidence that the ultimate barrier for smaller proteins the size 
of albumin resides within a structure known as the slit diaphragm (Edwards et al, 1999; 
Rodewald and Kamovsky, 1974). This is located within the filtration slits established by 
the inter-digitations of the foot processes, and is attached to their sides (Figure 1.10). 
Aside from its putative function as an isoporous filter contributing to the size limit of the 
GFB, the slit diaphragm may also reinforce the GFB against the relatively high tensile 
force resulting from the capillary filtration pressure of about 40mmHg. Alternatively, 
the slit diaphragm may impede filtrate flow, thus increasing the hydraulic pressure 
within the inflated GBM and preventing its collapse. Initial investigations into the 
structural and molecular composition of the slit diaphragm membrane were through 
ultrastructural studies. The most frequently cited configuration for the slit diaphragm is 
that of Rodewald and Kamovsky (1974), who describe a central filament orientated in 
parallel to the podocyte membranes and regularly spaced bridge fibres, alternating from 
side to side, that connect the central filament to the membranes. This arrangement has 
been termed the “zipper” structure and the reported dimensions of the openings were 40 
x 140 A, slightly smaller than albumin (Figure 1 .1 1 ). These dimensions are problematic 
as they imply a much more size-selective barrier than suggested by functional 
measurements, although all models are partly hampered by the lack of a satisfactory in 
vitro model able to incorporate both the charge and size restrictive elements (reviewed 
in Deen et al, 2001). A simpler ladder structure has also been postulated, based on the 
observations of Hora et al (1990), although this remains tentative, as specific 
dimensions for it have not been made. The slit diaphragm is thought to have a fairly 
constant width of about 40nm, although a few electron microscopic studies have 
indicated that the width may vary between 20 and 50 nm (Furunkawa et al, 1991; Ohno 
et al, 1992). Moreover, more recent evidence suggests that the slit diaphragm area may 
increase with increasing intraglomerular pressure, implying it is partially elastic (Kriz et 
al, 1996; Yu etal, 1997).
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40x140 A
Figure 1.10 Parallel view of slit diaphragm and structural model (a) Electron 
micrograph showing a zipper-like pattern in tannic acid-stained and 
glutaraldehyde-fixed rat glomerulus, (b) Proposed structural model of the 
isoporous slit diaphragm. Central filament (110 A) and cross bridges (70 A) 
delineate the 40x140 A pores. (Reproduced with permission, from Tryggvason and 
Wartiovaara, 2001).
100 nm
GBM
* 0  B 400 nm
Figure 1.11 (c) Transmission electron micrograph of the glomerular capillary wall 
with its three layers: endothelial (E) cells, glomerular basement membrane (GBM), 
and podocyte foot processes (FP). Arrows indicate filtration slits, (d) Enlargement 
from (c). Arrow points at the faintly stained slit diaphragm between foot processes 
(FP). (Reproduced with permission, from Tryggvason and Wartiovaara, 2001).
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Polarised epithelial cells such as podocytes typically possess typical tripartite junctional 
complexes: tight junctions, actin microfilament-anchoring adherens junctions and 
intermediate filament adhering desmosomes. It is unclear whether podocytes have true 
junctional complexes, and slit diaphragms appear to have a unique morphology as they 
express proteins typical of all three types of junction. For example, ZO-1, a tight 
junction protein is expressed on the cytoplasmic surface of podocyte foot processes at 
the point of insertion of the slit diaphragms (Schnabel et al, 1990; Kurihara et al, 1992). 
Tight junctions are occluding junctions, and maintain the polarized distribution of 
membrane proteins by restricting the intermixing of distinct apical and basolateral 
surface proteins (Gumbiner, 1987), which is seen in podocytes with a number of surface 
proteins including podocalyxin (Schnabel et al, 1989). However, slit diaphragms differ 
morphologically from tight junctions in that adjacent podocyte plasma membrane 
surfaces are separated by filtrations slits, rather than lying in apposition. These relatively 
wide intercellular spaces are a feature more commonly seen in association with 
desmosomes and adherens junctions. Furthermore, proteins commonly associated with 
anchoring junctions such as P-cadherin, a-, p-, and y-catenin (Reiser et al, 2000) and 
FAT, a novel member of the cadherin superfamily (Inoue et al, 2001) have been 
detected at slit diaphragm. Interestingly, ZO-1, initially thought to be specific to tight 
junctions, has also been detected in adherens junctions (Itoh et al, 1993). However, there 
is no apparent accumulation of actin microfilaments or intermediate sized filaments at 
the slit diaphragms, indicating a clear difference between slit diaphragms and adherens 
junctions and desmosomes. Moreover, the down regulation of catenins and 
desomosomal proteins during podocyte maturation corroborates their unique nature as 
intracellular junctions (Garrod and Fleming, 1990; Goto et al, 1998).
Study of rare inherited glomerular diseases and mouse models generated by gene 
targeting in embryonic stem cells has characterised other important components of the 
slit diaphragm, although its exact composition remains unclear. A key constituent of the 
complex to be identified in this way is the NPHS1 gene encoding nephrin, a member of 
the immunoglobulin superfamily. NPHS1 mutations are associated with severe 
glomerular protein leak both in human disease (Kestila et al, 1998), and in animal 
models (Putaala et al, 2001). Functional interdependence of nephrin on podocin, a 
protein similar to band-7 group of stomatins and also expressed at the slit diaphragm
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(Boute et al, 2000; Roselli et al, 2002), has recently been suggested through mutational 
analysis of human glomerular disease, binding assays and signal transduction 
experiments in transfected cells (Koziell et al, 2002; Schwartz et al, 2001; Huber et al, 
2001). A further recently identified slit diaphragm protein is NEPH-1 (Donoviel et al, 
2001), discovered by gene trapping through retrovirus-mediated mutagenesis. Although 
the IgG-like domain structure and phenotype in homozygous knockout mice are 
remarkably similar for nephrin and NEPH-1 (Donoviel et al, 2001; Putaala et al, 2001), 
it is not yet clear how NEPH-1 contributes to sit diaphragm patency.
1.5 Development of the Nephron and the Glomerular Filtration Barrier
1.5.1 General aspects
The kidney derives from the intermediate mesoderm that forms the nephric ridge. 
Although three kidneys differentiate in mammalian embryos, only the third or 
metanephros forms the permanent kidney in the adult. The first is the pronephros, which 
is the functional kidney in xenopus and zebra fish, but in mammals forms a rudimentary 
structure that degenerates. The pronephric tubule contributes to the formation of the 
pronephros, which elongates caudally into the intermediate mesoderm of the second 
kidney, or mesonephros, to form the Wolffian duct. The mesonephros functions as a 
primitive filtering organ in the embryo, and consists of nephron tubules and glomeruli 
connecting with the Wolffian duct, which may act as a signalling centre contributing to 
the determination of the both meso- and metanephric mesenchyme. The mesonephros 
regresses and remnants of the ductal systems ultimately contribute to the tubule system 
of the male and female reproductive tracts, rather than the permanent kidney. The third 
kidney, or metanephros, develops from an out branch of the Wolffian duct called the 
ureteric bud. Reciprocal inductive interactions between the ureteric bud epithelium and 
the surrounding metanephric mesenchyme result in the formation of the collecting duct 
system and the nephrons of the permanent kidney. Interestingly, the pronephros, 
mesonephros and metanephros all display similar filtration units with corresponding 
patterns of gene expression, for example for Pax-2 and WT1, suggesting a degree of 
conservation within the genetic programme of kidney organogenesis (Carroll and Vize, 
1996; Heller and Brandli, 1997).
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1.5.2 Development of the nephron
The metanephros starts to develop when the metanephric blastema appears, and the 
accepted model of nephron formation involves reciprocal inductive signalling between 
the tips of the ureteric bud to metanephric mesenchyme programmed to renal bias 
(Saxen, 1987). This signal induces mesenchyme condensation, migration, proliferation 
and mesenchyme-to-epithelial conversion resulting in the formation of a simple 
epithelial vesicle as shown schematically in Figure 1.12, which subsequently gives rise 
to the segmented nephron. The mesenchyme is transformed into a distinct epithelium 
that forms nephrons whereas the ureteric bud grows and branches, and eventually 
differentiates into the collecting ducts of the kidney.
Although nephron induction is initiated when the ureteric bud invades the nephrogenic 
mesenchyme, this process continues throughout most of embryogenesis. The conversion 
of nephrogenic mesenchyme to nephron epithelium is complex, and is arbitrarily divided 
into the induction period, when the mesenchyme condenses in response to inductive 
signals (Saxen, 1987), and the morphogenetic period, when actual epithelialisation takes 
place. Soon after the formation of the primary condensate the invading ureteric bud 
divides for the first time, yielding a T-shaped structure. At this stage, two small cell 
aggregates appear at the lateral side of the tips of the T-bud, and represent the induction 
of the first nephrons. These pre-tubular aggregates become detectable by three- 
dimensional confocal microscopy when they consist of only four to six cells and 
proliferate rapidly (Bard et al, 2001), with the first signs of epithelialisation appearing 
when they reach approximately thirty cells. With maturation, the pretubular aggregates 
undergo a mesenchymal to epithelial transformation forming a simple epithelial tubule, 
which then undergoes a complex pattern of differentiation through comma-shape and S- 
shape stages. This involves elongation, segmentation and convolution and results in the 
segregation of the simple tubule into different segments of the secretory nephron: 
glomerulus, proximal and distal tubules. As each nephron matures, a connection is 
established between the distal tubule and a portion of maturing collecting duct. The
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Ureteric bud 
(epithelium)
Figure 1.12. Embryonic development of the kidney. The ureteric-bud epithelium is induced to branch by 
interactions with the metanephric mesenchyme. A reciprocal induction drives the mesenchyme to form an 
epithelium that gives rise to the nephron (Modified from Molecular Cell Biology, 4th edition).
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condensed mesenchyme is also thought to generate renal stem cells, which are expressed 
in the extreme periphery of the nephrogenic zone and provide a constant supply of 
precursor cells until the generation of additional nephrons ceases (Bard et al, 1994). An 
additional event is formation of the vascular cleft during the comma and S-shaped body 
stages. This site ultimately develops into the vascular pole and provides an entry point to 
which progenitor endothelial and mesangial cells are recruited (Abrahamson, 1987), 
although the exact sequence of events that results in assembly of endothelial, mesangial 
and podocyte precursors into a filtering unit is unknown. Tightly controlled signals 
result in the coordinated endothelial cell assembly, followed by formation and 
maturation of the capillary network into the glomerular capillary tuft. Mesangial cell 
formation coincides with capillary tuft maturation, whereas the GBM appears to derive 
from both endothelial cells and podocyte precursors that invade the S-shaped body 
(Abrahamson et al, 1988; Sariola et al, 1984). As the glomerulus matures the two GBM 
precursors fuse, and synthesis of GBM components becomes exclusively mediated by 
podocytes (Abrahamson and Perry, 1986). Podocytes arise from induced mesenchymal 
cells and acquire a predominantly epithelial cell phenotype during the S-shaped body 
stage of glomerular development, when they form apical tight junctions and begin to 
express podocalyxin (Schnabel et al, 1989), and ZO-1 (Schnabel et al, 1990). Immature 
podocytes are strongly mitotic, but this mitotic activity is lost once they begin to mature 
and establish their characteristic complex architecture, which includes formation of foot 
processes and maturation of the slit diaphragms. The latter are thought to originate from 
the sub-apical junctional complexes seen in primordial podocytes, which resemble tight 
junctions and which migrate down towards the basolateral surface of podocytes during 
glomerular maturation to assume their position within the foot process (Reeves et al, 
1978). ZO-1 also migrates from an apical location to the level of the slit diaphragm, 
where it becomes distributed along the filtration slits (Schnabel et al, 1990). Glomerular 
maturation continues postnatally in mammals (Watanabe et al, 1996), and 
juxtaglomerular glomeruli appear to mature more rapidly than cortical ones. In humans, 
glomeruli become equal in size by 14 months of age, and reach adult size by 3Vi years of 
age, with the glomerular filtration rate reaching adult values by 1 to 2  years of age.
36
1.5.3 Molecular aspects of renal development
All stages of metanephric kidney development are under complex molecular control, but 
the molecular mechanisms of nephron patterning remain poorly characterised. Data has 
been provided by the study of mouse mutant models, but since tubule induction and 
nephrogenesis is repeated approximately one million times during the formation of the 
metanephros, the use of conventional knockout models is limited. In addition, since 
many metanephric genes are also expressed during the development of the pro- and 
mesonephros, the phenotype seen may represent secondary effects. It is likely that renal 
development proceeds as a consequence of sequentially activated genes, and that 
secreted and contact mediated signals are involved. Induced in-growth of the ureteric 
bud into the mesenchymal metanephric blastema may involve co-operation of genes 
such as Pax-2, (Rothenpieler 1993), Lim-1 (Barnes et al, 1994), formin (Maas et al, 
1994), Hox genes (Davies 1996), Emx2 (Miyamoto et al, 1997) and WT1 (Kreidberg, et 
al, 1993) which are regulated by GNDF and c-ret (reviewed in Piscione 1999; Kuure et 
al, 2000; Schedl and Hastie, 2000). Reciprocal inductive signalling is initiated and 
triggers condensation of the metanephric mesenchyme. Although WT1 is required for 
mesenchymal cells to complete this programme, studies in WT1 -/- embryos suggest that 
initial differentiation of the mesenchyme appears independent of WT1 expression and 
the ureteric bud (Donovan et al, 1999). This condensation results in the expression of 
adhesion molecules such as integrins (Novak et al, 1998) and cadherins (Cho et al, 
1998), which contribute to the assembly of pretubular cell aggregates. This process may 
be further modulated by proteoglycans, Eya-1,{ Xu et al, 1999), the Wnt pathway (Stark 
et al, 1994; Kispert et al, 1996) and various FGF growth factor signalling genes 
(Barasch et al, 1997; Plisov et al, 2001). BMP genes may also contribute, in particular 
BMP-7, which appears to control the maturation of mesenchymal, derived epithelial 
structures (Dudley et al, 1999). Pax-2 and WT1 appear to form a close regulatory circuit 
and to initiate the epithelialisation programme, with subsequent recruitment of integrins 
and laminins to facilitate the polarisation of epithelial cells during tubule formation 
(Ekblom, 1993). WT1 expression becomes restricted to the proximal part of the S- 
shaped body, which subsequently differentiates into podocytes, whereas PAX2 becomes 
restricted to the tubule forming part of the S-shaped body. An emerging framework of 
other genes such as Pod-1, a basic helix-loop-helix transcription factor expressed in
37
podocytes, also appears to regulate the mesenchymal epithelial switch and expression 
coincides with the onset of podocyte differentiation (Quaggin et al, 1998; Kuure et al,
2000). Glomerular endothelial cells are initially dispersed throughout the metanephric 
mesenchyme, and are then recruited to the clefts of the comma-shaped tubules where 
they proliferate and assemble in glomerular capillaries. An important mediator of this 
process appears to be VEGF/flk and Ephrin-B2 signalling between podocytes and 
endothelia (Neufeld et al, 1999; Takahashi et al, 2001). Conversely, the recruitment of 
glomerular mesangial cells appears dependant on PDGF-p (Lindahl et al, 1998). A 
schematic representation of some of the molecular events thought to surround the 
development of the kidney is made in Figure 1.13 (adapted from Piscione 1999).
Important data on glomerular differentiation and patterning is now also emerging 
through study of pronephric kidney development in zebrafish (Majumdar 2000; Serluca
2001), and Xenopus (reviewed in Brandli, 1999), which provide useful models as gene 
expression is extensively conserved between pronephric and metanephric kidneys. This 
has allowed study of the cell lineage of glomerular cells and their contribution to 
glomerular assembly and has provided important information about podocyte 
development. For example, studies of the zebrafish floating head mutant (flm) suggest 
that podocytes play a significant role in directing glomerular differentiation (Majumdar 
and Drummond, 2000), whereas study of another zebrafish mutant, cloche (clo) where 
endothelial cell development is blocked at an early stage, suggests that podocytes are 
able to differentiate in the absence of endothelia or endothelial-derived signals 
(Majumdar 1999). However, the subsequent appearance of irregular aggregates in the 
clo GBM, and apparent podocyte foot process effacement implies a role for endothelial 
cells in the maintenance of the mature pronephric GFB. Interesting new data has also 
been provided through the study of human congenital disorders resulting in glomerular 
dysfunction. The recently cloned genes NPHS1 and NPHS2, (Kestila et al, 1998; Boute 
et al, 2 0 0 0 ) are both required for the formation of slit diaphragms in podocytes and 
show similar patterns of expression within the developing kidney (Ruotsalainen et al, 
2000; Roselli et al, 2002). Both are expressed within the mesonephros and podocyte 
progenitors within the S-shaped body. However the exact contribution of these genes to 
the molecular pathways regulating glomerular development remains unknown.
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Figure 1.13 Schematic representation of the putative molecular control of kidney 
development. A) -  D) Branching morphogenesis: A) Ureteric bud outgrowth in 
response to inductive signals from the metanephric mesenchyme. B) Initiation of 
ureteric bud branching. C) Iterative branching and growth of the collecting 
system. D) Corticomedullary patterning. E) to F) Signals controlling the 
mesenchymal to epithelial switch: E) Initiation F) Mesenchymal -  epithelial 
transformation (adapted from Piscione 1999)
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1.6 Nephrotic syndrome in early life: clinical aspects
Nephrotic syndrome represents a heterogeneous group of disorders associated with 
significant morbidity and mortality. It is one of the commonest kidney conditions to 
affect children and adults, and may occur either as a highly kidney specific entity, in 
association with malformations in other organ systems, or as a major complication of 
systemic diseases such as diabetes mellitus and hypertension. Despite the apparent 
heterogeneity, the common denominator in all types of nephrotic syndrome is 
glomerular dysfunction, and the defect primarily targets the podocyte layer. Consequent 
disruption of the GFB leads to loss of glomerular permselectivity and leakage of 
essential plasma proteins into the urine. This is called proteinuria and is the defining 
clinical feature of the syndrome. Additional clinical manifestations are secondary to this 
leak, the most important of which is hypoabluminaemia and the consequent decrease in 
plasma oncotic pressure once urinary protein loss exceeds 2g /24 hours. Fluid diffuses 
out of the intravascular compartment resulting in tissue oedema. Other effects are 
decreased renal perfusion and activation of the renin-angiotensin system, and reduction 
in intravascular volume, which stimulates release of antidiuretic hormone. Both result in 
increased salt and water retention, which ultimately exacerbates tissue oedema. 
Continuous proteinuria in itself eventually instigates renal scarring, which in turn leads 
to renal failure.
Nephrotic syndrome in early life is traditionally classified on clinical grounds as either 
congenital or infantile, and this definition is primarily based on time of onset of disease 
rather than the underlying pathology. By convention, the term congenital nephrotic 
syndrome (CNS) is reserved for those infants presenting in the first three months of life, 
whereas early onset nephrotic syndrome (EONS) usually presents between 4 and 12 
months. Although somewhat arbitrary, these designations do have a use, as the clinical 
progress of infants with CNS tends to be more severe than nephrotic syndrome 
occurring at other ages. Further classification is based on clinical presentation, family 
history, laboratory findings and renal pathology as shown in Table 1.1. Some of the 
histological features are not pathognomonic, but many are of well-defined diagnostic 
significance, for example, the immune deposits characteristically associated with 
secondary causes of CNS such as SLE or syphilis easily recognisable on renal biopsy.
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Table 1.1 Causes of nephrotic syndrome in early life
A. Primary Causes of nephrotic syndrome in early life (based on renal pathology)
Congenital (CNS, onset 0-3 months o f life)
Finnish type congenital nephrotic syndrome (CNF)
Diffuse mesangial sclerosis (DMS)
Focal segmental glomerulosclerosis (FSGS)
Minimal change (MCNS)
Early onset (EONS, 4 - 1 2  months o f life)
Minimal change nephrotic syndrome (MCNS)
Focal segmental glomerulosclerosis (FSGS)
Diffuse mesangial sclerosis (DMS)
Diffuse mesangial proliferative glomerulonephritis (MPGN)
B. Secondary causes of nephrotic syndrome in early life
Infectious: syphilis, toxoplasmosis, CMV, rubella, hepatitis, malaria 
Toxic: mercury, drug reactions 
Systemic lupus erythematosus (SLE)
Haemolytic uraemic syndrome
C. Specific syndromes involving other organ systems
Denys Drash syndrome (DDS): intersex, DMS and nephroblastoma
Frasier syndrome (FS): intersex, FSGS and gonadoblastoma
Nephropathy associated with congenital brain malformations e.g. Galloway Mowat
Nail Patella syndrome
Lowe Syndrome
41
1.6.1 Congenital nephrotic syndrome (CNS)
1.6.1.1 Finnish type congenital nephrotic syndrome (CNF)
Finnish type congenital nephrotic syndrome (CNF) was first described by Hallman et al 
in 1956, and is the prototypic from of CNS with severe proteinuria beginning in utero. 
CNF is most common in Finland, with an incidence of 1.2 per 8200 live births (Hallman 
et al, 1967), but has also been described in various ethnic groups throughout the world 
where the incidence is unknown (Habib et al, 1971; Sibley et al 1985; Hamed et al,
2001). Inheritance is autosomal recessive and both sexes are equally involved. 
Heterozygous individuals are normal. Positional cloning identified NPHS1 as the 
causative gene for CNF in Finns (Kestila et al, 1998), and subsequently in non-Finns 
(Lenkkeri et al, 1999), as described in further detail in Section 1.7.2 and Chapter 4. CNF 
becomes manifest during early foetal life, beginning at a gestational age of 
approximately 15-16 weeks. The initial symptom is foetal proteinuria, which leads to a 
more than a 10-fold increase of the alpha-fetoprotein (AFP) concentration in the 
amniotic fluid (Seppala et al, 1976; Albright et al, 1990). A parallel, but less marked 
increase in the maternal plasma AFP level may be observed. Most CNF infants are bom 
between 35 and 38 weeks of gestation, have a low birth weight for gestational age and 
foetal distress is common. The placenta is enlarged, often representing more than 25% 
of the total birth weight. Distinctive physical features include wide cranial sutures and 
large open fontanelles due to delayed ossification, small nose, wide-set eyes, low-set 
ears and umbilical hernia, although these are thought to be a consequence of intrauterine 
proteinuria rather than associated dysmorphic features. In general, infants feed and grow 
poorly because of substantial loss of proteins, effects of oedema, and increased incidence 
of pyloric stenosis and reflux. Flexion deformities of the hips, knees and elbows may be 
present, and are thought to be secondary to the large placenta. Early diagnosis and 
aggressive medical and surgical intervention are required for survival.
In most cases of CNF, symptoms appear at birth or during the first week of life. Severe 
nephrotic syndrome with marked ascites is generally present by 3 months, and classical 
features are abdominal distension, umbilical hernias and generalised oedema (Norio, 
1966; Norio, 1974), as seen in Figure 1.14. This infant also demonstrates mottling of the
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skin associated with hypovolaemia, and nephrotic diarrhoea secondary to bowel 
oedema. Initially, urinary protein losses are always severe and accompanied by 
profound hypoalbuminaemia and severe hypogammaglobulinaemia, compounded by a 
concurrent loss of complement factors B and D. Affected infants are highly susceptible 
to bacterial infections particularly peritonitis and respiratory infections, (Huttunen 1976; 
Mahan et al, 1984, Harris et al, 1986; Mathias et al, 1989). Thromboembolic 
complications due to the severity of the nephrotic syndrome are also common (Huttunen 
1976; Alexander and Campbell, 1971), as is hyperlipidaemia and hypothyroidism due to 
urinary losses of lipid and thyroxine-binding proteins (Antikaninen et al, 1992; Mattoo 
et al, 1990; McLean et al, 1982). Seizures, frequently metabolic in origin, occur in 
approximately 30% of cases. Haematuria is uncommon, reflecting the lack of 
inflammation in the glomeruli and blood pressure and renal function are initially normal. 
Renal ultrasonography shows enlarged, hyperechogenic kidneys without normal 
corticomedullary differentiation.
Macroscopically, the kidneys are 2-3 times larger than normal, and accelerated 
glomerular maturation has been suggested (Autio-Harmainen, 1981). The number of 
glomeruli in CNF kidneys is increased (Tryggvason, 1978), and these are abnormally 
large and immature, which possibly mirrors defective podocyte development (Haltia et 
al, 1998). Numerous light and electron-microscopic studies of CNF kidneys have been 
made, and a wide variety of abnormalities detected (Huttunen et al, 1980; Autio- 
Harmainen, 1981; Autio-Harmainen et al, 1981; Habib and Bois, 1973; Sibley et al, 
1985). The salient histological features of CNF are shown in Figures 1.15 and 1.16. 
Initially there is epithelial cell proliferation with effacement of the foot processes, 
evident in foetal life. Mesangial cell proliferation may also been seen, with cystic 
dilatation of the proximal tubules, often filled with colloid-like material. In view of this, 
CNF has been called “microcystic disease” in the past, but this finding is not specific 
and only occurs in about 75% of cases. Later there is an increase in mesangial matrix 
and glomerular sclerosis with tubular atrophy and a slow but progressive accumulation 
of glomerular basement membrane material, particularly laminin and type IV collagen in 
the mesangium. Immunoglobulin and complement components are not detectable in the 
glomeruli, but the consequences of hyperlipidaemia are evident in the renal arteries of 
early nephrectomy specimens (Antikainen etal, 1994).
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Figure 1.14 (A) Infant with CNF showing the typical clinical features of severe 
congenital nephrotic syndrome such as oedema and abdominal distension.
Glomerulus with
mesangial Pseudocystic
hypercellularity dilatation of tubules
Figure 1.14 (B) Typical CNF histology under light microscopy (Jones silver stain, x 
40)
Figure 1.14 (C) Electron micrograph of CNS showing foot process fusion: A) fused 
podocytes B) GBM C) hypertrophied fenestrated epithelium
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CNF is usually a progressive disease, and end-stage renal failure occurs between 3 and 8  
years of age, although there are rare reports of spontaneous remission (Banton et al, 
1990; Smith et al, 1991; Haws et al, 1992). However, this is unusual, and if untreated, 
the majority of CNF cases have a dismal prognosis and die by the age of 4-5 years. 
Prolonged survival is now possible through the use of aggressive supportive treatment 
with albumin infusions, diuretics and anti-proteinuric drugs, followed by dialysis and 
renal transplantation.
1.6.1.2 Diffuse mesangial sclerosis (DMS)
Diffuse mesangial sclerosis (DMS) is the next most common variety of CNS (Habib et 
al, 1993), and its clinical course can be very similar to that of CNF, including onset of 
proteinuria in utero which causes diagnostic confusion. However, the nephrotic 
syndrome may be less severe than CNF at presentation, hypertension is more common 
and progression to end stage renal failure is often extremely rapid and occurs within the 
first year of life. Infants may be term, and without birth weight or placental 
abnormalities. Furthermore, in contrast to CNF where the pathology is confined 
exclusively to the kidney, DMS is also more commonly associated with extra-renal 
manifestations, especially neurological abnormalities. There does not appear to be any 
racial or ethnic predisposition, and the male to female incidence is equal. The molecular 
genetic background is less well defined than for CNF, as DMS represents a 
heterogeneous group of conditions. Many cases appear sporadic, but some families 
follow an autosomal recessive pattern of inheritance. Importantly, some cases are 
associated with WT1 gene mutations, especially those who go on to develop Denys 
Drash syndrome (Denys et al, 1961; Drash et al, 1970), described in detail in section
1.6.3 (i), but the causative genes have not been identified in the majority of cases. Apart 
from the clinical features that distinguish it from CNF, renal histology shows a 
characteristically different involvement of the glomeruli. This may not be detectable 
initially; so renal biopsy to distinguish between CNF and DMS should be performed 
after 3 months of age. Usual light microscopic findings in the early stages are a fibrillar 
increase in mesangial matrix, expanding in mesangial areas and with no increase in 
mesangial cells and normal capillary walls. In the fully developed lesion of DMS 
(Figure 1.15 a and b), widespread hypertrophy of the podocytes is seen, with thickening
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Shrunken 
glomerulus with 
mesangial sclerosis
Figure 1.15 (a) Typical light microscopic features of late DMS 
(Jones silver stain, x40)
Mesmagial
sclerosis
Figure 1.15 (b) Electron micrograph if DMS showing markedly increased 
mesangial matrix without hypercellularity
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of the basement membranes and accumulation of mesangial matrix, which almost 
obliterates the capillary lumens. In advanced stages, the mesangial sclerosis results in 
contraction of the capillary tufts and consequent expansion of the urinary space. A layer 
of hypertrophied and vacuolised podocytes surround the tufts, but crescents are unusual. 
These various stages may co-exist, and often a corticomedullary gradient is seen with 
the deepest glomeruli being less affected than the more superficial ones. Tubular 
dilatation is frequent, especially in the deeper cortex. On electron microscopy, there is 
typical foot process fusion as seen in CNF, mild hypertrophy of the endothelial cells and 
segmental splitting of the GBM. In addition, the mesangial cells are markedly 
hypertrophic and surrounded by abundant mesangial matrix that often contains collagen 
fibrils. Mesangial deposits of Ig M, C3 and Clq may be present in the mildly affected 
glomeruli, while deposits of Ig M and C3 outline the periphery of sclerosed glomeruli.
Other laboratory findings mirror those of CNF, although onset of end stage renal failure 
may occur earlier and proteinuria may be less severe. In common with CNF, DMS is 
refractory to all treatment and clinical management is focused around supportive 
therapies such as dialysis and eventual transplantation.
1.6.1.3 Congenital focal segmental glomerulosclerosis (FSGS) and minimal change 
(MCNS)
These morphological variants of congenital nephrotic syndrome exist, but are rare. 
FSGS and MCNS represent a heterogeneous mix of aetiologies, and their clinical 
features may overlap. Clinical and laboratory features usually mirror CNF, at least 
initially, but this type of CNS may respond to immunosuppressive therapy. The mode of 
inheritance is often unclear, although interestingly, the risk of a sibling affected by 
nephrotic syndrome is often higher in a family where an infant has developed congenital 
FSGS or MCNS, and some cases do appear to follow an autosomal recessive pattern of 
inheritance. As in DMS, cases of congenital FSGS in particular may be associated with 
developmental abnormalities in other systems.
The renal histology seen in FSGS and MCNS mirrors that seen in later life. MCNS is 
associated with normal light microscopic findings and foot process fusion on electron 
microscopy. In FSGS, initial histology shows mildly enlarged glomeruli with small
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Segmentally 
sclerosed glomerulus
Figure 1.16 (a) Typical light microscopic features of FSGS (Jones 
silver stain, x40)
Glomerular Ig M 
immunoflourescence
Figure 1.16 (b) Ig M immunofluorescence in FSGS
Podocyte foot 
process fusion
Figure 1.16 (c) Electron micrograph of FSGS showing podocyte foot process 
fusion, with early microvillous transformation, occasional vacuolisation and 
blebbing.
vacuolisation
hyalanosis
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peripheral foci of segmental sclerosis, intracapillary foam cells, prominence of overlying 
podocytes and some surrounding interstitial fibrosis. As the disease progresses, 
segmental sclerotic lesions increase in size and in number and eventually glomeruli 
become globally sclerosed. Although this is a common late feature of FSGS, this lesion 
can occur non-specifically, or in relation to any injury processes targeting the podocyte. 
In conjunction with the changes seen in podocytes, moderate to severe interstitial 
fibrosis and tubular atrophy also occur, and immunofluorescence studies may show Ig 
M deposition in mesangial areas. Another common appearance is hyalinosis, a smooth, 
glassy-appearing material, resulting from the insudation of plasma proteins and this is 
typical of FSGS.
Clinical management is again predominantly supportive, although cases of MCNS and 
isolated cases of congenital FSGS may respond to steroids or other immunosuppressive 
therapy. Those that do not, require the same aggressive supportive therapy as infants 
with CNF followed by dialysis and transplantation.
1.6.2 Early onset nephrotic syndrome (EONS)
Early onset nephrotic syndrome (EONS) usually presents between 3 and 12 months of 
age. Infants have normal gestational histories and are larger than those with CNS, as 
they have benefited from several more months of normal growth and development prior 
to the onset of symptoms. They generally present with severe oedema and ascites, and 
exhibit all the usual complications of nephrotic syndrome. Renal ultrasound shows 
relatively non-specific changes of enlarged kidneys with loss of corticomedullary 
differentiation. As a general rule, EONS responds to immunosuppressive drugs, and 
renal failure is the exception. The mainstay of diagnosis and clinical management rests 
on the renal histology, and if appropriate, subsequent response to steroid therapy.
A subset of EONS cases develops disease that behaves far more like CNS, is steroid 
resistant and culminates in early renal failure. Laboratory findings in this situation 
mirror those found in CNS, and cases may even present in end stage renal failure. In 
common with CNS, a number of morphological variants are represented, namely DMS, 
FSGS, MCNS, occasionally MPGN, but not CNF. Cases are often sporadic, and many 
do not have a clear genetic basis, although autosomal recessive inheritance is well
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described for familial DMS (Habib and Bois, 1993), familial MCNS (White 1973) and 
FSGS (Fuschuber et al, 1995). Autosomal dominant FSGS loci have also been identified 
predominantly in adult onset FSGS (Mathis et al, 1998; Winn et al, 1999), with cloning 
of ACTN4 as one of the causative genes (Kaplan et al 2000). A well-characterised form 
of autosomal recessive EONS is familial steroid resistant idiopathic nephrotic syndrome, 
or SRN1. This has an onset between 3 months and 5 years of age, is resistant to steroid 
therapy, progresses rapidly to renal failure and does not recur after renal transplantation. 
Linkage analysis of families with SRN1 initially mapped a locus to chromosome lq25 -  
q31 (Fuschuber et al, 1995), with subsequent cloning of the gene, NPHS2 (Boute et al,
2 0 0 0 ), described in detail in section 1.13.
1.6.3 Nephrotic syndrome in early life associated with extra-renal manifestations
As indicated previously, nephrotic syndrome in early life may be associated with extra 
renal manifestations, either in isolated organs, for example the association of DMS and 
ocular abnormalities is especiallly common (Barakat, et al, 1982; Zies et al, 1996), or as 
part of a more widespread malformation syndrome. All are rare, but the most common 
examples are the Denys Drash syndrome (DDS) and Frasier syndrome (FS), both 
associated with WT1 gene mutations (Pelletier et al, 1991; Barbeaux et al, 1997), 
Galloway Mowat syndrome in which no causative gene has as yet been identified, Nail 
Patella syndrome, which results from LMX1B mutations (Vollrath et al, 1998), and 
Lowe’s syndrome, associated with mutations of the OCRL1 gene (Leahey et al, 1993; 
Nussbaum et al, 1997). The WT1 gene is a presumptive transcription factor, with four C 
terminal Cys2-His2 zinc fingers mediating sequence specific binding, and an N terminal 
proline/glutamine rich domain implicated in transcriptional activation (Gessler et al, 
1990; Call et al, 1990). In view of the critical role the WT1 gene plays throughout the 
formation of the metanephros, nephrotic syndromes associated with WT1 gene 
mutations are thought to be associated with defective glomerular development. In view 
of this, DDS and FS were considered the most likely to provide insights into the 
molecular basis of nephrotic syndrome, and were examined in more detail.
50
1.6.3.1 The Denys Drash syndrome (DDS)
The Denys Drash syndrome (DDS) (Denys , 1967; Drash et al, 1970), consists of a triad 
of intersex, Wilm’s tumour and nephrotic syndrome secondary to DMS (Eddy, 1985). 
Extra-renal manifestations are exceedingly rare, but have also been described: namely 
ventriculoseptal defect, mental retardation, other cerebral and ocular abnormalities and 
diaphragmatic hernia (Gertner et al, 1980; Jadresic et al, 1990; Coze et al, 1993; 
Devriendt et al, 1995).
The classic presentation of DDS is within the newborn period as a child with ambiguous 
genitalia. Although some cases may present with normal male genitalia, the vast 
majority will appear phenotypically female or have ambiguous genitalia and a normal 
male karyotype. The relative paucity of cases with a female karyotype may be because 
of a relative under-diagnosis of the syndrome in females with DMS, but no intersex or 
Wilm’s tumour, which undoubtedly form part of the DDS spectrum. A wide variety of 
genital abnormalities are seen, and usually the internal gonad present is inappropriate for 
the external genitalia and the chromosomal sex, resulting in true hermaphroditism 
(Edidin, 1985). Most cases with a 46XX karyotype appear normal, but may occasionally 
have streak gonads, whereas most patients with a 46XY karyotype exhibit ambiguous 
genitalia or male pseudo-hermaphroditism. Thus in phenotypic females with 46 XY, the 
internal gonads are often dysgenetic, and present as streak ovaries, rudimentary 
testicular tissue, or a mixture of both (Edidin, 1985; Eddy and Mauer, 1985), with 
persistence of Wolffian duct structures, or a mixture of both Mullerian and Wolffian 
duct structures. Gonadoblastomas may occur, and these may be uni- or bilateral (Eddy, 
1985; Manivel et al, 1987; Pelletier et al, 1991).
The renal involvement in DDS is two-fold, the development of a progressive 
glomerulopathy and Wilm’s tumour. The glomerulopathy characteristically manifests as 
DMS, although an association with FSGS unrelated to hyperfiltration injury has also 
been documented (Schmitt et al, 1995). Onset of nephrotic syndrome is either at birth as 
a classical CNS with intrauterine onset (Devriendt et al, 1995), or in the first few years 
of life. The presence of nephrotic syndrome is now generally regarded as the key 
defining feature as DDS, as this can exist in either a complete form, consisting of all
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three components of the triad, or in an incomplete form in which the nephropathy is 
present in association with only one of the other features, either Wilm’s tumour or 
intersex (Manivel et al, 1987; Coppes et al, 1993; reviewed in Mueller, 1994). The 
average age of onset of the nephropathy is 1.37 years (range 0-17 years), and 
progression into renal failure inevitable. Other renal defects have also been described in 
association with DDS, namely unilateral hydronephrosis (Barakat et al, 1974), 
duplication of the renal pelves and ureters (Goldman et al, 1981), double left kidney, 
and horseshoe kidney (Gallo and Chemes, 1987), but these are uncommon.
Most but not all DDS patients develop Wilms’ tumour, with a median age of 
presentation in 18 months (range 0.01 -  13 years). Approximately 80% are unilateral 
and 20% bilateral (Coppes et al, 1993; reviewed in Mueller, 1994). This is in contrast to 
the median age of sporadic Wilms’ tumour, which is 44 months, and the incidence of 
bilateral tumours, which is 8 % (Coppes et al, 1989, Montgomery et al, 1991). The 
histological features of Wilms’ tumour are no different to the sporadic form, but 
intralobar nephrogenic rests are found in the kidneys of most cases of DDS compared 
with only 15% of cases with sporadic Wilms’ tumour (Beckwith et al, 1990). Intralobar 
nephrogenic rests are thought to arise as a result of disruption of early events in 
nephrogenesis, and to be precursor lesion of Wilms’ tumour (Beckwith et al, 1993).
DDS is usually sporadic. However there are reports of a probable affected male and 
female sib-pair (Stump et al, 1954), as well as affected male twins (Carter et al, 1980). 
The majority of DDS cases are now known to be associated with de novo constitutional 
mutations of the WT1 gene (Pelletier et al, 1991), although in isolated cases typical 
DDS-related mutations have been detected in the phenotypically normal father, raising 
the possibility of incomplete penetrance (Coppes et al, 1992; Nordenskjold et al, 1994). 
The most common mutation is an R394W change in exon 9, which encodes the third 
zinc finger. This is present in almost half of the cases studied, and DDS mutations tend 
to cluster within the third zinc finger region (reviewed in Little, 1997). However, WT1 
mutations have also been detected in other regions of the gene, and genotype-phenotype 
correlation has provided important insights into the molecular pathology of DDS.
52
1.6.3.2 Frasier syndrome (FS)
Frasier syndrome (FS) was first described in a pair of female monozygotic twins, one of 
whom presented with abdominal pain and was subsequently found to have a streak 
gonad and a teratoma, and went on to develop renal failure. Her twin was also found to 
have streak gonads with a gonadoblastoma in situ ( Frasier et al, 1964). Both twins had a 
normal male karyotype. Similar reports followed, and the entity of FS as a separate 
clinical syndrome to DDS eventually described (Moorthy et al, 1987).
The classic definition of FS includes only 46XY individuals with a female phenotype. 
Clinical presentation is similar to DDS, but with some important differences, as 
illustrated in Table 1.2. An association with CNS has not been described, and the 
nephropathy tends to present later in life, typically between 2  and 6  years of age or 
older. Progression to renal failure tends to be more gradual, and the renal pathology is 
characterised by FSGS, rather than DMS. There is no recurrence after renal 
transplantation, and no clear predisposition to Wilms’ tumour, although one case of 
Wilms’ tumour in association with FS has been described (Barbosa et al, 1999). This is 
the only description present in the literature, so it remains unclear as to whether this 
occurred by chance, or whether the features of FS should be redefined. In contrast, the 
risk for development of gonadal malignancies such as gonadoblastoma is more common 
than in DDS, and may be the presenting feature. This predisposition is likely to result 
from the presence of streak gonads and a Y chromosome in the same individual.
Although FS usually results from de novo heterozygous germline splicing mutations in 
intron 9 of the WT1 gene (Barbaux et al, 1997; Kikuchi et al, 1998; Klamt et al, 1998), 
there is increasing evidence that mutations may be also detected in 46 XX females with 
normal genital development and FSGS, and that familial cases may occur (Klamt et al, 
1998; Demmer et al, 1999), possibly following an autosomal dominant form of 
inheritance. This inherited form of FS is very rare, but does appear to give XY offspring 
a 50% likelihood of being phenotypic female with FS, and XX offspring a 50% risk of 
FSGS with normal ovarian development. However, the situation is complex as vertical 
transmission of a WT1 splicing mutation characteristically associated with FS, but 
resulting in classical DDS in the child, has also been reported (Denamur et al, 1999).
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This supports the hypothesis that FS and DDS form two ends of a spectrum of 
developmental disorders rather than distinct clinical entities, and that the clinical 
definition of FS should be broadened to include individuals with a 46XX karyotype. 
Progression of the FSGS nephropathy to end-stage renal disease in 46 XX cases occurs 
as expected, but whether there is an increased risk for gonadoblastoma is unknown. 
This is probably negligible, as when tested, normal ovarian function is present.
Table 1.21 Comparison of the clinical characteristics of Denys Drash and Frasier 
syndrome
Clinical features Denys Drash Syndrome Frasier Syndrome
Presentation Early presentation: 0-3 
years
Later presentation: 10-20 
years
Gonadal Development Broad spectrum of intersex 
phenotype
Sex reversal in 46XY 
individuals.
Little or no impairment in 
46 XX individuals
Renal disease DMS FSGS
Tumour development High risk of Wilms’ 
tumour
High risk of 
gonadoblastoma
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1.7 Nephrotic syndrome in early life: molecular aspects
1.7.1 Pathobiology o f the podocyte during nephrotic syndrome
The onset of nephrotic syndrome and loss of glomerular permselectivity is closely 
correlated with profound structural changes within the podocyte layer of the glomerular 
filtration barrier (Farquhar et al, 1957). It is thus likely that the primary cellular target in 
most types of nephrotic syndrome is the podocyte, which appears to react in a very 
stereotypic pattern to injurious stimuli irrespective of their nature. The understanding of 
the importance of podocytes in the pathogenesis of proteinuria is partly based on an 
increasing body of cell biological and molecular genetic evidence, and partly on 
anecdotal clinical reports. An example of the latter is the recent observation that the 
strongest predictor of renal disease progression in PIMA Indians with Type II diabetes 
and microalbuminuria is the number of podocytes detected per glomerulus; the fewer 
detected, the more rapid was disease progression (Meyer et al, 1999).
Podocytes may be particularly vulnerable to injury because of their relative inability to 
mount a proliferative response after injury. However, the factors controlling this are 
poorly understood. There is some evidence that the Cip/Kip family of cyclin-dependant 
kinase inhibitors (CDK-I), specifically p21, p27 and p57 may play a role (Combs et al, 
1998, Shankland et al, 1999, 2000), but the situation is complex. Whereas the presence 
of p27 and p57 is associated with persistence of a differentiated and quiescent podocyte, 
there is now evidence to suggest that p21 expression in podocytes is associated with a 
pro-proliferative antiquiescent effect. Since p21, p 27 and p57 null mice all have normal 
glomerular architecture (Kim et al, 1999; Ophascharoensuk et al, 1998; Hiromura et al,
2001), it is probable that the balance of all three members, as well as other as yet 
uncharacterised factors, determines the ability of a podocyte to proliferate.
Injured podocytes change phenotype and appear to de-differentiate, with loss of 
podocyte differentiation markers such as Gleppl, WT1, synaptopodin and podocalyxin. 
Numerous morphological changes are seen, but the most characteristic structural 
alteration is the retraction and effacement of podocyte foot processes, resulting in the 
formation of a diffuse sheet of flattened, simple epithelium along the GBM, as seen in
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Figures 1.17 and 1.18. Other structural changes include cell swelling, and reoccurrence 
of occluding junctions, with apical displacement of the slit diaphragms. Eventually the 
podocyte foot processes detach from the GBM, and this is considered the most severe 
structural manifestation of nephrotic syndrome (Caulfield et al, 1976; Ito et al, 1986). 
Moreover, mathematical models have demonstrated that initial partial detachment may 
propagate the process (Cho et al, 1993). Several studies now demonstrate that the 
detachment of podocytes from the GBM results in the leakage of protein across the GFB 
(Kanwar and Rosenzweig, 1982; Whiteside et al, 1989; Messina et al, 1987; Laurens et 
al, 1995), and nephrotic proteinuria is thought to result directly from this detachment. 
Subsequent adhesion of cells to the denuded GBM results in scarring and obliteration of 
the urinary space. Theses changes are irreversible and ultimately lead to 
glomerulosclerosis and end stage renal failure (Kriz et al, 1998).
In addition to the changes in foot process structure during nephrotic syndrome, 
significant changes also occur in the morphology of the intervening filtration slits and 
slit diaphragms. Foot process effacement results in narrowing of these structures, the 
development of tight junctions between the foot processes, and reduction in the total 
number of filtration slits along the GBM (Kurihara et al, 1992). These structural 
alterations to the GFB may act together to reduce glomerular filtration, which occurs in 
human nephrotic disease (Myers and Guasch, 1994). Furthermore, animal models of 
proteinuria resulting from many different types of injury induce similar type of podocyte 
damage, with concurrent disruption of the intervening slit diaphragms. For example, 
podocytes are particularly susceptible to oxidative damage, as seen in the puromycin 
aminoglycoside (PAN) rat, which has been used extensively as a model of podocyte 
injury. Injection of PAN induces oxidant injury in cells via the xanthine oxidase 
pathway (Diamond and Kamovsky, 1986), and this can be ameliorated by antioxidants 
(Ricardo et al, 1994). In addition, podocyte injury is the major phenotype in the Mpv-17 
antioxidant defective mouse (Weiher et al, 1990; Binder et al, 1999). Other 
experimental animal models indicating podocyte damage is key to the pathogensis of 
nephrotic syndrome are Masugi nephritis resulting from injection of heterologous anti- 
GBM antibody (Kondo, 1972), Heymann nephritis (Heymann et al, 1959; Kerjaschki et 
al, 1996), and more recently transgenic mice, a subject discussed in further detail in 
section 1.7.3.
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Figure 1.17 A schematic diagram of the effect of nephrotic syndrome on 
glomerular components. US=urinary space; MC=mesangial cell. (reproduced with 
permission from Somlo and Mundel)
GBM
Figure 1.18 Glomerular ultrastructure in nephrotic syndrome. The normal 
glomerular filter (top) consisting of a fenestrated endothelium (arrow), the GBM 
and podocyte foot processes with the interposed slit membrane (arrowheads). Actin 
filaments are present in normal foot processes (*). In nephrotic syndrome (bottom), 
the effaced foot process form a continuous band of cytoplasm containing a dense 
band of actin filaments (*) running parallel to the GBM (reproduced with 
permission from Somlo and Mundel, 2000)
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1.7.2 Genes directly associated with human nephrotic disease
1.7.2.1 The WT1 gene
The WT1 gene (Wilms’ tumour gene) was originally isolated from the chromosome 1 lp 
as a result of a positional cloning effort aimed at identifying a candidate gene for 
Wilms’ tumour, an embryonic kidney tumour which affects approximately 1:10,000 
children (Call et al, 1990; Gessler et al, 1990). This region was of particular interest as 
cytogenetically visible deletions of lip , of varying size but always involving band 13, 
had been reported in both sporadic Wilms’ tumour and Wilms’ tumour associated with a 
complex phenotype known as WAGR syndrome (Wilms’ tumour, aniridia, 
genitourinary malformation and mental retardation; Franke et al, 1979). It was presumed 
that a tumour suppressor gene lay within this region, and that inactivation of both copies 
would lead to tumourgenesis (Knudson and Strong, 1972). However it is becoming 
increasingly clear that the WT1 gene has a number of different roles in health and 
disease, and that its function is far more complex that simply tumour suppression. The 
WT1 gene is homozygously mutated in 5-10% of Wilm’s tumours (Little et al, 1992; 
Gessler et al, 1994; Little and Wells, 1997), and interestingly, remains the only gene 
cloned that is definitively involved in the development of Wilms’ tumour.
As well as its documented role in the pathogenesis of disease, there is considerable 
evidence that the WT1 gene plays a key role in the development of those mesodermally 
derived tissues experiencing a mesenchymal-epithelial transition during development. 
This includes the genital ridge, developing mesothelium, kidney, and gonads (Pritchard- 
Jones et al, 1990; Buckler et al, 1991). The critical role for WT1 in urogenital 
development is underlined by the failure of kidney and gonadal development in mice 
homozygous for a Wtl null mutation, which die in mid-gestation from an epicardial 
defect (Kreidberg et al, 1993). As mentioned in section 1.5.3, WT1 is expressed during 
all stages of renal development, and expression is linked to podocyte differentiation 
during nephrogenesis. Initial differentiation of the metanephric mesenchyme appears 
independent of WT1 (Donovan et al, 1999), and the gene is only weakly expressed in 
the uncondensed metanephric blastema (Armstrong et al, 1993). However, expression of 
WT1 increases dramatically during the mesenchymal to epithelial switch, and is highest
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in the proximal part of the S-shaped body, which subsequently flattens to form 
podocytes. Aside from an essential role in switching of cells between a mesenchymal 
and epithelial state, a requirement for WT1 is apparent at multiple stages of renal 
development. Data obtained from genetically modified mice (Kreidberg et al, 1993; 
Moore et al, 1999) has provided evidence that WT1 may be required for the inductive 
signalling that induces outgrowth of ureteric bud from the mesonephros, and that it is 
involved in either survival or the reception of a survival signal from the ureteric bud, 
which may involve BCL2 (Mayo et al, 1999). Furthermore, although WT1 does not 
appear to be required for the first step in nephron formation, its requirement becomes 
absolute in its maturation (Moore et al, 1999; Patek et al, 1999). W T l’s involvement in 
nephrogenesis is under complex control, and there is evidence for reciprocal interactions 
with the PAX2 gene modulating this process (Ryan et al, 1995). A number of other 
genes have also been implicated such as PAX 8, which is able to activate transcription of 
the WT1 gene (Dehbi and Pelletier, 1996), amphiregulin (Lee et al, 1999), syndecan-1 
(Cook et al, 1996) and E-cadherin (Hosono et al, 2000), although their combinatorial 
role with WT1 in renal development remains speculative.
The WT1 gene spans about 50kb at chromosome locus llp l3 , and comprises of 10 
exons encoding mRNAs of approximately 3kb (Gessler et al, 1992). Its protein product 
contains two domains with apparent functional properties: a C-terminal C2H2 zinc finger 
domain involved in DNA binding and an N-terminal proline/glutamine rich 
transactivation domain. Each zinc finger is coded for by exon 7 to 10 respectively, and 
in mammals exon 5 and 9 are alternatively spliced, giving rise to four different splice 
isoforms (Haber et al, 1991; Gessler et al, 1992). In all other vertebrates tested, exon 5 
is not present in the WT1 gene, so that only two different mRNA transcripts are 
generated (Kent et al, 1995). Inclusion of exon 5 inserts 17 amino acids between the 
proline and glutamine rich N-terminus and the zinc finger domain. Usage of an 
alternative splice donor site at the end of exon 9 results in the incorporation of three 
additional amino acids, lysine, serine and threonine (K,T,S) and this is highly conserved 
throughout evolution (Kent et al, 1995). The mRNA isoform containing both inserts is 
the most common form in humans and mice, whereas the least common is the transcript 
lacking both, and the ratio of splice variants is highly conserved in normal foetal kidney 
and maintained throughout development (Haber et al, 1991). Depending on the presence
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or absence of the two splice inserts, WT1 proteins have molecular masses of between 52 
and 54 kDa (Morris et al, 1991). A schematic representation of WT1 is made in Figure 
1.19.
Up to 24 different isoforms may result form the combination of the alternative RNA 
splicing described above, RNA editing and use of alternative translational start sites, and 
it is likely that balanced expression of all isoforms is essential for correct gene function. 
This clearly generates enormous potential for WT1 proteins to fulfil many different 
functions within the cell. Additional WT1 mRNA’s are also generated through mRNA 
editing at nucleotide 839, which replaces leucine 280 by proline (Sharma et al, 1994), 
and two alternative translational initiation sites located 204 base pairs upstream of the 
major ATG site (Breuning and Pelletier, 1994), and one located 127 base pairs 
downstream (Scharnhorst et al, 1999). Translation initiation at the upstream in frame 
CTG codon results in protein isoforms with molecular masses of 60-62 kDa, whereas 
internal translation initiation at an in frame ATG 127 codon generates smaller WT1 
isoforms with apparent molecular masses of 36-38 kDa. This downstream ATG is 
conserved in all species sequenced so far. A separate mechanism has also recently been 
suggested which produces N-terminally truncated WT1 proteins (Dechsukhum et al,
2000). RT-PCR and Northern blot studies detected the presence of short W77 transcripts 
containing only sequences downstream of exon 5. The presence of sequence deriving 
from intron 5 at the 5’ end suggests activation of a cryptic promoter during 
tumourgenesis, but further characterisation of these aberrant WT1 transcripts is required 
before any putative function can be assigned.
Initial predictions made from the primary structure of the WT1 protein suggested that it 
was a sequence specific transcriptional regulator. In addition, the zinc finger domain of 
WT1 was subsequently shown to contain two putative nuclear localisation signals, in 
zinc finger 1 and between zinc fingers 2 and 3 (Breuning et al, 1996). Many groups have 
performed extensive structure and function analyses, but despite this WT1 function 
remains poorly characterised. Aside from transcriptional regulation, WT1 may also have 
RNA binding capability (Caricasole et al, 1996), and play a role in modulating RNA 
metabolism and post-transcriptional regulation through its ability to interact with 
components of the splicing machinery.
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Figure 1.19 Schematic diagram of the structural features of the WT1 gene and its protein isoforms
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It is becoming increasingly clear that WT1 function is conformation and isoform 
dependant, and that +KTS and -KTS isoforms serve distinct functions within the 
nucleus. -KTS isoforms are generally more active in transcriptional regulation and are 
able to bind DNA well, whereas +KTS isoforms have been shown to co-localise with 
splicing factors, do not bind DNA and are may have a role in RNA metabolism (Larsson 
et al, 1995; Landomery et al, 1999; Englert et al, 1995). It is now well established that 
the WT1 (-KTS) isoform binds DNA via its Kruppel like C2H2 zinc fingers. Recent 
NMR relaxation experiments have demonstrated that this ability appears to be directly 
related to the absence of the KTS insertion between zinc fingers 3 and 4. Insertion of 
KTS in this position increases the flexibility of the linker between fingers 3 and 4, which 
prevents zinc finger 4 from binding to its cognate site on the DNA (Laity et al, 2000). 
The WT1 zinc finger domain binds to the characteristic GC-rich ERG1 DNA-binding 
element, although with about 40-fold less affinity (Rauscher et al, 1990; Drummond et 
al, 1994). Zinc fingers 2-4 are known to have 61% amino acid homology with those of 
the early growth response 1 gene {ERGI) (Sukhatme et al, 1988), although the three 
zinc fingers of ERG1 are only encoded for by a single exon, rather than three separate 
ones. This suggests that WT1 and ERG1 do not have a common evolutionary origin. A 
second potential DNA-binding site for WT1 consists of TCC repeats, mapped by 
analysis of the WT1 responsive promoters of PDGF-A (Wang et al, 1993), and 
epidermal growth factor receptor EGFR ((Englert et al, 1995). More recently, PCR 
selection of genomic DNA sequences with high affinity for the WT1 (-KTS) zinc 
fingers coupled with extensive mutational studies, led to the characterisation of an 
optimised binding site 5’-GCGTGGGAGT-3’ (Nakagama et al, 1995). This binding 
site, called WTE, displays a 20-30 fold higher affinity for WT1 than the ERG1 
sequence. This high affinity site has been recently reported to mediate WT1 (-KTS) 
binding to the promoters of amphiregulin (Lee et al, 1999) and Bcl2 (Mayo et al, 1999), 
two genes that appear to be regulated by WT1 in vivo. There is some evidence to 
suggest that WT1 (+KTS) isoforms also bind DNA, but the precise binding sites and 
whether this happens in vivo remains uncertain (Bickmore et al, 1992; Little et al, 
1996).
WT1 (-KTS) isoforms can both repress and activate transcription, and more than 20 
putative downstream targets have been identified (summarised in Lee and Haber, 2001;
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Schamhorst et al, 2001). However, WT1 effects can either be repressing or activating 
depending on the cell type, and the target gene with which it interacts. Moreover, most 
target genes have been identified in transfection assays and therefore the data should be 
interpreted with caution as the effects of chromatin and other interacting proteins are 
usually not assessed. In many cases there is no in vivo data to support the in vitro 
observations, although some corroboration of in vitro findings has been made for a few 
putative downstream targets, namely EGFR (Englert et al, 1995), PAX2 (Dressier et al, 
1990), insulin-like growth factor-2 (IGF-2) (Drummond et al, 1992) which appear 
repressed by WT1, and more recently, for targets that appear to be activated such as 
amphiregulin (Lee et al, 1999) and podocalyxin (Palmer et al, 2001). Post-translational 
modification may also play a part in determining DNA binding, although little is known 
about how these alter DNA-binding and/or transcription-regulating properties. WT1 can 
be phosphorylated by both PKA and PKC, and phosphorylation inhibited its DNA 
binding activity (Sakamoto et al, 1997; Ye et al, 1996). The PKA phosphorylation sites 
have been mapped to two serine residues in zinc fingers 2 and 3 (Sakamoto et al, 1997).
The first clue that WT1 (+KTS) played a non-transcriptional role emerged from its sub- 
nuclear expression pattern (Larsson et al, 1995). Confocal microscopy revealed that this 
isoform preferentially co-localised with molecules implicated in RNA splicing, resulting 
in a “speckled” pattern, whereas WT1 (-KTS) appeared to be expressed diffusely 
through the nucleoplasm. Treatment of cells with RNA-ase after fixation significantly 
decreased the number of nuclei with this pattern, and WT1 proteins were able to co- 
immunoprecipitate with proteins of the splicing apparatus. A putative RNA recognition 
motif in amino acids 11-72 has also been identified (Kennedy et al, 1996), but it remains 
speculative as to whether this can bind RNA. In addition, WT1 has been shown to bind 
via the zinc finger domain to RNA sequences present in exon 2 of IGF2 (Caricasole et 
al, 1996), although a biological role for WT1(+KTS) in the post-transcriptional 
regulation of IGF2 mRNA has yet to be demonstrated. WT1 (+KTS)-RNA interactions 
could potentially stabilise or destabilise certain RNA forms, or could be involved in 
RNA editing or splicing. There is however more convincing evidence that WT1(+KTS) 
modulates posttranscriptional regulation via protein-protein interactions with 
components of the splicing machinery. A recent study showed that WT1 (+KTS) 
directly associates with the constitutive splicing protein U2AF65, and was incorporated
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into spliceosomes during an in vitro splicing assay (Davies et al, 1998). Further 
evidence that WT1 proteins may bind splicing factors has come from the observation 
that WT1 proteins co-purify with nuclear poly(A)+ ribo-nuceloprotein (Landomery et 
al, 1999). This complex, purified by oligo(DT) chromatography, also contains amongst 
others, the U2AF65 protein and pi 16, an essential splicing factor.
However, WT1 isoforms are likely to participate in more general protein binding than 
just components of the splicing apparatus, and a number of other protein partners have 
been identified through yeast two hybrid assay and co-immunoprecipitation experiments 
(summarised in Table 1.4). Although none of the candidates detected so far has as yet 
have given direct clues about the role of WT1 in kidney disease, in contrast they have 
provided important information about the role of WT1 in gonadal development and sex 
determination. The detection of SF-1 as a WT1 binding partner, and its putative role in 
the regulation of Dax-1 (Nachtigal et al, 1998; Kim et al, 1999), as well as SRY 
(Hossain and Saunders, 2000) have been instrumental in this process.
A summary of the contrasting properties of -KTS and +KTS isoforms is made in table 
1.3. This predominantly in vitro evidence to date was recently underpinned by the 
recent generation of specific mouse strains in which either the -KTS or +KTS isoforms 
were ablated. Reduction of +KTS levels resulted in glomerular disease and complete sex 
reversal in XY animals, whereas reduction of the -KTS isoform resulted in hypo- 
dysplastic kidneys and the streak gonads in both XY and XX animals. This provided 
further important in vivo evidence that the + and -  KTS splice variants have distinct 
roles in both renal and gonadal development (Hammes et al, 2001).
Table 1.3 Summary of the properties of (+KTS) and (-KTS) WT1 isoforms
| Isoform DNA
binding
affinity
Activation of 
transcription
RNA
binding
affinity
Co-localisation 
with splicing 
speckles
SF1
binding
U2AF65
binding
Induction of 
Bcl2 and 
cell survival
| -KTS +++ yes +++ low ++ weak yes
| +KTS + no +++ high + strong no
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Table 1.4 Protein binding partners of the WT1 protein (adapted from Schamhost et 
al, 2001)
Protein WT1 binding 
site
Physiological effect References
WT1 First 180 amino 
acids
Homodimerisation; possible perquisite 
for TR by WT1. Mutant WT1 proteins 
may inhibit wt WT1 protein function 
through a dominant negative effect
Englert et al,
1995 a,b; Holmes 
etal, 1997; 
Reddy et al, 1995
p53 Zinc fingers Stabilisation of p53; increased DNA 
binding by p53; modulation of TR by 
WT1 and p53; inhibition of apoptosis 
by p53
Maheswaran et 
al, 1993; Zahn et 
al, 1998; 
Schamhorst et al, 
2000
p73 Zinc fingers Inhibition of DNA by WT1 (-/-); 
modulation of TR properties of WT1 
and p73
Schamhorst et al, 
2000
p63 Not determined ? Schamhorst et al, 
2000
SF-1 N- terminus Competition between WT1 (-KTS) 
and DAX1 for SF-1 binding leads to 
elevated MIS transcription
Nachtigal et al, 
1998
Par 4 Zinc fingers Inhibits WT1 dependant TA; augments 
transcriptional repression by WT1; 
rescues growth suppression effects of 
WT1
Johnstone et al, 
1996
+17 amino 
acids
Stimulates WT1+17 amino acid TA; 
prevention of UV induced apoptosis
Richard et al, 
2001
Ciao 1 N- terminus Decrease TA by WT1, no effect on TR Johnstone et al, 
1998
UBC9 N- terminus ? Wang etal, 1996
Hsp70 N- terminus Promotes WT1 mediated growth arrest Maheswaran et 
al, 1998
Splicing
complexes
(U2-B,
UI-70K,
coilin
Not determined Co-localisation of WT1 (+KTS) 
isoforms with splicing complexes
Larsson et al, 
1995
U2AF65 Several: zinc 
fingers essential
Preferential binding by WT1 (+KTS) 
isoforms; ?RNA metabolism
Davies etal, 1998
WTAP C-terminus, all 
forms
Partial co-localisation with splicing 
factors; ?sex determination
Little et al, 2000
Key: TR, transcriptional regulation; TA, transcriptional activation; wt, wild-type; MIS, 
Mullerian inhibiting substance
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1.7.2.2 The NPHS1 gene
The NPHS1 gene was positionally cloned through linkage disequilibrium analysis of a 
Finnish population with the rare form of autosomal recessive congenital nephrotic 
syndrome known as Finnish Type or CNF (Kestila et al, 1998). Initial studies mapped 
the locus to chromosome 19ql3.1 (Kestila et al, 1994), and the critical region was 
subsequently narrowed to 150kb (Manniko et al, 1995). Exon prediction programmes 
and database searches predicted at least ten genes within this region, of which only 
NPHS1 was specifically expressed in the kidney on Northern blot analysis (Kestila et al, 
1998). In situ hybridisation revealed the highest expression to be in the periphery of 
mature and developing glomeruli, the location of podocytes (Figure 1.20), subsequently 
confirmed by immunofluorescence study (Figure 1.21). The NPHS1 gene is 26kb long 
and contains 29 exons, of which one, exon 23, has an unconventional donor site in that a 
GC replaces the usual conserved GT. The cDNA transcript is 4.3 kb. Sequence analysis 
of the Finnish CNF families has revealed the presence of two mutations in over 90% of 
CNF cases suggesting that NPHS1 was the causative gene. Approximately 78% of 
Finnish CNF cases carry a two base pair deletion in exon 2 (ntl21 (del 2), Fin major), 
which causes a frameshift resulting in a truncated 90 residue protein, whereas the 
remainder carry a nonsense mutation in exOn 26 (R1190X, Fin minor), which results in a 
truncated 1109 residue protein. A variety of NPHS1 mutations have now also been 
detected in many CNF cases with no demonstrable Finnish ancestry (Lenkkeri et al, 
1999; Aya et al, 2000; Beltcheva et al, 2001; Koziell et al, 2002), and in contrast to 
Finnish CNF, these are distributed throughout the whole gene. Mice knockout studies 
provide further supportive evidence that mutations or absence of NPHS1 results in a 
congenital nephrotic syndrome, as mice with a null mutation died from proteinuria and 
oedema within 24 hours (Putaala H, et al 2001). The importance of the NPHS1 gene in 
the pathogenesis of other types of nephrotic syndrome is unknown, although there are 
reports of diminished NPHS1 expression in human nephrotic syndrome (Furness et al 
1999, Doublier et al, 2001), including diabetic nephropathy (Aaltonen et al, 2001) and 
an apparent causal link between NPHS1 and some experimental models of nephrotic 
disease (Topham et al, 1999; Luimula et al, 2000).
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Figure 1.20 Expression of nephrin mRNA in human embryonic tissue. A) Renal 
cortex showing exclusively glomerular expression B) Intense expression in the 
periphery of glomeruli (straight arrows), but none in Bowman’s capsule (bent 
arrow) ot proximal tubules (open arrows) (reproduced with permission from Kestila 
et al, 1998)
Glomerulus
Figure 1.21 Immunofluorescence staining in human kidney using antibodies 
against recombinant human nephrin. Immuno-reactivity is present in the 
glomerulus, but not mesangial or endothelial cells. (Bar = 20 nm)
(Photo courtesy o f Prof Karl Tryggvason)
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The NPHS1 gene encodes nephrin, a 1,241 amino acid single pass transmembrane 
protein predicted to be a type-1 glycoprotein belonging to the immunoglobulin 
superfamily (Kestila et al 1998). This represents a diverse collection of proteins with 
multiple roles such as mediation of immune response, various aspects of cell surface 
recognition and cell signalling. Superfamily members contain immunoglobulin (Ig) 
domains, which typically belong to one of three different subclasses V, Cl and C2 and 
are one of the commonest motifs found in mammalian proteins (Henikoff et al, 1997). 
The subclass represented to some extent confers protein function, so that the Cl domain 
is restricted to proteins associated with the immune system, whereas the C2 domain is 
prevalent among immune receptor related proteins and cell adhesion molecules 
participating in cell-cell and cell-matrix interactions (Brummendorf et al, 1994 and 
Chothia et al, 1997). Examples of this group are the N-CAM group (Cunningham et al, 
1987), MAG (Fahrig et al, 1987), LI (Moos et al, 1988), KIM-1 (Ichimura et al, 1998) 
and gicerin (Tsukamoto et al, 1998). C2 modules are also found in proteins participating 
in various developmental pathways, such as basgrin (Igakura et al, 1998), gicerin 
(Tsukamoto et al, 1998) and irregular chiasm C-roughest protein (Ramos et al, 1993).
Immunoelectron microscopy has shown the nephrin expression in the kidney occurs 
almost exclusively in the slit diaphragm region of podocyte foot processes (Figures 1.22 
A, B and C) (Ruotsalainen et al, 1999; Holthofer et al, 1999; Holzman et al, 1999), 
further supporting an integral role in the slit diaphragm function. This is supported by 
the concurrent detection of nephrin within the slit diaphragm itself (Figure 1.22 C). 
More recently, nephrin expression was also detected in a restricted fashion in the brain 
and pancreas (Putaala et al, 2000; Putaala et al, 2001) and testis (Liu et al, 2001), 
although it remains unclear what role it plays in these locations. Local regulation of 
nephrin functions may be modulated by usage of alternatively spliced forms, as can 
occur in the kidney (Ahola et al, 1999; Holthoffer et al, 1999). Of note, male mice 
heterozygous for a null mutation of NPHS1 do not have diminished fertility. Two 
alternative splice isoforms of nephrin have been detected in humans and rats, the first 
represents the full-length protein, whilst the second lacks the transmembrane domain 
and may produce a truncated soluble form of nephrin. However, the role these 
alternative splice isoforms may play in vivo is not known.
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Figure 1.22 (A,B>C) Immunoelectron microscopic localization of nephrin in human 
renal glomeruli. Indirect postembedding staining for nephrin by using affinity 
purified IgG against extracellular region of recombinant human nephrin and 
10 nm gold-coupled secondary antibody. (A) The GFB. Gold label (arrowheads) is 
detected between foot processes of podocytes (P). Endothelium (E) is unlabeled. 
(Bar = 200 nm). (B) Tangentially sectioned podocyte (P) foot processes: several 
gold particles in a row (boxed) can be seen. (Bar = 500 nm). (C) Blow-up of boxed 
area of B. The GBM is marked with asterisk. (Bar = 50 nm). (D) Gold particle 
between slit diaphragm joining two podocytes (P). (Bar = 50 nm).
(photos courtesy o f Professor Karl Tryggvason)
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Nephrin has a molecular weight of 150 kDa without post-translational modification and 
180 kDa with, as shown on western blotting of transfected COS-7 lysates and human 
glomerular lysates with antibodies directed against both extra- and intracellular epitopes 
(Ruotsalainen et al 1999). The N terminal is extracellular and consists of a 22-residue 
signal peptide, eight C2 Ig domains and a fibronectin type III like domain connecting 
via a transmembrane domain to a cytoplasmic tail rich in serine, threonine and tyrosine 
residues (Figure 1.23). The Ig motifs are each encoded by two exons, except for Ig 
domain two, which is encoded by three exons. There is also a putative spacer domain 
between Ig modules six and seven. Two cysteine residues are present in each of the Ig 
repeats and are thought to form disulphide bridges. Four additional cysteines are located 
in Ig domain one, the spacer, the fibronectin motif and in the transmembrane domain. It 
has been postulated that the free cysteine in the first Ig repeat may form a disulphide 
bond with the cysteine residue in the spacer region of a nephrin molecule in an adjacent 
cell (Ruotsalainen et al, 1999; Tryggvason, 1999). This would lock together the first six 
Ig repeats of two adjacent nephrin molecules, resulting in a homophilic interaction 
within the slit diaphragm (Figure 1.24), comparable to that seen with other Ig cell 
adhesion molecules, such as N-CAM (Kiselyov et al 1997), C-CAM (Obrink 1997) and 
LI (Sonderegger et al, 1992). This cross-linking could represent the zipper like 
isoporous filter structure shown identified by electron microscopy (Rodewald and 
Kamovsky, 1974), but would result in a relatively inelastic structure. In this situation, 
the spacer domain and possibly also the fibronectin domain would have to be elastic, 
allowing the nephrin protein to stretch in response to the changes in filtration pressure 
that occur in vivo (reviewed in Tryggvason et al, 1999). However, experimental data 
confirming this dimerisation either in vivo or in vitro is lacking, and it is likely that 
additional components are also required to assemble the slit diaphragm.
Recent evidence indicates that nephrin may be a component of lipid rafts, dynamic 
assemblies within cell membranes enriched with glycosphingolipids, cholesterol, GPI- 
anchored proteins and signalling molecules such as Src kinases. Lipid rafts are known to 
participate in a variety of cellular processes such as cellular trafficking, signal 
transduction and cell adhesion, and that kinases and phosphatases may be required to 
regulate the assembly of the complex, and to facilitate the integration of newly 
synthesised proteins (Simons et al, 1997; Brown et al, 1998; Simons et al, 2000).
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Figure 1.23 Schematic representation of the domain structure of nephrin. The Ig 
repeats are shown by incomplete circles (Ig 1 - 8) connected by disulfide bridges 
(C-C). The locations of free cysteine residues are indicated by a —C. FNIII 
represent the fibronectin motif and TM the transmembrane domain (adapted from  
Rutosalainen etal, 1999)
P la s m a  m e m b ran e P la sm a  m e m b ran e
Podocyte Slit Diaphragm Podocyte
Figure 1.24 Hypothetical model of nephrin assembly to form the isoporous filter of 
the podocyte slit diaphragm. Cysteine residues and two potential disulfide bridges 
cross-link the four nephrin molecules (black lines). The remaining single free 
cysteine in the fibronectin domain may react with another nephrin molecule, or 
another unknown molecule within the slit diaphragm (reproduced with permission 
from Rutosalainen etal, 1999)
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There is preliminary data that podocyte lipid rafts may participate in nephrin 
phosphorylation and thus organisation of the slit diaphragm (Simons et al, 2001). 
Interestingly, these appear to contain a specific 9-O-acetylated GD3 ganglioside, and 
intravenous injection of a monoclonal antibody to this ganglioside into rats resulted in 
flattening of podocyte foot processes. However, the rats did not develop proteinuria, 
which makes the apparent changes in morphology difficult to interpret. In addition, 
nephrin may reside as part of a large complex within the lipid rafts. Two key putative 
interacting proteins have been identified, CD2AP (Shih et al, 2001) and podocin (Huber 
et al, 2001; Schwartz et al, 2001). CD2AP was originally cloned in T cells, and is an 80 
kDa protein containing 3 SH3 domains and multiple poly-proline motifs in a tandem 
array, suggesting that it may function as an adapter molecule (Dustin et al, 1998). Mice 
with a null mutation for CD2AP have immune abnormalities, but surprisingly die at 6-7 
weeks of nephrotic syndrome and renal failure, with histology reminiscent of human 
DMS (Shih et al, 1999). Immunofluorescence studies indicate that CD2AP is expressed 
in podocytes, proximal tubule, distal tubule and collecting duct of the kidney as well as 
being widely expressed in both mouse and human tissues, and that nephrin and CD2AP 
co-localise in both murine and human podocytes (Li et al, 2000). Dominant negative 
experiments have suggested a role for CD2AP in cytoskeletal rearrangement and CD2 
clustering upon antigen receptor engagement (Dustin et al, 1998). CD2AP may play an 
analogous role in podocytes, anchoring nephrin to the cytoskeleton. Currently there is no 
direct link between CD2AP mutations and human nephrotic disease, except for 
preliminary data that CD2AP mutations may be associated with some cases of 
congenital DMS, and these may result in diminished nephrin-CD2AP binding (Green, 
Koziell and Shaw, unpublished observations). Another intracellular binding partner may 
be podocin (Schwartz et al, 2001), encoded for by the NPHS2 gene, and the causative 
gene for familial steroid resistant nephrotic syndrome (SRN1, Boute et al, 2000). 
Podocin appears to also bind CD2AP, suggesting that all three proteins may be 
associated in a complex within lipid rafts at the slit diaphragm (Schwartz et al, 2001).
There is speculation that as well as playing a major role in the function of the mature slit 
diaphragm, nephrin participates in its development during nephrogenesis (Ruotsalainen 
et al, 2000). Nephrin is first detected in late S-shaped bodies, and expression is maximal 
adjacent to the vascular cleft. In the normal situation, maturing glomeruli all become
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strongly positive for nephrin, especially during the capillary loop stage before the 
appearance of either foot processes or slit diaphragms. Nephrin co-localises with ZO-1, 
although their patterns of expression do not completely overlap. Interestingly, nephrin 
expression in foetal kidneys with Fin major/Fin minor genotype is absent, whereas that 
of ZO-1 and P-cadherin is normal. Here, early podocyte junctional complexes appear to 
form normally, but slit diaphragms subsequently fail to develop, which indicates that 
although there is no absolute requirement for nephrin in early junctional complex 
formation, it is indispensable for the development of slit diaphragms. Of note, this 
failure of slit diaphragm development is also seen in nephrin null mice (Putaala et al, 
2001). These observations further underpin nephrin’s crucial role in slit diaphragm 
function and in glomerular permselectivity.
1.7.23 The NPHS2 gene
Positional cloning recently identified a third gene associated with nephrotic syndrome in 
early life, NPHS2 (Boute et al, 2000). Initial linkage analysis of families with autosomal 
recessive steroid-resistant nephrotic syndrome (SRN1; onset between three months and 
five years) mapped the causative gene to a 12cM region on chromosome lq25 to q31 
(Fuchshuber et al, 1995). SRN1 is characterised by FSGS renal histology, variable 
mesangial cell proliferation and presence of immuno-reactants. Patients do not respond 
to steroid treatment and end stage renal failure is rapid following the onset of 
proteinuria. The locus was subsequently fine mapped to a 2.5cM region within this area, 
and the NPHS2 gene identified (Boute et al, 2000). NPHS2 encodes a transcript 
approximately 2kb in length, with a 1,149 base pair open reading frame and 635 base 
pair 3’ UTR containing an atypical polyadenylation signal. Northern blot analysis 
detected strong NPHS2 expression in adult and foetal kidney, but not in other tissues, 
and in situ hybridisation studies specifically localised expression to the podocyte layer 
of the glomerulus. Although homozygous mutations of the NPHS2 gene were detected 
in most of the of SRN1 cases tested, only the paternal mutation was detected in four 
individuals.
NPHS2 encodes a 49kDa integral membrane protein called podocin with sequence 
homology to the band-7 stomatin family. Database searches indicate strong homology
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with human stomatin (47% identity, 67% similarity) and Caenorhabditis elegans MEC2 
(44% identity, 67% similarity). Human stomatin (Band 7.2b) is a 31 kDa erythrocyte 
integral membrane protein, initially isolated from erythrocyte plasma membranes, and 
subsequently found to have more widespread expression (Stewart et al, 1992). 
Stomatins are thought to belong to a novel protein superfamily, bound by similar 
primary and secondary predicted protein structures and hydropathy profiles. This 
superfamily is named PID (proliferation, ion, and death), because it contains prohibitins, 
involved in proliferation and cell cycle control, stomatins which are involved in ion 
channel regulation, and the plant defence-related genes, which are involved in cell death 
(Nadimpalli et al, 2000). Members of this family expressed in eukaryotic cells have 
been implicated in the control of ion channel permeability and cytoskeletal organisation 
(Stewart et al, 1993), mechanoreception (Huang et al, 1995), tumour suppression 
(McClung et al, 1989), and lipid domain organization (Salzer, 2001).
The podocin protein is 383 amino acids long, and the band-7 stomatin signature is 
located between amino acids 238 and 266 (Figure 1.25). It consists of a cytoplasmic N- 
terminal domain, a short transmembrane domain (amino acids 105-121) and a 
cytoplasmic C-terminal domain, which results in a hairpin structure that probably loops 
through the cell membrane. The C-terminal tail also contains a characteristic SPFH 
(stomatin, prohibitin, flotilin, Hflk/c) or PHB (prohibitin homolgue) domain (Pfam 
entry: Band_7, accession number:PF1145), predicted to lie close to the membrane- 
associated region (http://smart.embl-heidelberg.de/), but other than the band-7 signature, 
the remaining sequence shows no homology with any known proteins. So far, little is 
known about the functions of podocin within the podocyte, although there is evidence 
that this group of proteins from independently organised high order homo-oligomers, 
resulting in a wide spread structure, which as well as serving as a stabilising molecule, 
interacts with other podocyte proteins and function as a linker between the plasma 
membrane and the cytoskeleton. There is increasing evidence that stomatin-like proteins 
form core components of membrane associated proteolytic complexes (reviewed in 
Tavemarakis et al, 1999), and of lipid rafts (Salzer and Prohaska, 2001). Podocin 
expression is confined to glomerular podocytes in the mature kidney, and clusters at the 
basolateral cellular surface of the foot process, on either side of the slit diaphragm 
(Figure 1.26).
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Figure 1.25 Schematic representation of podocin, showing predicted intra-cellular 
structure
Amino acids 1 123 282 383
N term inal
(intra-cellular)
C term inal
(intra-cellular)
Key: Transm em brane segments as predicted by the TM H M M 2  program  (fitf),
segments of low compositional complexity, determined by the SE G  program  ( """). 
PHB represents PHB domain, located within the stomatin signature (not shown).
Figure 1.26 Localization of podocin in the glomerular capillary wall of normal mice 
(immunogold labelling); magnification: a-b, x24,000; c-d, x40,000 (reproduced 
with permission from Roselli et al, 2001)
N-terminal (a and c) or C-terminal (b and d) antibodies. With both antibodies, 
podocin is seen at the base of podocyte foot processes, along the GBM, on either 
part of the slit diaphragm (arrow), predominantly at the inner face of the plasma 
membrane
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Recent data suggests that, like nephrin, podocin is also associated with lipid rafts, and 
may form a complex with nephrin and CD2AP within these structures (Schwartz et al,
2001). Whether this is direct or indirect is not known, but GST pull down assays have 
predicted a direct interaction between the C-terminal portion of podocin, and with both 
CD2AP and nephrin (Huber et al, 2001; Schwartz et al, 2001). Since nephrin is also able 
to bind directly to CD2AP in vitro (Shih et al, 1999) and in vivo (Shih et al, 2001), 
CD2AP may act as an adaptor molecule between nephrin and podocin, in addition to a 
possible direct interaction, forming a link between these proteins and the podocyte 
cytoskeletal machinery. In addition, there is in vitro evidence to suggest that when 
present in a complex with nephrin, podocin synergistically contributes to the activation 
of the mitogen-activated protein kinase (MAPK) pathway by nephrin, although this 
study did not detect binding to CD2AP (Huber et al, 2001).
Podocin has a very similar expression pattern to nephrin during renal development 
(Roselli et al, 2002). The NPHS2 transcript was first detected in the mesonephros, 
specifically in mesonephric podocyte precursors (Roselli et al, 2002). NPHS2 was 
subsequently detected in the metanephros in podocyte precursors in the lower limb of 
the S-shaped body, but not in future parietal cells. Expression persisted throughout 
glomerular differentiation and in mature glomeruli. During this and the early capillary 
loop stage, podocin is distributed at the basal pole and along the lateral surface of 
immature podocytes that have not yet developed foot processes. Podocin expression 
increases with glomerular maturation, and persists at a high level at the basal pole of 
mature podocytes. Interestingly, using specific antibodies raised against either the bl­
and C- terminal domains of the protein, it is possible to detect their co-localisation at the 
cytoplasmic face of the plasma membrane, which is in agreement with the proposed 
hairpin -  like structure (Figure 1.26).
1.7.2.4 The a-Actinin 4 gene (ACTN4)
Genotype analysis of two different families mapped an FSGS locus to chromosome 
19ql3, and subsequent mutation screening revealed that the causative gene was ACTN4 
(Kaplan et al, 2000). ACTN4 encodes for a-Actinin 4, an actin-filament crosslinking 
protein, with widespread expression (Honda et al, 1998) and belonging to a family of
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homologous proteins highly conserved among species. a-Actinin 4 is expressed in the 
kidney, and in podocytes is located predominantly within the foot process (Kuihara H et 
al 1995). Competitive co-sedimentation experiments performed using labelled and 
unlabeled F-actin along with mutated (K228E, T232I or S235P) and wild type full 
length a-Actinin 4 suggest that the mutated form has a higher affinity for F-actin 
(Kaplan et al, 2000). This suggests that an intact sub-membranous actin cytoskeleton 
play a crucial role in maintaining the podocyte architecture. This is supported by recent 
unpublished reports on an ACTN4 mouse knock out, which suggest that the renal 
phenotype is similar to that seen in other mouse models of nephrotic syndrome such as 
in NPHS1 and NEPH-1. However, this data still requires confirmation.
1.7.3 Mouse models of nephrotic syndrome
A number of transgenic models of nephrotic syndrome are now available, however the 
major limitation of this approach is that many glomerular genes are expressed during all 
three stages of mammalian development, which complicates the interpretation of the 
eventual phenotype seen. However, a number of clues for the molecular basis of 
glomerular permselectivity have come from studies of mouse models of nephrotic 
syndrome. Null mutations of CD2AP (Shih et al, 1999), s-laminin/laminin beta 2 
(Noakes et al, 1995), M pvl7  (Binder et al, 1999) Glepp-1 (Wharram et al, 2000), 
NEPH1 (Donoviel et al, 2001), podocalyxin (Doyonnas et al 2001), and over expression 
of Pax2 (Dressier et al, 1994), all result in glomerular damage in mouse models, and 
indicate which genes may play an important role in podocyte homeostasis. In many 
cases, null mice develop either typical effacement of podocyte foot processes, or normal 
foot processes and slit diaphragms simply fail to form. Various abnormalities may be 
seen on histological examination of the kidneys including FSGS, DMS and interestingly 
over-expression of Pax2 in transgenic mice, results in a histology reminiscent of CNF 
(Dressier et al, 1994). However, in the majority of cases, mutations within these genes 
have as yet not been detected in humans, and the relevance to human nephrotic disease 
remains speculative.
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1.8 Rationale for study
Proteinuria, the hallmark of nephrotic syndrome, occurs as a consequence of the loss of 
normal permselective properties of the glomerular filtration barrier. Although the 
consequences of this phenomenon are well studied, the actual pathophysiological 
mechanisms involved are poorly resolved and as a result, many scientific studies of 
nephrotic syndrome are confusing. Traditionally, childhood nephrotic syndrome has 
been attributed to various mechanisms, such as immune derangement (Neuhaus et al, 
1995 a,b), loss of negative charge/charge neutralisation in the GFB (Taylor, 1997), or 
aberrant proteoglycan composition of the glomerular basement membrane (van den 
Heuvel et al, 1995), with little understanding of how these cause the protein leak. 
However, it is becoming increasingly recognised that although the aetiology of 
nephrotic syndrome may vary, the primary target for cellular injury is the glomerular 
podocyte, and many nephrotic syndromes presenting in early life are inherited disorders, 
with a genetic basis.
The aim was to explore the genetic basis of congenital and early onset nephrotic 
syndrome by examining the roles of three renal glomerular genes WT1, NPHS1 and 
NPHS2 in the pathogenesis of glomerular protein leak. Although these diseases are rare, 
many are both inherited and kidney specific. Consequently, elucidation of the 
underlying genetic defects might be expected to contribute significantly to current 
knowledge about the role of the different regions and protein components of the GFB, 
and thus the molecular basis of glomerular filtration.
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CHAPTER 2: Materials and Methods
2.1 Materials
2.1.1 Reagents
All reagents used were of AnalaR grade and obtained from either British Drug Houses 
(BDH) or Sigma Aldrich, except as indicated below. Glassware, solutions and media 
were autoclaved at 15psi, 121°C for 20 minutes as required. Water was purified using a 
MilliRo 15 Water Purification System (Millipore SA), further purified were necessary 
using a Milli-Q Reagent Grade Water Ultrafiltration System (Millipore), and sterilised 
by autoclaving.
Buffer Saturated Phenol was from Life Technology. Proteinase K Solution was from 
Boehringer Mannheim/Qiagen. Tris-buffered phenol and NaOH pellets were from 
Fisons Scientific Equipment. Sequagel and Protogel polyacrylamide gel products and 
buffers were obtained from National Diagnostics. Agarose and TEMED (N,N,N’,N*- 
tetramethylethylenediamine) were obtained from Gibco-BRL Life technologies and 
NuSeive GTG low melting point agarose from FMC Bioproducts. Acrylamide solution 
40% w/v, (29:1 acrylamide:N,N@-methylene bisacrylamide), Protogel acrylamide 
solution 30% acrylamide, 0.8% bisacrylamide (37.5:1 acrylamide:N,N@-methylene 
bisacrylamide) and urea were from Bio-Rad Laboratories. Amberlite resin (50mg/ml) 
was from Perkin Elmer. Alconox detergent was from Alconox Inc. Bacto-agar, 
bactotryptone, agar, nitrogen base without amino acids and yeast extract were from 
Difco laboratories. Absolute alcohol was from Hayman Ltd. Ultrapure dNTP’s, NAP5 
Sephadex columns, and poly(dI-dC).poly(dI-dC) were supplied by Pharmacia Biotech.
2.1.2 Materials
In addition to standard laboratory items, use was made of the following special items. X- 
OMAT AR and BioMax-MR autoradiography film (Kodak) was used for 32P and 35S 
applications. For chemiluminescent methods XB-200 Blue Sensitive, High definition X-
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ray film (X-ograph Imaging Systems) was used. Slides and slide boxes were from BDH 
laboratory supplies and cover slips from Chance Pepper Ltd. ART aerosol resistant 
barrier tips were obtained from Molecular Bioproducts. Miniflex 0.2mm flat tips were 
from Sorenson BioScience, Inc. Glassware was obtained from Pyrex® (USA) and 
Schott Duran (Germany). Plastic ware was sourced from Becton Dickson Lab ware or 
Bibby Sterilin Ltd. 0.2ml PCR tubes from ABgene®. Sterile loops, cryotubes and filter 
sterilisation units were acquired from Nunc Nalgene®. Hybond N+ and Hybond C 
nylon membranes were from Amersham International PLC. Microsample™ plates and 
NAP5 Sephadex G-25 columns were obtained from Pharmacia. DNA electrophoresed 
on agarose gels was visualised through ethidium bromide fluorescence detected at 
300nm on a Chromato-vue transilluminator. Gels were photographed on a Polaroid 
Direct Screen Instant camera using Polaroid Film (Polaroid Corporation), or on a 
Herolab digital camera (Molekulare Trenntechnik) printed onto thermal paper 
(Mitsubishi Electric Corporation). PCR amplification and cycle sequencing reactions 
were performed on a GeneAmp PCR System 2400 (Perkin Elmer Applied Biosystems) 
or RoboCycler gradient 96 (Stratagene). DNA sequence analysis and microsatellite 
repeat analysis were performed on an ABI PRISM™ 377 DNA Sequencer (Perkin 
Elmer Applied Biosystems).
2.1.3 Commercial Kits
Sequenase™ Version 2 DNA sequencing kits and Thermo Sequenase dye terminator 
cycle sequencing pre-mix kits were purchased from Amersham International. pCR- 
Script™ Amp SK(+) Cloning Kits were from Stratagene. QIAmp Blood kits, QIAquick 
PCR purification Kits, QIAquick Gel extraction kits and QIAprep Spin Miniprep and 
Maxiprep kits were from Qiagen Ltd.
2.1.4 Enzymes
Restriction endonucleases were obtained from Gibco-BRL Life Technologies. Biopro™ 
DNA polymerase was from Bioline. Cloned Pfu DNA polymerase was from Stratagene. 
All enzymes were used with the appropriate lOx buffers supplied by the manufacturers.
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2.1.5 Radioisotopes
[a-32P] dCTP and [y-32P] dATP (3000 Ci/mmol was from ICN Biomedicals Inc. [a-35 S] 
dATP (>600 Ci/mmol) was from Amersham.
2.1.6 Nucleotide Size Markers
50 bp and 1 kb DNA ladders were purchased from Gibco-BRL Life technologies, and 
the GENESCAN-350™ TAMRA internal lane standard from Perkin Elmer.
2.1.7 Immunoglobulins
The anti-HA tag and anti-WT (F6) mouse monoclonal IgG (200pg/ml) antibody used 
was made commercially by Santa Cruz. Anti-nephrin antibodies were kindly donated 
by Professor Karl Tryggvason, Karolinska Institute, Stockholm.
2.1.8 Vectors, cDNA Clones and Libraries
pCR-Script™ Amp SK(+) vector was purchased from Stratagene. Rc/CMV-WTl +/- 
KTS cDNA, and GAL4-WT1 +/- KTS fusions in pASl and pACTII vectors were kindly 
donated by Professor Nick Hastie (MRC unit, Edinburgh), and the pVP16 mouse E 9.5 
and 10.5 day cDNA library by Stan Holleberg (Vollum Institute).
2.1.9 Bacterial Strains
HB101: A(g/??-pl0A)62, leuB6, thi-1, lacY 1, hsdS^lO, recA, r/?sL20(str+),
aral4, Gatkl, xyl-5, mtl-1, supE44, mcrBe
Epicurian Coli® XL 1-Blue MRF’ Kan supercompetent cells were supplied with the 
pCR-Script™ Amp SK(+) Cloning Kit (Stratagene) and used according to the 
manufacturer’s instructions.
81
2.1.10 Yeast Strains
Y190 MATa, gal4, galSO, his3-200, trp1-902, ade2-101, ura3-52, leu2-3,
-112 +URA:GAL(UAS) -> HIS3, cyti.
This was kindly provided by Stephen Elledge (Baylor College of Medicine, Houston, 
Texas).
2.1.11 Oligonucleotides
All oligonucleotide primers were synthesised to order by Genosys Biotechnologies Inc. 
Primers used for general PCR and sequencing of clones during this project are listed in 
Tables 2.1 to 2.5. Exon 1-10 WT1 gene oligonucleotide primer pairs used were those 
published by Baird et al (1992). NPHS1 micro-satellite repeats were amplified using 
oligonucleotide primer pairs published by Mannikko et al 1995. The forward primer of 
each pair was labelled with a fluorescent dye. NPHS1 primers (Lenkkeri et al 1999) 
were a kind gift from Professor Karl Tryggvason, Karolinska Institute, Stockholm. 
NPHS2 exon amplification was performed using primers published by Boute et al 
(2000). All primers were designed using flanking sequence between 30-50 base pairs 
upstream and downstream of exons to be amplified, to include exon-intron boundaries. 
Melting temperature (Tm) was estimated as follows:-
For oligonucleotides < 25 bp:
Tm = 2 (A + T) + 4(G +C)
For oligonucleotides > 25 bp:
Tm = 69.3 + (0.41 x GC content as a %) -  (650/length of primer)
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Table 2.1 General primers for PCR
Primer
name
Sequence 5’—> 3’ Annealing
temperature
(°C)
Uses
T7 taatacgactcactataggg 48 General PCR and 
sequencing of clones in 
pCR-Script™ SK(+)T3 aattaaccctcactaaaggg 48
pAS-1 tcatcggaagagagtag 50 Sequencing of Gal4 
binding and activation 
domain fusions
pACTII | ataccactacaatggatg 52
i
VP16F j gagtttgcgcagatgttt
\
52 Amplification and 
sequencing of VP 16 
library insertsVP16R gttgtaaaacgacggccagt 60
Table 2.2 Primers used for PCR amplification and sequencing of the WT1 gene
Exons 5’ Primer 
(Sequence 5’-> 3’)
3’ Primer 
(Sequence 5’—» 3’)
Product
size
(bp)
Annealing
temperature
(°C)
1 ccagcgctgaacgtctccag taggggcgctccccggccta 526 67
2 accgctgacactgtgcttctctccg agaggaggatagcacggaag 215 64
3 ggcagcactcgctcagctgtcttcg ggtcccaaggacccagacgcagagc 180 70
4 gtggttatgtgttctaactctagat ataagttactgtggaaaggcaatgg 158 60
5 gctccattccccactccccacctct ttgctttgccatctccgcattgtcc 120 60
6 cactgaccctttttcccttc ggccggtaagtaggaagaggc 189 61
7 gacctacgtgaatgttcacatg ctcttgaaccatgtttgcccaagac 255 60
8 ccagtatcatttcaaatagatatgtg agggaacacagctgccagcaatgag 167 58
9 tagggccgaggctagaccttctctg atccctctcatcacaatttcattcc 204 60
10 gcaagtgtctctgactggcaattgt tgcctgggacactgaacggtccccg 190 60
DDS1 gcgaaagttctcccggtcc - 60
Fras 1 ccagctcaaaagacaccaaag - 60
Fras2 - tttctgacaacttggccacc 60
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Table 2.3 Primers used for PCR amplification and sequencing of the NPHS1 gene
Exons 5’ Primer 
(Sequence 5’-> 3’)
3’ Primer 
(Sequence 5*-> 3’)
Product
Size
(bp)
Annealing
temperature
(°C)
5’UTR gctgactctgccagtgcctg cagggccatcacaggtcccc 643 60
1-2 gagaaagccagacagacgcag agcttccgctggtggct 491 60
3-4 agccaccagcggaagct ctcccttcccactccagagg 530 60
5 cagaatctatcttgcggggag catggggaaaattaggggtcaag 187 60
6-7 tctccctgactccccaaatttc ctcaggactggctcccagac 544 60
8-9 gacagtggggtctgggagccagtcctgag gagtcatgccctcagcccc 623 60
10-11 cacgatggataggggtgctg cctggtccttcccccacatt 465 60
12-13 aacccagtgggcagggtagggg gacatgcgtggagggggcga 668 60
14 cctagtgcctctccagcc gagtagtttagggtcaagaagg 288 60
15-16 cctgatctccaatctgtccttg ccacaatgggcaaggttccttg 484 60
17 cacccagacctgtctgggcc gtccccactcccaaggaactc 257 60
18-19 gaggctacagaagggacaatttg gctggaggtccagacctggg 561 60
20 ggatggatgcatagatgattcc caatcagggatgtgggaatg 297 60
21-22 cctggacagaatcttctggaatt cctacacatcctctgaggaatac 487 60
23 gaggctgagaaatatttaaagcttat gagaccaggaggttccattct 188 60
24-26 ctcggggagacccacccc cctgatgctaacggcagggc 611 60
27-28 tgcccttccgggcacagtgg tacaagcaataggaggtaggc 438 60
29 cagatcttcaatgaagacctaca gagacagaatctcgctctg 747 60
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Table 2.4 Primers used for PCR amplification of the NPHS2 gene
Exons 5’ Primer 
(Sequence 5’—> 3*)
3* Primer 
(Sequence 5’—» 3’) ProductSize
(bp)
Annealing
temperature
(°C)
1 gcagcgactccacagggact tcagtgggtctcgtggggat 410 60
2 aggcagtgaatacagtgaag ggcctcaggaaattaccta 195 55
3 ttctgggagtgatttgaaag tgaagaaattggcaagtcag 175 56
4 aaggtgaaacccaaacagc cggtaggtagaccatggaaa 210 55
5 cataggaaaggagcccaaga tttcagcatattggccatta 295 56
6 ctcccactgacatctga aatttaaaatgaaaccagaa 156 50
7 ctaaatcatggctgcacacc cttcctaaagggcagtctgg 176 60
8 ggtgaagccttcagggaatg ttctatggcaggccccttta 395 60
Table 2.5 Chromosome 19ql3.1 microsatellite repeats
Locus Sequence 5’-> 3* Hetero­
zygosity
Number
of
alleles
Size of 
Alleles 
(bp)
Annealing
temperature
(°C)
Primer 
Labelling 
dye and 
display 
colour
D19S608F
D19S608R
gcagactgcttgagctca
cgtgcccagctaaccagg
.89 10 112-
140
56 5’TET
(green)
D19S609F
D19S609R
gtcgactgaggcttacaga
gtcgactgcaggcttacaga
.35 4 114-
120
54 5’FAM
(blue)
D19S610F
D19S610R
ctctctccaaggactcgg
gtggatctatctgccaatctc
.75 10 204-
220
54 5’TET
(green)
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2.2 Solutions, Buffers and Media
2.2.1 DNA related solutions
2.2.1.1 Genomic DNA extraction
Nuclei Lysis Buffer lOOmM Na Cl, lOOmM Tris pH7.8, lOmM EDTA
DNA extraction solution lOOmM Tris-HCl, 4mM EDTA (pH 8.0)
IX TE lOmM Tris-HCl, 1 mM EDTA, pH 7
2.2.1.2 Solutions fo r  DNA preparation
Solution I 50mM glucose, 25mM Tris-HCl, lOmM EDTA (pH 8.0)
Solution II 0.2M NaOH, 0.1 % w/v SDS
Solution III 3M KAc , adjusted with glacial acetic acid to pH 5.2
QBT 750Mm NaCl, 50mM MOPS (pH 8.0), 15% ethanol,
0.15% Triton X
QC 1M NaCl, 50mM MOPS (pH7.0), 15% ethanol
QF 1.25mM NaCl, 50mM Tris-HCl (pH 8.5), 15% ethanol
2.2.1.3 DNA Electrophoresis buffers
XI TAE buffer 40mM Tris-Acetate, ImM EDTA pH 7.0
XI TBE buffer 89mM Tris-borate, ImM EDTA pH 8.3
2.2.1.4 DNA Gel loading buffers
Orange G 
Bromophenol Blue
Formamide buffer
Amplification dilution 
Solution (ADS)
0.25% w/v orange G, 20% w/v Ficoll 400, lOOmM EDTA 
0.25% w/v bromophenol blue, 0.25% w/v xylene cyanol, 
15% w/v Ficoll 400
95% formamide, 20mM EDTA, 0.05% bromophenol 
blue, 0.05% xylene cyanol FF 
0.1% SDS lOmM EDTA
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2.2.1.5 RNA extraction solution
RNA digestion buffer lOmM Tris (pH8.0), lOOmM NaCl, 25mM EDTA, 0.5%
SDS and lOOpg/ml of Proteinase K.
2.2.1.6 Restriction Enzyme Buffers
The buffers used in restriction enzyme digest were enzyme specific and supplied at lOx
concentration by Gibco BRL. All were stored at -20°C.
lx BRL restriction buffer 50mM Tris HC1 (pH8.0), lOmM MgCl2, 0 - lOOmM NaCl,
0 - lOOmM KC1
2.2.7.7 Taq PCR Buffer
Taq PCR buffer was supplied by Bioline at 10X concentration and stored at -20°C.
lOx Taq buffer 670mM Tris HC1, pH 8.8, 160 mM (NH4)2S 04
1% Tween 20
2.2.1.8 Pfu PCR buffer
Pfu PCR buffer was supplied by Stratagene at 10X concentration and stored at -20°C.
lOx Pfu PCR buffer 200mM Tris-HCl pH 8.8, 20mM Mg S04,lOOmM KC1,
100 mM (NH4)2S 04,1% Triton X-100,1 mg/ml nuclease- 
free BSA
2.2.2 Protein related solutions
2.2.2.1 General buffers
10X TBS 0.5M Tris-HCl (pH 8.0), 1.5M NaCl
10X PBS 137mM NaCl, 1.5mM KH2P04, 8mM Na2HP04, 2mM
KC1
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22.2.2 Protease inhibitors
The following protease inhibitors were added immediately prior to use to solutions used 
in the majority of protein techniques.
Protease Inhibitor Specificity Stock Solution Final
Concentration
PMSF Serine and cysteines proteases 0.1M in isopropanol ImM
Aprotinin Serine proteases lOmg/ml in H20 1 pg/ml
Leupeptin Serine and cysteines proteases 1 mg/ml in H20 1 pg/ml
Pepstatin Aspartate proteases 1 mg/ml in ethanol 1 pg/ml
Trypsin Inhibitor Trypsin 1 mg/ml in H20 lOpg/ml
EDTA Metalloproteases 0.5M in H20 0.5-lmM
2.2.23 Protein gel buffers
4X SDS resolving gel buffer 
4X SDS stacking gel buffer
10X Tris-glycine/SDS electrophoresis 
buffer
2X Laemmli loading buffer
Protein transfer buffer
Bradford buffer (estimation of protein 
concentration)
0.15M Tris base, 0.4% SDS 
0.05M Tris base, 0.4% SDS
0.25M Tris base, 2M glycine, 1% SDS
250mM Tris-Cl (pH6.8), 4% SDS, 25% 
glycerol, 0.1% bromophenol blue, 5% p 
mercaptoethanol (added fresh).
0.5X Tris-glycine/SDS electrophoresis 
buffer, 20% methanol
lOOmls 85% phosphoric acid + lOOmg 
Coomassie Brilliant Blue G-250 dissolved 
in 50ml 95% ethanol, made up to 1L with 
ddH20.
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22.2.4 Hybond-C membrane blocking and wash buffers
TBS-T
Blocking buffer 
Wash buffer
IX TBS, 0.05% Tween-20
IX TBS, 5% non-fat milk, 0.05% Tween-20
IX TBS, 0.5% Tween-20
2.2.3 Yeast Analysis
2.2.3.1 Yeast media
10X dropout solution 
(- L, - W, - H)
YPD 20g/l Bacto-peptone, 10g/l yeast extract, 2% glucose
YPAD YPD + 0.002% adenine
Minimal media 6.7g/l yeast nitrogen base (without amino acids), 2%
glucose, 0.002% adenine, 0.0002% uracil, 0.0003% 
lysine (+ 25-50ml 1M 3-Aminotriazole as necessary) 
300M g/1 isoleucine, 1500mg/l valine, 200mg/l 
arginine-HCl, 300mg lysine-HCl, 200mg/l 
methionine, 500mg/l phenylalanine, 2000mg/l 
threonine, 300mg/l tyrosine, 300mg/l adenine, 
200mg/l uracil 
Added according to selection criteria:
0.003% leucine, 0.002% histidine, 0.002% 
tryptophan
Plates:
Appropriate medium containing 20g/l agar
2.2.3.2 Yeast manipulation solutions
10X LiAc 
10XTE 
LiAc/TE 
Li/SORB
1M LiAc
lOOmM Tris-HCl (pH8.0), lOmM EDTA 
lOOmM LiAc, lOmM Tris-HCl (pH8.0), ImM EDTA 
0.1M LiAc, lOmM Tris-HCl (pH8.0), ImM EDTA, 
1M Sorbitol
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LiAc/TE/PEG 
Yeast lysis buffer 
Z-buffer 
Cracking Buffer
2.2.4 Bacterial Analysis
2.2.4.1 Media
L-Broth (LB)
SOB broth 
SOC broth
Minimal medium (1 litre)
5X M9 salts 
Plates
0.1M LiAc, lOmM Tris-HCl (pH8.0), ImM EDTA,
40% polyethylene glycol (PEG)
lOmM Tris-HCl (pH8.0), 2% Triton X-100,1% SDS,
lOOmM NaCl, ImM EDTA
60mM Na2HPO4.7H20,40mM NaHP04.H20 , lOmM
KC1, ImM MgS04.7H20 , adjusted to pH 7.0
125 mM Tris-HCl (pH 6.8), 8M urea, 4% SDS, 10%
glycerol, 0.05% bromophenol blue
+ “fresh” p -  mercaptoethanol (50 pi per ml)
10g/l Bacto-tryptone, 5g/l yeast extract, 
5gA NaCl
20g/l Bacto-tryptone, 5g/l yeast extract, 
0.5g/l NaCl
9.6ml SOB broth, with lOOpl 1M MgCl2, 
lOOpl M gS04 and 200pi 20% w/v glucose 
solution added immediately prior to use. 
200ml 5XM9 salts, 100ml dropout 
solution, 5ml 40% glucose, 1ml 1M 
M gS04)4ml lOmg/ml proline, 1ml 1M 
thiamine, 2ml 1% histidine, 2ml 1% 
tryptophan, 1.5ml ampicillin 
30g Na2HPO4.7H20, 15g NH2P 04) 5g 
NH4C1, 2.5g NaCl, 15mg CaCl2 (optional)
Appropriate medium containing 20g agar
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2.2.4.2 Antibiotics
Ampicillin 50mg/ml, filter sterilised stored at 20°C as 1000X stocks
2.2.4.3 Colour selection
X-gal (1000X) 25mg/ml in dimethyl formamide
IPTG (1000X) 25 mg/ml, filter sterilised
2.2.5 Solutions used in the preparation o f  cytoplasmic and nuclear extracts
Buffer A
Buffer B 
Buffer C 
NSB
HSU buffer 
Hypotonic Buffer
10 mM Hepes (pH7.6), 85 mM KC1, 5.5% sucrose, 0.5 mM 
spermidine, 0.5 mM DTT, 0.5 mM EDTA 
+ protease inhibitors
Buffer A + 0.8% NP-40
Buffer A minus EDTA
20 mM Hepes (pH 7.9), 140 mM NaCl, 40 % glycerol, 0.5 
mM DTT, 0.5 mM EDTA + protease inhibitors
2M NaCl, 8M urea in TE
10 mM Hepes (pH 7.6), 10 mM KC1, 1.5 mM MgCl2,
0.5 mM DTT, 0.2 mM EDTA, 0.5 mM EGTA,
+ protease inhibitors
2.2.6 Solutions used fo r  electrophoretic mobility shift assay (EMSA)
BBO binding Buffer 25mM HEPES pH 7.4, 10% glycerol (v/v), 75mM NaCl,
0.25mM EDTA, ImM MgCl2) ImM DTT, 0.1% NP-40
T4 DNA polymerase 50mM NaCl, lOmM Tris-HCl, lOmM MgCl2, ImM DTT 
buffer (PNK buffer) (pH7.9)
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2.3 METHODS
2.3.1 Isolation and purification o f  DNA and RNA
2.3.1.1 Preparation o f  DNA from  human venous blood
Two methods were used. For routine isolation and purification of genomic DNA from 
whole venous blood, the QIAmp Blood and Tissue kit (Qiagen Ltd) was used in 
accordance with the manufacturer’s instructions. This was suitable for DNA preparation 
from both fresh and frozen blood, including samples treated with citrate, heparin or 
EDTA and yielded pure DNA, at a concentration of 30-60 ng/pl which could be used 
directly as a template for PCR reactions. Since only 200 pi of blood was required, 
sufficient quantities of DNA could be obtained from small-volume blood samples, such 
as those taken from infants and young children.
If larger quantities were required, standard phenol chloroform extraction was used. 5-10 
mis of blood was subjected to detergent lysis with 0.1 % NP40 and 0.1% SDS, followed 
by incubation with Proteinase K (lOOpg/ml) and lysis buffer overnight at 37°C. The 
sample was subsequently phenol/chloroform extracted and the DNA precipitated with 
0.3M sodium acetate and 2 Yi times the sample volume of ice-cold 100% ethanol. DNA 
was re-suspended in xl TE (pH 8.0) and quantified as described above.
2.3.1.2 Extraction o f  DNA from  paraffin sections
Again two methods were employed. For larger sections, the QIAmp Blood and Tissue 
kit (Qiagen Ltd) was used according to the manufacturer’s instructions. However, if 
only small sections were available, a modified phenol/chloroform extraction protocol 
was followed. Paraffin was dissolved using xylene, followed by a 100% ethanol wash. 
DNA extracted by incubation with Proteinase K (12.5mg/ml) in DNA extraction buffer 
(lOOmM Tris-HCl and 4mM EDTA (pH8.0)) at 37°C overnight. The samples were then 
phenol/chloroform extracted, and the DNA precipitated with 0.3M sodium acetate (pH
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8.0) and x3 sample volume of 100% ethanol at -70°C. The DNA was subsequently 
pelleted and resuspended 25-lOOpl xl TE to a concentration of 50-100ng/pl.
2.3.1.3 Extraction o f RNA from  paraffin sections
A method originally described by O’Driscoll et al (1996) was followed. Ten 5pm 
sections were deparaffinised using xylene and 100% ethanol. These were then air-dried, 
suspended in 200pl of RNA digestion buffer (section 2.2.1.4) and digested for 16 hours 
at 50°C. Total RNA was then extracted using phenol/chloroform extraction and 
precipitated with 100% ethanol, followed by a 70% ethanol wash. The pellet was 
suspended in lOOpl of DEPC water prior to use in RT-PCR.
2.3.1.4 Plasmid minipreps
Initially, a standard alkaline lysis plasmid miniprep technique was used as described in 
Sambrook et al (1989). 5-10mls of an overnight bacterial culture was centrifuged at 
12,000 rpm for 5 minutes. The supernatant was poured off and this procedure repeated 
three times. The final supernatant was removed and the cell pellet was resuspended in 
lOOpl of solution I. 200pl of solution II was then added, the suspension inverted several 
times and kept on ice for 10 minutes. After addition of 150pl of solution III, the sample 
was again inverted and kept on ice for a further 10 minutes. The sample was then spun 
at 4°C for 10 minutes to remove cellular debris. After a 1:1 phenol chloroform 
extraction, the DNA was precipitated by addition of x2 volumes of 100% ethanol and 
left on ice for 20 minutes. The DNA was pelleted by centrifugation at 4°C for 20 
minutes, washed in 70% ethanol and resuspended in 50pl of xl TE containing 10pg/ml 
RNase A.
Later in this project, preparation of plasmid DNA was carried out using QIAprep Spin 
minipreps (Qiagen Ltd), in accordance to the manufacturer’s instructions. In this system, 
alkaline lysis of bacterial cells in followed by adsorption of DNA onto a silica-gel 
membrane, thus eliminating the need for phenol/chloroform extraction. The DNA is 
eluted in Tris pH 8.0 and can be used directly in subsequent applications.
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23.1,5 Plasmid Maxipreps
Large-scale DNA preps were performed according to the Qiagen handbook, using the 
Qiagen-100 or 500 tips. 200ml bacterial cultures were harvested for 5 minutes at 
3000rpm, and the cell pellet resuspended in 10ml Solution I containing RNase A 
(50pg/ml). 10 mis of Solution II was added, the sample mixed by inversion and left on 
ice for 20 minutes. The lysed cells were centrifuged at 4°C at 12,000rpm for 20 minutes 
to remove cell debris. During this time, a Qiagen-500 tip was equilibrated with 10 mis 
QBT buffer under gravity flow. The cleared lysate was then added to the pre­
equilibrated column. Due to the salt and pH conditions of the lysate, the DNA will 
selectively bind to the resin, while the degraded RNA and cellular proteins can be 
removed by two washes using buffer QC. DNA was eluted from the tip by addition of 
15mls of buffer QF, and then precipitated using 0.7 x volume of isopropanol. The DNA 
was pelleted by centrifugation at 12,000 rpm for 25 minutes at 4°C. After a 70% ethanol 
wash, the pellet was dried and resuspended in 200pl lOmM Tris pH8.0.
For long-term storage, 20 % glycerol stocks were made by combining 400pl overnight 
culture with 600pl 50% glycerol in a cryotube, followed by storage at -70°C. When a 
fresh supply of plasmid DNA was required, lOpl of stock was removed for inoculation 
into LB broth, followed by overnight culture.
2.3.2 Analysis o f  DNA and RNA
2.3.2.1 Quantification o f  nucleic acid concentration
Nucleic acid concentration was determined by measuring the absorbance of the solution 
at 260 nm as quantified by a UV spectrophotometer. A value of A260 = 1, correlates to a 
concentration of ~ 50pg/ml for a solution of double stranded DNA, and 40pg/ml of 
RNA. The A260:280 ratio was also determined to ensure that the sample was relatively 
free of proteins. If this is the case, this should have a value of 1.8 for a pure DNA 
solution. For dilutions, DNA concentration was calculated using the following equation:
OP x dilution x 50 = concentration in pg/pl
1000
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2.3.3 PCR Amplification of DNA
2.3.3.1 General PCR
DNA was amplified using some modifications to the standard conditions as described by 
Saiki et al (1985,1988). Reactions were carried out in lx  PCR buffer (enzyme 
dependant), 25 mM each dNTP’s, between 100-250 ng each primer and 1 unit 
polymerase. Between 60-90 ng DNA was used as template. For routine amplification, 
Biopro™ Taq polymerase (Bioline) was used. Amplification reactions contained lx 
NH4 PCR buffer (Bioline), 1.5 mM MgCh, 0.25 mM dNTP’s,100-250 ng each primer, 
and 1U of Taq polymerase in a 25pi reaction. If proof reading or the production of blunt 
ended products for blunt ended ligation was required, Pfu polymerase was used. This 
produces blunt ended products and has a 12-fold lower error rate than Taq polymerase. 
Amplification reactions contained lx  Pfu buffer (Stratagene), 25 mM dNTP’s, 100-200 
ng each primer and 0.6-1.2 units of Pfu polymerase in a final volume of 25-50 pi. For 
GC rich areas, co-solvents such as 10% DMSO and 0.4M betane were used in addition 
to the standard PCR mix. PCR of DNA extracted from paraffin sections was often 
problematic due to carry-over of polymerase inhibitors. However, this was overcome by 
the use of Pfu polymerase and addition of 10% bovine serum albumin to the PCR 
reaction. The primer pairs used were described in section 2.1.11 and in Tables 2.1, 2.2, 
2.3, 2.4 and 2.5. Standard precautions were taken to avoid PCR contamination, such as 
use of autoclaved MilliQ water and aerosol resistant ART tips. A negative control, 
consisting of a reaction mix with no template DNA, was included in most experiments 
to check for overt contamination. PCR was generally performed on either a Hybaid 
Omnigene, Perkin Elmer Geneamp PCR system 2000 or a Stratagene Robocycler 
gradient 96. The following programmes were used:
Hybaid/Geneamp:
1 cycle 
30-40 cycles
Denaturation: 94-96 °C, 2 minutes
Denaturation: 94-96 °C, 30 seconds 
Annealing: specific annealing temperature
calculated for primers (Tm -  5°C), 30 
seconds
1 cycle
Extension: 72°C, 30 seconds
Final extension 72°C 5 minutes
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Robocycler:
1 cycle 
30-40 cycles
Denaturation: 94-96 °C, 2 minutes
Denaturation: 94-96 °C, 30 seconds 
Annealing: specific annealing temperature 
calculated for primers (Tm -  5°C), 1 
minute 30 seconds
Extension: 72°C, 1 minute 10 seconds
1 cycle Final extension 72°C 5 minutes
23.3.2 Colony PCR
The general PCR method described above was followed. Template DNA was prepared 
by suspension of a bacterial colony in 30pl of LB. 5pi of the suspension was aliquoted 
into a screw cap tube and boiled for 5 minutes. 2 - 4 pi of this was then added to the 
PCR reaction.
23.3.3 SSCPPCR
A similar protocol was followed, using either Taq or Pfu polymerase. However, only 
0.2mM dCTP was initially added to accommodate the addition of lOpCi/pl CTP 
labelled with 32P as a final step, yet maintain a concentration of dNTP’s at 25 mM in the 
final PCR mix. 5pl of the amplified PCR product was then diluted 1:8 in ADS, and 3pl 
of the diluted mix used for polyacrylamide gel electrophoresis, unless the PCR product 
was generated using DNA extracted from paraffin sections, in which case neat product 
was loaded.
2.43.4 RT-PCR
First strand cDNA synthesis was performed by mixing the following components on ice 
in the following order:- 7pl 5x reverse transcriptase buffer, 3.5pl DTT (0.1M), 2pl 
20mM dNTP’s, lp l RNA-ase inhibitor, lOOOpM random primer and 1-2 pi RNA. The 
final volume was made up to 33pl with DEPC H2O and the samples heated at 65°C for 
10 minutes. These were placed on ice and 2pl of reverse transcriptase added, followed
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by incubation at 42°C for 90 minutes. Samples were stored at -20°C prior to second 
strand synthesis by PCR.
2.3.4 Agarose gel electrophoresis
PCR and digested PCR products larger than lOObp, were routinely separated by 
horizontal gel electrophoresis on 1-2% agarose minigels (0.5 -  lg agarose/1 OOmls TAE 
buffer, 2.5pi lOmg/ml ethidium bromide). Samples were loaded in one-fifth to one-third 
volume of Orange G loading buffer, and a lkb ladder routinely used as a molecular size 
standard. Gels were run in xl TAE buffer containing 5 pi lOmg/ml ethidium bromide 
per 1 OOmls at 100V, until the orange G dye had reached the desired position. This was 
in turn dependant on the size of the fragments and the resolution required. DNA was 
then visualised by ethidium bromide fluorescence under UV light. To separate 
fragments < lOObp, 4% NuSieve GTG agarose was used for gels with a 50bp size marker 
as standard for sizing DNA fragments; electrophoresis performed as described above, 
whereas 1 -  1.5% low melting point agarose was used in preparative gels for the 
purification of DNA fragments.
2.3.5 Purification o f PCR products
PCR products were purified by one of two methods in order to obtain pure, concentrated 
DNA, which could be used in subsequent manipulations. For restriction enzyme digest 
and subcloning, PCR products were generally purified using the QIAquick PCR 
Purification Kit (Qiagen Ltd), according to the manufacturer’s instructions which 
removed unwanted components such as template DNA, excess primers, unincorporated 
nucleotides, salts, DNA polymerase and co-solvents if these were used in the reaction. 
To remove non-specific PCR products amplified during the PCR reaction, PCR products 
were electrophoresed on a 1-1.5% low melting point agarose gel, and then gel extracted 
using a QIAquick Gel extraction kit (Qiagen Ltd). The band of interest was excised after 
visualisation by ethidium bromide fluorescence under UV light. The DNA was then 
extracted and purified according to the manufacturer’s instructions and eluted in 
between 30-50pl of elution buffer (Tris pH 8.0).
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2.3.6 Restriction Enzyme digest of DNA
DNA was digested according to the manufacturer’s guidelines using the appropriate 
reaction buffer for any given enzyme. Digestion of non-genomic DNA was performed 
for 1.5 to 2 hours at the recommended temperature, which in the majority of cases was 
37°C. PCR products were digested in lOpl, and plasmids in 20-50pl..
2.3.7 Subcloning o f DNA
2.3.7.1 Subcloning into pCR-Script™ Amp SK(+)
This kit is manufactured by Stratagene and was in routine use for cloning of PCR 
products prior to sequencing, as it allows rapid and efficient cloning of blunt ended 
products with a low false positive rate, as blue/white colour selection is employed to 
pick colonies likely to contain inserts. The pCR-Script™ Amp SK(+) cloning vector is 
derived from pBluescript II SK(+) phagemid, comes pre-digested with Srf I, and contains 
an ampicillin resistance gene for antibiotic selection. Ligation reactions were carried 
according to the manufacturer’s instructions, using the appropriate quantity of purified 
PCR product (usually 50-150ng to give an insert: vector molar ratio of 40:1 to 100:1) 
diluted in water and lp l T4 ligase, and performed in the presence lpl of Srfi to digest 
any residual empty vector and increase ligation efficiency. The ligation reaction was 
then transformed into 200pl of Epicurian Coli XLl-Blue MRF’ Kan supercompetent 
cells supplied with the kit by heat shock, and the cells recovered in pre-warmed SOC 
medium by incubation for 1 hour at 37°C. The transformation reactions were then 
spread on LB- agar (LBA) plates containing X-Gal (1 ml of 25mg/ml in dimethyl 
formamide/litre of LBA), IPTG (25mg/ml (filter sterilised)/litre LBA) and 1ml of 
ampicillin (50mg/ml), and incubated overnight at 37°C. Plates were then incubated at 
4°C for 1 hour to enhance the blue colour of negative colonies, and facilitate colour 
selection. Pure white colonies expected to contain insert only were selected for further 
analysis.
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2.3.7.2 General ligation of DNA into vectors
Vector and inserts were digested with the appropriate enzyme and checked on an 
agarose gel. Vector and insert DNA was gel extracted using a QIAquick Gel extraction 
kit (QIAGEN Ltd) according to the manufacturer’s instructions. Ligation reactions were 
generally carried out in 20pl volumes containing lx ligation buffer, 25 ng vector, 10- 
lOOng insert DNA and 1U T4 ligase and incubated at 16°C overnight.
2.3.7.3 Transformation o f  bacteria with plasmid DNA
2.3.7.3.1 Preparation o f  chemically competent bacterial cells
A single, fresh colony of cells was used to inoculate a 5 ml LB culture, and grown 
overnight. 1 ml of this culture was used to inoculate 400mls of LB and this was grown at 
37°C until Aeoo was in the range of 0.37 -  0.38. The culture was then aliquoted into 8 x 
50ml pre-chilled Falcons and left on ice for 10 minutes. The cells were spun at 3000g 
and 4°C for 5 minutes, and the pellet resuspended in 10 mis ice-cold CaCL solution. 
After spinning again, each pellet was resuspended in 10 mis ice-cold CaCL solution and 
left on ice for 30 minutes. The cells were re-spun and the final pellets resuspended in 
1.5mls cold CaCL solution. lOOpl aliquots were made and stored at -70°
2.3.7.3.2 Chemical heat shock
The method originally described by Dagert and Ehrlich (1974) was followed. l-2pl of 
reaction mix was added to lOOpl of chemically competent cells in an Eppendorf and 
incubated on ice for 30 minutes. The cells were transformed by heat shock at 42°C for 
45 seconds and then chilled on ice for a further 2 minutes. The cells were then diluted in 
500pl of SOC and placed in a 37°C orbital shaker for 1 hour. The transformed cells 
were then plated out on LB agar containing the appropriate antibiotic.
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2.3.7.3.3 Preparation of electro-competent bacterial cells
5 mis overnight LB culture was inoculated with a single fresh colony of cells. 1 ml of 
the culture was then used to inoculate 500mls LB, and grown until the A6oo was in the 
range of 0.45-0.55. The culture was then placed on ice for 20 minutes and then 
harvested at 4°C, 3000rpm for 5 minutes and the pellet resuspended in 500mls of 10% 
glycerol and left on ice for 20 minutes. After another spin, the pellet was resuspended 
in 50mls 10% glycerol, and left for a further 20 minutes on ice. The suspension was then 
spun, the supernatant removed and the pellet resuspended in 400pl of 10% glycerol for 
every lOOmls of starting culture. Cells were stored in 40pl aliquots at -70°C.
2.3.8 SSCP Analysis
2.3.8.1 Preparation ofPC R Samples.
3pi of PCR product diluted 1:8 in APS or neat PCR product if generated by PCR using 
paraffin sections (previously described in section 2.3.3.3) was added to an equal volume 
of formamide buffer. Samples were then denatured for 5 minutes at 94°C and 
subsequently quick chilled on ice, ready for immediate loading onto an SSCP 
polyacrylamide gel.
2.3.8.2 SSCP Polyacrylamide gel electrophoresis.
Glass plates for use with Hybaid vertical electrophoresis tanks were cleaned with 
detergent and then wiped with 70% and 100% ethanol. The smaller of the two plates 
was siliconised by coating with dimethyldichlorosilane solution. Plates were sandwiched 
together separated by 0.4mm spacers and clamped along the edges. Acrylamide gels 
were prepared at 6% and 10% acrylamide concentrations as shown in Table 2.6 below, 
with 5% and 10% glycerol respectively and polymerised using 10% ammonium 
persulphate (APS) and TEMED. The gel mix was poured between the plates using a 50 
ml syringe, a sharks tooth or square tooth comb inserted, and the gel allowed to 
polymerise for 1-2 hours. The gel was run either at 4°C or room temperature at 30-50V
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for between 10-16 hours, until the cyanol marker reached the bottom of gel. The plates 
were then prised apart, the gel transferred onto 3mm Whatman chromatography paper, 
covered in cling film and dried on a gel dryer (Rapidry) at 80°C for 90 minutes. Gels 
were exposed overnight on Kodak X-Omat or Biomax paper at -70°C.
Table 2.4 SSCP gel mixes
10% Acrylamide 
10% Glycerol (60mls)
6% Acrylamide 
5% Glycerol (60mls)
10X TBE 6 mis 6 mis
50% glycerol 12 mis 6 mis
Acrylamide (Protogel) 20 mis 12 mis
MilliRo H20 21.6 mis 35.5 mis
10% APS 50 pi 50 pi
TEMED 400 pi 400 pi
2.3.9 DNA Sequencing
Manual sequencing was performed until the department purchased an ABI Prism 377 
Automated DNA sequencer (Perkin Elmer). Subsequent to this, all sequencing was 
carried out using this technique and some manual sequencing was repeated to improve 
result quality.
2.3.9.1 Preparation o f double stranded template by alkali denaturation
20pl of template was denatured by adding 20pl of 0.4M NaOH + lOmM Na EDTA and 
incubating the sample at 37°C for 30 minutes. The DNA was then precipitated using 
0.3M Na Acetate (pH 5.5) and 2-4x the volume of 100% ethanol for 15 minutes on dry 
ice. The pellet was washed briefly using 70% ethanol and kept in pellet form until use.
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The recovered pellet was resuspended in 7 pi of autoclaved MilliQ water immediately 
prior to use in the sequencing reaction.
23.9.2 Manual Sequencing
All sequencing reactions were performed using a Sequenase™ Version 2.0 DNA 
Sequencing kit and run in 0.5ml Eppendorf tubes. Annealing reactions were set up by 
adding 2pl 5x Sequenase Reaction Buffer and lp l (0.5-1.0 pM) of each primer to 7pl 
denatured template. The reactions were heated at 65°C in a beaker for 2 minutes and 
then allowed to cool slowly to <35°C over a period of about 20 minutes. The tubes were 
centrifuged briefly and samples chilled on ice. While the reactions were cooling, 2.5pl 
of each termination mix (dideoxy-G,A,T and C) were aliquoted into wells in a 
Microsample™ plate, which was kept covered at room temperature for use later. A 
labelling reaction mix consisting of lp l DMSO, lpl 0.1M DTT, 2pl diluted Labelling 
mix (1:5), 0.5pl 35S dATP and 2pl of diluted Sequenase (1:8 dilution in enzyme dilution 
buffer) was added to the ice-cold annealed DNA mixture, and this was incubated on 
slush (4°C) for 5 minutes. Finally, 3.5pl of each reaction mix was added to the 
termination mix (G,A,T and C) pre-warmed to 37°C with careful mixing and the 
termination reactions incubated at 37°C for 5 minutes. To stop the termination reactions, 
4pl of stop solution was then added sequentially to each. Samples could be kept at - 
20°C until gel electrophoresis.
23.9.3 Polyacrylamide gel electrophoresis o f  sequencing reactions
Sequencing plates were cleaned with detergent and wiped with 70% and 100% ethanol. 
The smaller plate was siliconised with dimethyldichlorosilane solution. Plates were 
sandwiched together separated by 0.4mm spacers and clamped along the edges. 
Denaturing gels were poured generally consisting of 6% acrylamide and 7M urea and 
made according to the manufacturer’s instructions. For 60 ml gels, 40mls of Sequagel 
diluent, 14.4mls Sequagel concentrate, 6 mis lOx TBE, 500pl of 10% APS and 30pl of 
TEMED were mixed and poured between the plates using a 50ml syringe. A sharks 
tooth comb was placed inverted along the top of the gel and then replaced with teeth into
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the gel, once this had set. Sequencing reactions were denatured for 2 minutes by placing 
the Microsample™ plate on a boil block for two minutes and then onto ice . 3 pi of each 
sequencing reaction was loaded onto the gel and samples electrophoresed at 70V for 2-4 
hours depending on the required length of run. Plates were then prised apart and the gel 
lifted off onto a sheet of 3MM Whatman chromatography paper, covered in cling film 
and dried for 90 minutes at 80°C on a Rapidry gel dryer. The gel was exposed to Kodak 
Biomax film at room temperature for 1 - 4 days.
2.3.9.4 Automated Sequencing
Sequencing reactions were performed using a Thermo Sequenase™ dye terminator 
cycle sequencing pre-mix kit (Amersham International). This system relies on the same 
principles as the chain termination methods described above, but employs ddNTP’s 
labelled with fluorescent dyes instead of radiolabelled ddNTP’s. Also the four ddNTP’s 
are labelled with different dyes, and since these can be distinguished on an automated 
sequencer, all four sequencing reactions can be set up in one tube and electrophoresed in 
the same gel lane. In addition, multiple rounds of template denaturation, primer 
annealing and DNA extension are carried resulting in a larger amount of product and 
hence a stronger signal. This approach is made possible by the use of a thermostable 
DNA polymerase, Thermosequenase™, which can withstand the repeated thermal 
denaturation at the beginning of each sequencing cycle.
Approximately 50-100ng of PCR product or lpg of plasmid DNA was used for 
reactions, lpl of a 1:2 dilution of the primer originally used to generate the PCR product 
(typically 50-100ng) or 5pM of plasmid primer (T7 or T3, as shown in Table 2.1) was 
added to the DNA and the mixture made up to 6pl with autoclaved MilliQ water. 4pi of 
sequencing reagent pre-mix was added as a final step and the samples cycle sequenced 
using the following cycle sequencing protocol:
Initial denaturation step at 94°C 2 minutes
Followed by,
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25 cycles of denaturation (94°C) 
annealing (50°C) 
extension (60°C)
30 seconds
3 minutes 30 seconds
30 seconds
Unincorporated dNTP’s were removed from the completed sequencing reactions by 
ethanol precipitation. 3.5pl of 7.5mM ammonium acetate was added to a 1.5ml 
Eppendorf tube, followed by the cycle sequencing sample. lOOpl of 100% ice cold 
ethanol was then added to each tube and samples precipitated for 20 minutes at -70°C, 
followed by centrifugation at 12,000 rpm at 4°C to pellet the sample. The supernatant 
was poured off and pellets washed in 250pl of 70% ethanol. Samples were then vacuum 
dried in a vacuum centrifuge for 5 minutes and stored at -  20 °C until further use.
For electrophoresis on the ABI PRISM™ 377 DNA Sequencer, 4.5% acrylamide gels 
were prepared. A pair of 42.4 x 25.5 cm sequencing plates (36cm well-to-read distance) 
were soaked for 30 minutes in 0.1M NaOH as necessary. They were then cleaned 
thoroughly with Alconox detergent, washed first with tap water, rinsed comprehensively 
with MilliRo water and allowed to dry upright before being clamped into position in a 
clean gel cassette, separated by 0.2mm spacers. 16.3mls of MilliQ water and 3.4 mis of 
acrylamide stock solution was added to 10.8g of urea and 0.2g of Amberlite deionising 
resin. This was mixed by stirring for 30 minutes before removing the resin by filter 
sterilisation. 3 mis of filtered xlO TBE was also added to yield a 30 ml gel mix. The 
polymerisation reaction was catalysed using 150j l l 1 of freshly made 10% APS and 2lp l 
of TEMED and poured using a 20 ml syringe between the plates. A sharks tooth comb 
was inserted flat side to the top of the gel, and clamped into place with a Perspex clamp. 
The gel was left to set for 1 Vi to 2 hours, after which the comb was removed, cleaned 
and reinserted with the teeth just penetrating the top of the gel. The gel cassette was 
clamped into a vertical position in the electrophoresis chamber of the automated 
sequencer. The upper and lower buffer chambers were filled with xl TBE and samples 
electrophoresed and analysed on the ABI PRISM™ 377 sequencer according to the 
manufacturer’s instructions using Sequencing Data Collection and Analysis software, 
run on a Apple Power Macintosh 7100 computer. The gel was pre-heated to 51°C by 
running for 20 -  30 minutes at 1,000V. Samples were resuspended in 4pl of formamide
104
loading dye supplied with the sequencing kit and then denatured at 94°C for 4 minutes. 
The samples were then placed on ice and 2pi loaded immediately in alternate lanes of 
the gel. The gel was run for 5 minutes before loading the remainder in the empty 
alternate gel lanes. This procedure was followed to maximise the clarity of reading of 
each lane during gel analysis. Samples were electrophoresed for either 7 hours at 
1,200V or 3.5 hours and 2,400V and a gel temperature of 51°C.
Direct sequencing was the method of choice for mutation screening, and 
electropherograms interpreted on the basis of substitution and changes in peak heights. 
However, if a mutation was detected, but the actual change could not be accurately 
interpreted, verification was through sequencing of single stranded subcloned products 
which provided an accurate method of delineating the actual sequence change.
2.3.10 General sequence analysis.
Computer programmes used for general sequence analysis and database searching were 
accessed at the Human Genome Mapping Project (HGMP) web site 
(www.hgmp.mrc.ac.uk). The Basic Local Alignment Tool (BLAST; Altschul et al 1990) 
was used to compare sequences with Genbank (Benson et al 1993), EMBLE (Emmert et 
al 1994) and SWISS-PROT protein database (Emmert et al 1994).
2.3.11 Microsatellite Repeat Analysis
Microsatellite repeats were amplified by PCR as described previously, using primers 
listed in Table 2.5. The forward primers were labelled with 5’ FAM (blue) and 5’ TET 
(green) respectively. 5pi of PCR product was first checked on a 2% agarose gel, and the 
remaining sample diluted either 1:5 or 1:10 in sterile purified water, depending on the 
quantity of product obtained.
lpl of diluted PCR product was added to 4pl of a loading mix made up of blue dextran 
(50mg/ml)/EDTA (25mM): deionised formamide: GENESCAN-350™ TAMRA 
internal lane standard in a 1:3:1 ratio. This dye-labelled internal dye standard (displayed
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as red) allowed accurate sizing of DNA fragments in the 35-350 bp range. Samples were 
denatured at 95 °C for 5 minutes and then held on ice before 2pl was loaded onto an 
acrylamide gel prepared exactly as described for automated sequencing. The gel was 
preheated to 48°C by pre-running at 1,000V for 20-30 minutes, and the samples 
electrophoresed for 2 hours at 3,000V and a gel temperature of 48°C on an ABI 
PRISM™ 377 DNA Automated Sequencer according to the manufacturer’s instructions 
using ABI PRISM™ GeneScan™ Analysis software.
2.3.12 Detection o f glomerular WT1 and nephrin protein expression
Slides were provided by Professor Risdon, Professor of Histopathology, Great Ormond 
Street Hospital NHS Trust. These were first de-waxed by two histaclear washes, 
followed by progressive washes in diminishing concentrations of ethanol as follows: 
100%, 95%, 75%, 50% and 30%. The slides were rinsed in purified water, and then 
washed in PBS for 1-2 minutes. 4% peroxide was applied, followed by another PBS 
wash. Citric Acid (pH 6.0) was then applied and the slides micro-waved at high heat for 
10 minutes. They were then cooled and after a further PBS wash, the slides blocked for 
half an hour with 10% calf fetal serum. WT1 (Santa Cruz) or nephrin (gift from Karl 
Tryggvason) primary antibodies were then applied in a 1:80 dilution and the slides left 
for 1 hour in a 37°C incubator. The secondary antibody labelled with biotin was then 
applied in a 1:100 dilution for half an hour and finally the tertiary antibody (streptavadin 
and peroxidase) was applied in a 1:100 dilution in TBS. DAB was then applied briefly, 
the slides washed and stained with methyl green. The slides were washed with water and 
100% butanol, dried and mounted.
2.3.13 Yeast Analysis
2.3.13.1 Genotyping o f yeast strainY190
Yeast strain Y190 (MATa gal4 gall80 his3trpl-190 ade2-101 ura3-52 leu2-3,-122 + 
URA3::GAL-> lacZ, Lys::GAL—»HIS3 cyhr) was used for yeast two hybrid analysis. 
This was first grown on appropriate selective minimal media with sequential omission 
of His, Trp, Ade, Ura, and Leu to ensure that the yeast genotype was correct. Once this
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had been established, a yeast glycerol stock was made, stored at -70°C and the yeast 
could be used for transformation experiments after initial propagation on YAPD 
complete medium.
2.3.13.2 Preparation o f  yeast competent cells fo r  transformation
A colony was used to inoculate 200mls of minimal medium + His, Trp, Ade, Ura, and 
Leu and grown overnight at 30°C. This was then used to inoculate 500 mis YAPD to an 
OD of 0.2 -  0.25 and grown to until 0.5 to 0.8. The culture was spun for 5 minutes at 
3.500 rpm, washed with 100 mis of MilliQ water and re-spun for 5 minutes. The pellet 
was resuspended in 50mls LiSORB warmed to 30 - 50°C, and spun at 3.500 rpm, 
followed by re-suspension in 15 mis pre-warmed LiSORB + 75pl 2M DTT and lyticase 
(1000U). This was spun at 2000 rpm for 5 minutes, washed in a further 15mls LiSORB 
and respun at 2000 rpm for 5 minutes. The final pellet was resuspended in 1 ml of 
LiSORB, and either used directly or 75pl DMSO added and the suspension aliquoted 
prior to storage at -70°C. Stored cells were thawed rapidly for 1 minute at 30°C prior to 
use.
2.3.13.3 Transformation o f  pA S l-W T l +or - KTS into the Y190 strain
0.1 pg pASl plasmid + or -  WT1 KTS Gal 4 fusion protein DNA was added to 100 pi of 
Y190 competent cells. 300pl of 0.1M LiAcetate 0.1M TE and 40% PEG was also added 
and the mixture incubated for 30 minutes at 30°C. 70pl of DMSO was added and the 
DNA transformed into the yeast cells by heat shock at 42°C. Cells were spun for 10 
seconds and resuspended in 500pl of MilliQ water prior to plating on minimal medium 
+ Trp.
2.3.13.4 Yeast protein extraction to check expression o f bait protein
Six colonies were picked and re-streaked on minimal medium -Trp. Once these had 
grown, a generous scoop was taken to inoculate 20 mis of minimal medium -Trp, and 
the sample vortexed. The culture was grown overnight at 30°C, an OD estimated and a
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further 5 mis of minimal medium -Trp inoculated to an OD of 0.2. This was grown at 
30°C top an OD of between 0.3 and 1.1.5 mis of this culture was pulse spun for 10 
seconds, the pellet resuspended in 75pl of cracking buffer and the suspension vortexed 
for 30 seconds. This was then subjected to two freeze cycles of 1 minute in liquid 
nitrogen, followed by 2 minutes at -70°C with a fifteen second vortex at each step. The 
sample was boiled at 100°C for 10 minutes, vortexed and 20 pi subjected to SDS-PAGE 
electrophoresis.
2.3.13.5 Yeast Cell preparation fo r  library screening
A colony transformed with GALA-WT1 was used to inoculate lOOmls of minimal 
medium -Trp, for pASl bait plasmid selection, and this was grown overnight at 30°C to 
saturation. The following day, the culture was used to inoculate 500mls of YAPD such 
that within 2 generations (3-4 hours), the ODeoo had reached between 0.5 -  0.8. Cells 
were then harvested at 5000rpm for 5 minutes, washed with 100 mis YPD and 
resuspended in 50 mis LiSORB, followed by 30minute incubation at 30°C. The cells 
were then spun down again, resuspended in 625 pi of LiSORB and chilled on ice until 
further use.
2.3.13.6 Small scale library transformation
The carrier DNA mix was prepared by adding 800pl of LiTE or LiSORB to 200pl 
cooled to room temperature, boiled sheared salmon sperm DNA(20mg/ml). l-2pg of 
library DNA was combined with 50pl of the carrier mix, and 40pl of prepared yeast 
cells added. Carrier mix alone was used for a negative control. The 40pl of cells + 
carrier/library DNA mix was then incubated for 30 minutes at 30°C, followed by heat 
shock at 42°C for 7 minutes. The cells were recovered by washing 2-3X with XI TE, 
then resuspended in 200pl of xlTE and plated on the appropriate selective media.
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2.3.13.7 Large scale library transformation
A carrier DNA mix was prepared using 800pl LiTE or LiSORB to 200pl of cooled to 
room temperature, boiled sheared salmon sperm (20mg/ml). 40pg library DNA was 
combined with the carrier mix and 625pi of freshly prepared yeast competent cells and 
incubated at 30°C for 30 minutes. Carrier mix and cells alone were used as a negative 
control. 900pl of LiTEPEG solution was then added for every lOOpl of cell-DNA mix 
(usually 18 mis LiTEPEG solution added to 2 mis mix), and the mixture incubated for a 
further 30 minutes at 30°C. Cells were heat shocked at 42°C for 7 minutes and 5pi 
inoculated onto minimal medium -Trp Leu plates to test transformation efficiency. The 
remaining cells were recovered by adding 100 mis liquid minimal medium-His-Trp-Leu 
and shaking for 1-3 hours at 30°C. Cells were then harvested and resuspended in 15 mis 
of liquid minimal medium-His-Trp-Leu. 300pl of cells were then plated on selective 
media + 50mM 3AT and incubated at 30°C for approximately 5 days.
2.3.13.8 X-Gal colony filter assay
Colonies that grew after 3 to 5 days were then tested for p-galactosidase activity using 
the X-Gal colony filter assay, p-galactosidase assay buffer was prepared by adding 
137pl of P-mercaptoethanol and 1.25 ml X-Gal (40mg/ml in DMSO) to 50mls Z-buffer. 
A circle of 3MM paper was placed in a 150mm petri dish and 6 mis of assay buffer 
added, ensuring that the paper soaked up the buffer uniformly. Colonies were lifted onto 
Hybond N+ nylon filters ensuring that the filter and plates were orientated with respect 
to each other. The filters were then immersed in liquid nitrogen for 30 seconds and 
allowed to thaw. These were then placed colony side up into the petri dishes containing 
assay buffer, and the filters incubated at 30°C for a maximum of 5-6 hours, or un til a 
blue coloration appeared. Blue colonies were taken for further study.
2.3.13.9 Recovery o f  activation domain plasmid DNA from  yeast.
A  single transformant colony was used to inoculate 5 mis of selection medium and 
grown overnight at 30°C. 1.5 mis of the culture was then spun at 12,000rpm for 5
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seconds to pellet the cells. The supernatant was discarded, and the pellet resuspended in 
200pl yeast lysis solution. 200pl of phenol chloroform mix (1:1) and 0.3g of acid- 
washed beads were added and the mixture vortexed vigorously for 2 minutes. This was 
then spun for 5 minutes at 12,000rpm at room temperature, and the supernatant 
transferred to a clean Eppendorf. The DNA was ethanol precipitated and resuspended in 
20pl X1TE. The DNA was then transformed into HB101 cells by electroporation and 
plated onto M9 minimal medium selecting for leucine.
2.3.13.10 Analysis o f positives
Once the yeast DNA had been transformed into HB101 bacterial cells, these were grown 
overnight and colonies picked and cultured overnight in LB ampicillin liquid medium. 
Plasmid DNA was extracted using the alkaline lysis miniprep technique and checked for 
inserts by Not I restriction enzyme digest. Inserts were then sequenced using VP16 
primers and analysed using database analysis programmes accessed through the Human 
Genome Mapping Project (HGMP) at www.hgmp.mrc.ac.uk.
2.3.14 Electromobility Shift Assay (EMSA)
2.3.14.1 Preparation o f  nuclear extracts by detergent cell lysis
Renal tissue was homogenised in Buffer A containing protease inhibitors using a 
Dounce homogeniser. An equal volume of Buffer B containing protease inhibitors was 
added, the solutions mixed, and incubated on ice for 5 minutes. Nuclei were then 
pelleted by centrifugation at 2000g for 5 minutes at 4 C, whereas the supernatant 
containing the cytoplasmic fraction was aliquoted and stored at -70°C. The pellet was 
resuspended in 0.5 mis Buffer A containing protease inhibitors and layered onto 5 mis 
of 0.8M sucrose (in Buffer A). This was spun for a further 10 minutes at 4000g at 4 C to 
sediment the nuclei, which were then washed once in Buffer C containing protease 
inhibitors. Nuclei were either used immediately or resuspended in NSB for storage at - 
70 C.
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2.3.14.2 Estimation of nuclear concentration.
Cell lysis was verified by light microscopy, using 0.4% Trypan Blue as a stain. Intact 
cells exclude this dye, but upon lysis nuclei stain blue. Nuclear concentration was 
estimated from the OD26o of an aliquot lysed in HSU buffer. A 10 pi aliquot of nuclei 
was resuspended in 0.5 ml HSU buffer, boiled at 100°C for 5 minutes, and an OD26o 
taken. Each mammalian nucleus is estimated to contain approximately 6pg of DNA, and 
the OD260 corresponds to approx. 70% genomic DNA, 30% nuclear RNA.
2.3.14.3 Nuclear extracts.
Nuclei were prepared in Hypotonic Buffer and purified through a 0.8 M sucrose cushion 
as follows. First, nuclei were resuspended in Hypotonic Buffer at 5xl07 nuclei/ml and 
an equal volume of 2x extraction buffer (0.6M KC1 and 1% NP-40 in Hypotonic Buffer 
containing protease inhibitors) added. This was extracted at 4 C for 1-2 hours on a 
rotating wheel, followed by centrifugation at 25,000g for 15 minutes to sediment nuclear 
debris. The supernatant was removed, aliquoted and snap-frozen for storage at -70°C.
2.3.14.4 Preparation o f  P labelled probes 
2.3.14.4.1. Probe labelling
Single stranded palindromic oligonucleotides corresponding to the region of interest 
within the NPHS1 promoter, namely 5’cccaacacttggggaggccaaggtgggagg 3’ and the 
antisense equivalent were chemically synthesised by Genosys UK Ltd. The 
oligonucleotides were annealed in lOOpl of lOOmM NaCl by boiling in a beaker for 5 
minutes, and then allowing the mix to cool slowly to room temperature. 100-150ng (1- 
2pl) of the annealed oligonucleotides was 5’-end labelled using l-2pl T4 polynucleotide 
kinase (T4 PNK) in 2pl of PNK buffer (lx) and 2-3pi of [y-32 P] ATP in a total reaction 
volume of 20pl and incubating the mixture at 37°C for 1 Vi - 2 hours. T4 PNK enzyme 
activity was then inactivated by adding 480pl of xl TE, giving a total volume of 500pl.
I l l
2.3.14.4.2 Removal of unincorporated y- P- dATP and probe elution.
NAP5 Sephadex G-25 columns were used. These were washed 2-3 times with xl TE to 
equilibrate (l-2mls) and then the 500pl probe sample was applied to filter matrix in 
column discarding eluent. Finally the probe was eluted in 1ml xl TE into 1.5ml 
Eppendorf. The aim was to have at least 50% incorporation, which was measured by 
cpm/dpm of l-2pl pre-filtration sample (500pl) compared to a 2-4pl post-filtration 
sample.
2.3.14.4.3 Binding Reaction
Once the gel was undergoing pre-electrophoresis (as described in the next section), 
binding reactions were performed so that samples could be loaded immediately. 
Reactions were performed in 20pl volumes and contained labelled probe, competitor 
DNA and protein sample in the relevant buffer, lpg poly (dl-dC) (1 mg/ml), l-3pg of 
nuclear protein extract, 5 pi 4x BBO buffer, lp l 10 pg/ml BSA (binding stabiliser) and 
lpl ImM PMSF/protease cocktail were mixed together and made up to 17pl with 
MilliQ H2O.This was incubated at room temperature for 20 minutes and then 3pl y- 32 P 
-dATP probe was added, followed by a further incubation for 30 minutes at room 
temperature or on ice. 2pl sample loading buffer (150mM Tris (pH7.6), 20% glycerol, 
0.25% bromophenol blue was added and samples chilled on ice before loading.
2.3.14.4.4 EMSA Gel Electrophoresis
Plates were thoroughly cleaned with detergent, dried and wiped with 70% ethanol. 
These were sandwiched together using 1.0mm spacers, clamps applied at equal tension 
and the clamped plates placed into a Pharmacia Biotech gel cassette. A 5% non­
denaturing polyacrylamide gel mix consisting of 6 ml polyacrylamide (40% 49:1 
acrylamide/bis-acrylamide), 1.25ml lOx TBE (x0.25 TBE) and 42mls MilliQ water was 
made using 300pl 10% APS and lOOpl TEMED for polymerisation, and poured 
between the plates. Once set, the gel was put at 4°C to cool, generally overnight. 2L of 
0.25x TBE was made up and also cooled to 4°C. The gel was pre-run in a Pharmacia
112
Biotech gel tank in x0.25 TBE for 60-90mins at 150V at 4°C, and then the samples 
loaded and electrophoresed at 180V for 2.8 hours, also at 4°C. The gel was then dried at 
80°C for 1 hour on a Rapidry gel dryer and exposed on Kodak MXB Xograph film at 
-70°C overnight.
2.4 Patient selection and control material
The patients studied in this project were drawn primarily from the specialised tertiary 
referral nephrotic syndrome clinic and the Nephrology ward at Great Ormond Street 
Hospital NHS Trust. In addition, patients were acquired through collaborations with 
other Paediatric Nephrology units, Paediatric Endocrinology units, and Clinical Genetics 
departments in the UK, following calls for patients made during interim presentations of 
the work at the Royal College of Paediatrics and Child Health annual conference, the 
Renal Association, British Society for Human Genetics and British Association for 
Paediatric Nephrology. Patients were also obtained from overseas through further data 
presentations at European Society of Paediatric Nephrology, International Society of 
Paediatric Nephrology, European Society of Paediatric Endocrinology and the American 
Society of Nephrology through direct liaison with local clinical teams. The largest 
cohort of patients studied from outside the UK was from the island of Malta, through 
collaboration with Dr Victor Grech, Senior Registrar at St Luke’s Hospital, 
Guardamangia, Malta. Almost all of the Maltese patients were assessed as inpatients at 
Great Ormond Street Hospital, by virtue of a special arrangement between the Maltese 
and British governments for their clinical care.
The majority of patients studied had non-syndromic nephrotic disease confined to the 
kidney. However two types of syndromic disease were also studied, namely Denys 
Drash and Frasier syndromes associated with intersex and Wilms’ tumour and 
gonadoblastoma respectively. Again, these patients predominantly originated from the 
Paediatric Nephrology and Endocrinology units at Great Ormond Street Hospital NHS 
Trust and Drs Detlef Blockhause in Boston, USA and Dr Mariana Arcena in Santiago, 
Chile.
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Control DNA samples were also obtained from consenting individuals, with thirty 
English and Asian normal controls and twenty Maltese normal controls studied in total. 
For NPHS1 mutation analysis, there was further access to a database of 50 controls 
originating from the United States, Scandinavia and Europe, characterised by Professor 
Karl Tryggvason’s teams at the University of Oulu, Oulu, Finland and the Karolinska 
Institute, Stockholm, Sweden.
Patients were examined either at Great Ormond Street Hospital NHS Trust or by the 
referring specialist clinician. A diagnosis of congenital nephrotic syndrome was made 
on the basis of the presence of proteinuria at birth or nephrotic syndrome appearing 
within the first three months of life. The additional feature of large placenta was present 
in many cases, indicative of significant proteinuria in utero. Early onset nephrotic 
syndrome was defined as a nephrotic syndrome appearing after 3 months, but before 2 
years of age. Clinical diagnosis was confirmed by a family history if present and in 
addition, a renal biopsy performed after three months of age. Further sub-classification 
was based on renal histological appearance, examined in the majority of cases by 
Professor Risdon, Professor of Histopathology at Great Ormond Street Hospital NHS 
Trust. Histology determined by the referring centre, was also reviewed if possible at 
Great Ormond Street Hospital NHS Trust. Patients were identified as having renal 
histology compatible with congenital/early onset CNF, FSGS, or DMS as defined 
previously, and wherever possible, the histology was confirmed in at least two centres.
If stored blood or DNA was not already available for laboratory analysis, referring 
clinicians were asked to obtain samples of venous blood from consenting individuals, 
and these were forwarded for DNA extraction. Karyotyping was performed at the 
referring hospital as necessary. In accordance with the guidelines laid down by Great 
Ormond Street Hospital NHS Trust and Institute of Child Health Research Ethics 
committee, the laboratory findings of this study whether positive or negative were fed 
back to the referring clinician, who was then able to inform the patients, their GP’s and 
other clinicians involved in the patients care. Identification of a causative mutation in 
the proband, allowed the referring clinician to offer mutation screening to the other 
members of the family, followed by the appropriate genetic counselling if this was 
accepted.
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CHAPTER 3: Molecular analysis of the WT1 gene in nephropathic 
phenotypes associated with Denys Drash and Frasier syndrome
3.1 Background
As outlined in Chapter 1, disruption of the glomerular filtration barrier is characterised 
by leakage of plasma proteins into the urine, resulting in nephrotic syndrome. 
Presentation during childhood is typically as a congenital nephrotic syndrome (0 to 3 
months), an early onset nephrotic syndrome (4 to 36 months), or later in childhood. 
Although Finnish type congenital nephrotic syndrome is the most common type of 
hereditary nephrotic syndrome seen in early life, less common aetiologies such as 
diffuse mesangial sclerosis (DMS) and focal segmental glomerulosclerosis (FSGS) also 
form a significant component of the overall pathology. These may occur together with 
developmental abnormalities in other organ systems, and importantly form the defining 
features of Denys Drash syndrome (DDS), a triad of DMS, intersex and Wilms’ tumour 
(Denys et al, 1967; Drash et al, 1970), and Frasier syndrome (FS), characterised by 
FSGS, intersex and gonadoblastoma (Frasier et al, 1967; Moorthy et al, 1987). 
However, the characteristic nephropathies connected with these syndromes occur more 
commonly as disorders confined to the kidney, and although the association of 
constitutional heterozygous WT1 gene mutations with the majority of cases of DDS (e.g. 
Pelletier et al, 1991; Baird et al, 1992) is well described, it was unknown whether 
mutations also affected this wider population. The initial aim was therefore to identify 
whether WT1 gene mutations are also responsible with DDS/FS nephropathic 
phenotypes occurring in isolation. Glomerular WT1 protein expression was examined in 
affected individuals, in conjunction with screening for WT1 mutations (Section 3.2). 
Secondly, although preliminary investigation did not detect WT1 gene mutations in FS 
(Poulat et al, 1993), it was noted that only exonic regions and a very small number of 
cases had been screened. In view of this, four new cases of FS were assessed for the 
presence of WT1 mutations (Section 3.3), and functional analysis subsequently 
performed to establish the effect of the abnormalities detected on + and -  KTS protein 
isoforms (Section 3.4). Finally, yeast two hybrid analysis was used to determine
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downstream protein binding partners of both + and -  KTS WT1 isoforms, in order to 
identify novel renal genes contributing to the pathogenesis of glomerular disease 
(Section 3.5). Results are discussed in Section 3.6.
3.2 WT1 gene mutations are an infrequent cause of isolated DMS and 
FSGS
3.2.1 Patient selection
A total of twenty-nine cases of congenital and early onset nephrotic syndrome were 
studied. A diagnosis of DMS or FSGS was established on the basis of the clinical 
history, and confirmed by renal biopsy and/or by post-mortem renal histology. Patient 
details are summarised in Table 3.1 and 3.2. Twenty-six cases had documented 
karyotype analysis, and any coincident abnormalities of the internal gonads were 
determined by pelvic ultrasound, or by laparotomy. The majority of surviving patients 
with isolated DMS were followed up with yearly renal ultrasounds to exclude Wilms’ 
tumour formation. Other congenital malformations were investigated by clinical 
examination and the appropriate investigations. None of the patients with psychomotor 
abnormalities fitted any particular syndrome.
Twenty-two of the cases studied had a renal histology of DMS, unaccompanied by the 
extra-renal features of DDS or FS. Twelve had a diagnosis of congenital nephrotic 
syndrome, and the remainder early onset nephrotic syndrome, with onset of disease 
ranging from between six and eighteen months. Of note, case 14 had an equivocal report 
for karyotype, and thus a possible intersex state. However, by the time of study, case 14 
had died and the karyotype analysis could not be repeated. Three cases of DDS (cases 
20, 21 and 22; Table 3.1) were also analysed. Case 22 represented a novel diagnosis of 
DDS, whereas characteristic R394W WT1 missense mutations had already been detected 
in cases 20 and 21 (Baird et al, 1992), and these were used as positive controls. Seven 
cases of isolated FSGS, again unaccompanied by features of DDS or FS were also 
screened for WT1 gene mutations.
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3.2.2. WT1 protein expression is normal in cases of DMS, FSGS and DDS
Glomerular WT1 protein expression was examined in selected cases of DMS and 
congenital/ early onset FSGS, occurring in the absence of other features of DDS or FS. 
Renal biopsy specimens from cases of benign haematuria were used as normal controls. 
Immunoperoxidase staining was performed using a WT1 monoclonal antibody (Santa 
Cruz) raised against the C-terminal portion of the WT1 protein. No abnormalities of 
expression were detected in the glomeruli of cases of isolated DMS, FSGS, or in the two 
cases of DDS with pre-determined R394W mutations (Figure 3.1). This indicated that if 
WT1 gene mutations were present, these did not appear to result in abnormalities of 
WT1 protein expression. This suggested that either missense mutations, or mutations 
that did not result in either truncated or unstable proteins might be responsible.
3.2.3 WT1 gene mutations are not present in isolated DMS and FSGS
The two most common DDS mutations are located in exon 9 (1180 C—»T R394W 60%, 
1186 G—»A D396N 15%), and abolish an Rsr II site in zinc finger 3 (Little et al 1993). 
This was used as an initial screen to exclude cases of DDS that might have been missed 
through incomplete clinical criteria. As expected, heterozygous loss of the site was 
observed in cases 2 0  and 2 1 , as well as case 2 2 , whose clinical phenotype was 
compatible with DDS. Cases 1 to 19, and 23 to 29, showed normal restriction enzyme 
digest, virtually excluding a diagnosis of DDS. A representative agarose gel is shown in 
Figure 3.2. Single stranded conformational polymorphism (SSCP) was then used to 
screen WT1 exons 1 to 10 and intron/exon boundaries for mutations, performed at 4°C 
under two different non-denaturing polyacrylamide gel concentrations ( 6  % and 1 0 %). 
In addition, WT1 exons 5, 8  and 9 were directly sequenced in all affected individuals.
Any sequence changes were first detected as an aberrant band on SSCP analysis. 
However, since this was unable to indicate whether the change represented a silent 
polymorphism or a change likely to affect gene function, any samples demonstrating 
changes detected on SSCP were examined further by sequencing. The only sequence 
changes detected were in case 14, who demonstrated a novel C—»T polymorphism in 
codon 178 (exon 4) conserving a threonine, and in case 16 and three of the parents
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screened, who all carried a previously described polymorphism, an A->G transition in 
codon 301 (exon 7) conserving an arginine (Groves et al 1992). This base change 
destroys an Afl III restriction enzyme recognition site, which allowed additional 
confirmation by Afl III restriction enzyme digest. Aside from these two polymorphisms, 
DDS cases 20 and 21 showed expected 1180 C—»T mutations (R394W) in exon 9, as 
previously reported by Baird et al, 1992a. The same mutation was also detected in case 
22, a case of congenital DMS, with a 46XY karyotype and hypospadias, but no Wilms’ 
tumour. Since case 22 died of septicaemia at the age of four months, these clinical 
features were compatible with a diagnosis of DDS despite the lack of Wilms’ tumour at 
presentation.
Direct sequencing provided corroborative evidence that WT1 gene mutations were 
absent in the 19 patients with isolated DMS, and 7 patients with isolated FSGS as had 
been suggested by SSCP analysis and confirmed the polymorphisms detected. These 
findings provided the first evidence for the genetic heterogeneity of nephropathic 
phenotypes associated with Denys Drash and Frasier syndromes (Koziell et al, 1998). 
Results are tabulated in Tables 3.1 and 3.2, and representative results for the R394W 
missense mutation detected in cases 20, 21 and 22 are shown in Figure 3.3.
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Figure 3.1 (a) Representative picture of immuno-peroxidase staining for normal 
WT1 protein expression in isolated DMS.
Brown immunoperoxidase staining 
of podocyte nucleus to show 
nuclear expression of the WT1 
protein
(b) Control glomerulus showing normal distribution of WT1 protein 
expression.
Brown immunoperoxidase staining of 
podocyte nucleus to show nuclear 
expression of the WT1 protein
Figure 3.2. Representative Rsr II restriction enzyme digest analysed on a 2% 
agarose g e l. The only sample to demonstrate heterozygous loss is sample 20, 
with DDS and a R394W mutation (demarcated by *).
*
1Kb 1 2 3 20 4 5 6 7 8
ladder
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Table 3.1 Clinical details and results of WT1 mutation analysis of cases with a renal histology compatible with DMS (n=22)
Case Karyotype Nephropathy Syndromal Genital Other renal Family WT1 gene age at last
onset of ESRF/ nephrec transplant tumour status or extra- history mutation follow-up
proteinuria Dialysis -tomy int/ext renal
1 46 XX day 1 yes no yes no F psychomotor yes no:exons 1-10 10 years
2 46 XX day 1 yes yes R, L yes no F no no no:exons 1-10 4
3 46 XX day 1 yes yes R, L no no F no yes no:exons 1-10 8
4 46 XY day 1 yes no no no M no no no: exons 1-10 died 3 1/2
5 46 XY >1 year yes yes R, L yes no M no no no:exons 1-10 13
6 46 XY >1 year yes yes R,L yes no M no no no:exons 1-10 11 1/2
7 46 XY >1 year no no no no M no no no:exons 1-10 3
8 46 XX day 1 no no no no F
psychomotor,
hypothyroid no no:exons 1-10 died: 7 months
9 46 XY 6 months yes no yes no M
pulmonary
stenosis no no:exons 1-10 14 1/2
10 46 XX >1 year no no no no F psychomotor no no:exons 1-10 died 3 1/2
11 46 XY 18 months yes no no no M no no no: exons 1-10 5 1/2
12 46 XX day 1 yes no no no F psychomotor ? yes no: exons 2-10 died: 2 months
13 NK dayl yes no no no F no yes no: exons 2-10 died: 7 months
14 46 XY dayl no no no no F no no exon 4 polym died: 3 months
15 46 XX dayl no no no no F psychomotor no no: exons 2-10 died: 10 months
16 46 XY day 1 no no no no M no no Afllll polym died: 2 months
17 NK day 1 no no no no NK no no no: exons 2-10 died: 10 weeks
18 NK day 1 no no no no NK no no no: exons 2-10 died: 8 months
19 46 XX 1 year yes no no no F
L dysplastic 
kidney no no: exons 5,8,9 2 1/2
20 46 XY >2 years yes yes R, L yes Wilms' F no no exon9: 1180C->T 
R394W
13
21 46 XY 1 year yes yes R,L yes Wilms' ambiguous no no exon9: 1180C->T 
R394W
11 1/2
22 46 XY day 1 yes no no no
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hypospadias no no exon9: 1180C-»T 
R394W
died: 3 months
Table 3.2 Clinical details and results of WT1 mutation analysis of cases with a renal histology compatible with FSGS (n=7)
Case Karyotype Nephropathy Syndromal Genital Other renal Family WT1 gene age at last
onset of ESRF/ nephrec-transplant tumour status or extra- history mutation follow-up
proteinuria dialysis tomy int/ext renal (exons 1-10)
23 46 XX 4 months no no - F no no no 12
24 46 XX > 1year ? ? ? - F no yes no died
25 46 XY > 1year ? ? ? - M no yes no died
26 46 XX Day 1 no no no - F no yes no 8
27 46 XY 18 months yes no yes - M no yes no 14
28 46 XY > 1year yes ? yes - M no
spondyloepiphyseal
no no 15
29 46 XX 1 year yes yes R,L no - F dysplasia no no died
KEY: NK: not known; R: right; L.left; F: female; M:male
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Figure 3.3 (A to D). The typical 1180 C-»T (R394W) mutation detected in >60% of 
DDS cases, used as a positive control for this study and detected as a novel event in 
case 2 2 .
(A) WT1 exon 9 1180 C—>T missense mutation 5’ to 3’
i
A U f » C  T C  C N G G T
(B) WT1 exon 9 normal control
4-
A A A G T T C T C C C G  G T C  
50
(C) WT1 exon 9 1180 C-»T missense mutation 5’ to 3’
4-
(D) WT1 exon 9 normal control
4-
G G T C G  G ANC  G G G  AG A A C T T T C G t  
100 110 120
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3.3 WT1 gene mutations are responsible for Frasier Syndrome (FS)
In common with DDS, FS is also characterised by intersex and renal disease, although 
the associated nephrotic syndrome typically results from FSGS rather than DMS. 
Patients may develop gonadoblastoma, but there is no true predisposition to Wilms’ 
tumour. Since mutations of the WT1 gene were not initially detected in this condition 
(Poulat et al, 1993), its molecular origins were thought to differ from DDS. However, 
since there were a number of limitations to this particular study, four new cases of FS: 
DG, CC, SS and CO were re-examined for mutations of the WT1 gene. Clinical details 
are given in Table 3.3. All were phenotypically normal girls, but with a 46XY 
karyotype and characteristic features of FSGS nephropathy. DG and CC presented with 
gonadoblastoma, whereas SS presented with nephrotic syndrome and delayed puberty, 
and CO with nephrotic syndrome, short stature and delayed puberty. Nephrotic 
syndrome developed between 3 and 8  years of age in all four cases, with a mean age of 
onset of 5 years. DG and CO had developed renal failure and had been transplanted. 
None of the cases had Wilms’ tumour. The clinical features are described in Table 3.3.
The focus for mutation screening was the region of the mutation “hot spot” for DDS. 
Intronic PCR primers amplifying exon 9 of the WT1 gene together with the intron/exon 
boundaries were designed 34 base pairs upstream, and 77 base pairs downstream of the 
exon 9 coding region. This ensured any mutations within these boundary areas would 
be reliably detected. Direct sequencing of PCR products on an ABI 377 detected 
mutations in all four FS cases examined, but not in parents or siblings. Three carried 
identical heterozygous 1228+5 (G —» A) substitutions, and one case a 1228+4 (C —» T) 
substitution within the exon 9 splice donor site (Table 3.3; Figures 3.4 A to D), which 
indicated a consistent association between intronic mutations within the splice donor 
site of exon 9 of the WT1 gene, and FS. This area lies within the second and highly 
conserved region of alternative splicing of the WT1 gene, which results in inclusion or 
exclusion of three amino acids K, T and S in WT1 protein isoforms. Sequence analysis 
of exon 9 using Neural Network, a splice site prediction programme identified these 
two splice donor sites (http://www.fruitflv.org/seq tools/splice.html). Subsequent 
introduction of the two base substitutions detected in the cases of FS, and reanalysis of 
the two sites resulted in a marked reduction of the score of the second splice site
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(Figure 3.5). This finding suggested that the effect of these mutations might be to 
severely impair the use of the second alternative splice donor site, and thus alter the 
ratio of WT1 protein isoforms produced.
3.4 Intronic WT1 gene mutations in Frasier Syndrome result in 
defective alternative splicing of WT1, and reversal of the normal +/- 
KTS isoform ratio
Since the predicted effect of the two heterozygous WT1 gene mutations detected in FS 
was to severely impair alternative splicing at the second splice donor site in exon 9, the 
most likely outcome was an alteration of the normal +/- KTS protein isoform ratio, 
suggesting that aberrant splicing might underlie the pathogenesis of FS. Alternative 
splicing of the WT1 gene normally results in four different zinc finger protein isoforms 
with either inclusion or exclusion of exon 5 encoding 17 amino acids and/or three 
amino acids, K T S  (Lys, Thr, Ser) between the third and fourth zinc fingers, generating 
four splice isoforms. In general -KTS isoforms bind DNA well, and are thought to 
participate in transcriptional regulation, whereas +KTS isoforms do not bind DNA and 
may modulate RNA metabolism (Larsson et al, 1995; Ladomery et al, 1999; Englert et 
al, 1995). The insertion of KTS between zinc fingers 3 and 4 is thought to increase the 
flexibility of the linker, preventing DNA binding (Laity et al, 2000). The usual ratio of 
+ and -  KTS protein isoforms detected is approximately 2:1 in all tissues tested (Klamt 
et al, 1998), and in view of the different physical properties conferred to the protein 
isoforms, their interplay is clearly critical for correct gene function.
Archival gonadoblastoma tissue was available from case DG, which allowed the 
analysis of in vivo expression of WT1 protein isoforms in FS. RT-PCR was performed 
with exon specific primers to quantify the protein isoform ratio in DG, one specimen of 
normal kidney and one specimen of Wilms’ tumour. Experiments performed in parallel 
detected a range of 1.5 to 2.8 for the +/- KTS isoform ratio in archival Wilms’ tumours 
not associated with WT1 gene mutations (Klamt et al, 1998).
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Table 3.3 Clinical characteristics of the four FS cases screened in this study (n=4)
case
DG
CC
SS
CO
karyotype nephropathy gonadal syndromal family WT1
onset of histology ESRF/ nephrec- transplant development tumour history mutation
protienuria dialysis tomy
(years)
46 XY 5 FSGS yes no yes gonadal dysgenesis gonadobalstoma no +5 G to A
rudimentary uterus
46 XY 6 FSGS yes no no gonadal dysgenesis gonadobalstoma no +4 C to T
46 XY 8 FSGS yes no no gonadal dysgenesis no no +5 G to A
delayed puberty
46 XY 4 FSGS yes no yes gonadal dysgenesis no no +5 G to A
delayed puberty
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Figure 3.4 (A) Electropherogram  to show the WT1 1228+5 (G -»  A) splice site 
m utation detected in FS
I
A A G T G C A T A A A C T T T T C  
110
(B) Electropherogram  of norm al control
4-
A A G T G  C G  T A A A C T T T T  
110
(C )) E lectropherogram  to show the WT1 1228+4 (C ->  T) splice site 
m utation detected in FS
4
A A G T G T G T A A A C T T T T  110 120
(D) Electropherogram  of norm al control
4
A A G T G  C G  T A A A C T T T T  
110
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Figure 3.5 Splice site prediction by Neural network. This is able to indicate the 
potential effect of a base substitution or other putative mutation within the 
consensus sequence of a splice site in mammals. The results given are for the two 
different base substitutions detected in the four cases of FS within the WT1 exon 9 
alternative splice donor site (http://www.fruitflv.org/seq tools/splice.html).
Exon 9 wild type sequence analysed:
5’gtgcagaatcagtgattcttgttgggcctgggggactggggaaatctaaggtgaggcagatgcagacattgcaggcatggcaggaaat
gctgggctcctccagctgccggaagtcagccttgtgggcctcactgtgcccacattggttagggccgaggctaaccttctctgtccattt
AGGTGTGAAACCATTCCAGTGTAAAACTTGTCAGCGAAAGTTCTCCCGGTCCGACC
ACCTG A AG ACCC AC ACC AGG ACTC AT AC AG g jA  AAACAA |  g 1 11 aaa
tttcttcacatttatttttcattatttttttaaactattgtggaatgaaattgtgatgagagggattggaaaagactagtgtaaagttctaaggtttaga
ctcagttgagagaaggaatagtgcgtggctatctttaaataataaataataacattttaaagaaggggagggtggaaatacagagaaggag
aagatggaaagatgctgactg 3'
Donor site predictions for wild type exon 9 :
Start End Score Exon Intron
2 62  2 7 6  0 . 9 4  C A T A C A G ^ H a a a a c a
2 7 1  2 8 5  0 . 7 6  A A A A C A A ^ ^ c g t a a
Donor site predictions with 1228 + 5 G to A substitution:
Start End Score Exon Intron
2 6 2  2 7 6  0 . 9 4  C A T A C A G ^ H a a a a c a
2 7 1  2 8 5  0 . 0 0  A A A A C A A ^ | g c | t a a
Donor site predictions with 1228 + 4 C to T substitution:
Start End Score Exon Intron
2 6 2  2 7 6  0 . 9 4  C A T A C A G ^ H a a a a c a
2 7 1  2 8 5  0 . 5 5  A A A A C A A |||g |g ta a
hrt
To quantitate WT1 splice isoforms, a second round of hemi-nested PCR was performed 
using DDS1 and FRAS2 primers (Chapter 2, Table 2.2), and [32P] dCTP radio-labelled 
products separated (Figure 3.7). Only tissue from case DG was available at the time. 
Quantification of band intensity performed using a Phospho-imager (Molecular 
Dynamics) revealed that, in contrast to normal kidney and Wilms’ tumour, there was an 
apparent reversal of the normal +/- KTS isoform ratio in vivo. The experiment was 
repeated twice, and this reversal from approximately 2 : 1  to approximately 1 : 2  was 
present on each occasion (Figure 3.6). These findings supported the results of computer 
predictions that WT1 gene mutations in FS lead to abnormal splicing at the second 
splice donor site in exon 9, disrupting the normal ratio of + to - KTS WT1 isoforms 
present, which resulted in an FS phenotype. These findings provided one of the first 
pieces of experimental evidence that the different WT1 protein isoforms have different 
functions, and that renal and gonadal development may be especially sensitive to 
imbalance or relative under-representation of the WT1 +KTS isoform. These results 
were subsequently supported by the detection of WT1 mutations in a larger series of FS 
cases (Klamt et al, 1998), and provided key evidence for a critical role for the WT1 
gene in ensuring correct differentiation of the indifferent gonad and renal tract.
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Figure 3.6 RT-PCR analysis of WT1 in Wilms tum our, normal kidney and 
archival gonadoblastoma tissue from case DG.
1 kb B 1 2 3 1 2  1 2
ladder NK W
Exon 9 +/- KTS
(KEY: G = gonadoblastoma; NK = normal kidney; W = Wilms’ tumour)
Figure 3.7 RT-PCR analysis of +/- KTS isoforms in FS. Lanes A and B 
demonstrate the normal pattern seen in tissues of approximately 2 :1 +  KTS : -  
KTS, whereas lanes C and D the reversal seen in FS.
Ratio of band 
intensity of +/- KTS 
isoforms as measured 
on phospho- imager
A B
Wilms Normal 
tum our kidney
2.3
C
DG1
D
DG2
2.4
Heterodimer ? 
+ KTS
-K TS
0.57 0.56
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3.5 Yeast two hybrid analysis of murine + and -  KTS WT1 protein 
isoforms
3,5.1 Rationale for yeast two hybrid analysis
The discovery that WT1 gene mutations are able to cause at least two different types of 
glomerular damage in DDS and FS provided important supporting evidence for a 
critical role for the WT1 gene in genitourinary development. This was further 
underpinned by the detection of a reversal of the normal +/- KTS WT1 protein isoform 
ratio in FS. These initial results confirmed that the WT1 gene is likely to have a number 
of different roles in health and disease, and that its function is far more complex than 
simply tumour suppression. However, unanswered questions remained regarding the 
exact role WT1 plays in podocyte maintenance and the integrity of the glomerular filter, 
and how abnormalities might contribute to nephrotic disease. Accumulating evidence 
supported a regulatory role for WT1 in kidney development, but little was known about 
what its targets may be or which cascades may be affected by its abnormal function.
The conclusion that could be drawn from sections 3.2 to 3.4 was that WT1 gene 
mutations form a key feature of DDS and FS. Although mutations may occur 
throughout the WT1 gene, missense mutations affecting the second and third zinc 
fingers are present in the majority of DDS cases as seen in this series, whereas specific 
intron 9 mutations affecting alternative splicing were detected in all FS cases examined. 
In contrast, when DMS and FSGS occurred in isolation WT1 mutations appeared 
unusual, which is in common with pure intersex states (Nordenskjold et al, 1995). 
These findings suggested that some effects of mutations may be mediated through 
altered regulation of genes and/or altered interaction with proteins important for normal 
renal and gonadal development. Isolated DMS and FSGS might therefore be a 
consequence of mutations in genes downstream of WT1.
The following hypothesis was tested on the basis of these findings:
Inappropriate protein-protein interactions caused either by abnormalities in WT1 
proteins, or their isoform ratio results in malformed renal glomeruli, abnormal gonadal 
development and oncogenesis.
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3.5.2 The yeast two hybrid system
Yeast two hybrid analysis was used to establish potential target proteins in vivo, 
concentrating primarily on those that may result in abnormal glomerular development. 
This technique was first proposed by Fields and Song (1989), and utilises the yeast 
genetic machinery to detect protein-protein interactions in vivo. The protocol is based 
on the essentially modular properties of many transcription factors, and the fact that 
they have two distinct domains: one able to bind to specific DNA sequences upstream 
of target genes, and the other to activate transcription of the target gene in question 
(Keegan et al, 1986). Transcription factors may be split into these two separate 
functional domains, which when expressed separately, are unable to independently 
activate transcription. In the two hybrid approach, these domains are used to generate 
hybrid proteins, which are then tested for potential protein-protein interaction through 
their ability to activate specific reporter genes. The majority of yeast two hybrid 
systems are based on either the yeast GAL4 transcription factor, or the prokaryotic 
LexA transcription factor found in E. coli. In addition, exchange of DNA binding 
domains and activation domains between these transcription factors can occur without 
compromising function.
The bait protein is first fused to a DNA binding domain, forming a fusion cDNA, which 
is then transferred to a yeast strain. This expresses the protein as a fusion, and can be 
transformed with a library of cDNA’s fused to a corresponding activation domain. If no 
interaction occurs between the bait and library proteins, the domains remain apart. If 
interaction does occur, they come into apposition and reconstitute the transcription 
factor. This specifically activates reporter genes, allowing detection of the interaction 
by growth in selective media and/or colorimetric assay (Figure 3.8). Once isolated, 
potential interactors can be sequenced, and the appropriate databases interrogated 
allowing correct identification of interacting proteins. Any novel proteins detected can 
be assessed for the presence of motifs indicative of their putative function.
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Figure 3.8. The yeast two hybrid system
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AD = activation domain
BD = binding domain
UAS = upstream activation sequence
X = bait protein fused to binding domain
Y = prey protein with cDNA library fused to activation domain
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3.5.3 Subcloning of full-length murine WT1 constructs
-KTS WT1 isoforms were subcloned in as a BamHI fragment, whereas + KTS isoforms 
as a Smal/BamHI fragment in pASl and pACTII respectively to form in frame GAL4 
DNA binding domain (BD) and GAL4 activation domain (AD) full-length murine WT1 
fusion proteins (Figures 3.9 and 3.10). The presence of inserts was confirmed prior to 
transformation into yeast by Smal and BamHI digest (Figure 3.11). All constructs were 
sequenced to confirm in-frame subcloning of the WT1 cDNA, and absence of mutations 
within the WT1 sequence.
3.5.4 Auto-activation analysis
GAL4-DNA BD WT1 fusions were then tested for auto-activation potential by 
transforming into Y190, and observing yeast growth on the appropriate media. Y190 is 
a modified yeast strain, which contains either mutations or modifications of the GALA, 
LEU2, TRP1 and HIS3 genes allowing the use of GAL4 based yeast two hybrid vectors, 
and their selection using metabolic markers. The pASl vector contains a wild type 
TRP1 gene, whereas the pACTII vector contains a wild type LEJJ2 gene allowing 
growth on deficient media. The HIS3 gene and an engineered lacZ gene under the 
control of the GAL (UAS), and thus the GALA gene product, were used as reporters.
Y190 was transformed using a standard Lithium acetate protocol with both empty 
pASl, and with - and + KTS WT1 fusion proteins in pASl. Transformations were 
plated on minimal medium containing -Trp selection alone, -Trp, -His selection, and -  
Trp, -His together with either 25 and 50 mM 3-amino triazole (3-AT). Growth was 
observed on the -Trp plate as expected, which selected for bait plasmid alone. Some 
minimal growth was observed on -Trp, -His selection, suggesting either leakage of the 
His reporter, or a mild degree of autoactivation. This was completely abolished by the 
addition of 25 and 50 mM 3-AT, a structural analogue of histidine able to act as a 
competitive inhibitor of histidine synthesis, thus reducing the level of histidine within 
the cell to a minimum.
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Figure 3.9 GAL4 DNA-BD - full length m urine +/- WT1 isoforms in fram e fusions in 
pAS2 generated using S m al and/or Bam H I (red arrows)
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Figure 3.10 GAL4 DNA-AD - full length m urine +/- WT1 isoforms in fram e fusions in 
pACTII generated using S m a l and/or B am H I (red arrows)
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Figure 3.11. SmaUBamHA  and B am H I  digest of WT1 Gal4 fusion proteins in pAS2 and 
pACT2 analysed on a 1%  agarose gel
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3.5.5 Confirmation of WT1 fusion protein expression within Y190
By convention, expression of the bait protein within the yeast is confirmed prior to 
library screening by Western analysis. This was attempted unsuccessfully for the WT1 - 
/+ KTS fusion proteins to be used for the yeast two hybrid screen. Western blot analysis 
of eighteen colonies transformed on three separate occasions (in batches of six) did not 
demonstrate presence of WT1, either using HA specific or WT1 specific antibodies. 
This was however not unusual with the pASl vector/Y 190 combination, and may have 
resulted from the expression of the bait protein being at levels too low for antibody 
detection. Although the pASl vector contains a strong constitutive full length ADH 
promoter to drive the expression of chimeric proteins, expression may be repressed as 
much as 10-fold by ethanol accumulation in the medium (Denis et al, 1983). This 
occurs if the yeast is allowed to grow beyond logarithmic growth, a situation difficult to 
manage with the Y190 yeast strain. Since mild autoactivation was observed for both 
isoforms, by definition the fusion proteins should have been expressed, however it was 
observed that the pAS 1 HA tag itself is able to result in mild autoactivation of the yeast 
reporter. In view of the resulting uncertainty, an additional test was undertaken to 
confirm presence of the WT1 GAL4 BD fusion proteins. Since WT1 is known to self­
associate (Holmes et al, 1997), this was used as an additional test of protein expression. 
pASl plasmids containing the full length WT1 GAL4 BD fusion proteins to be used for 
library screening, and pACTII plasmids containing full length WT1 GAL4 AD fusion 
proteins were co-transformed into Y190, and grown on minimal medium selecting for 
both plasmids (-Trp, -Leu) and reporter activation (-His and +25 mM 3-AT). Good 
growth was observed on selective media, suggesting that a protein-protein interaction 
between the BD and AD fusion proteins had occurred, enabling activation of the His 
reporter gene. This was considered sufficient proof that the WT1 GAL4 BD fusion 
proteins were being expressed within the yeast, despite negative Western analysis.
3.5.6 Yeast two hybrid interaction assays
pASl - and + KTS WT1 constructs were used as baits to perform two separate library 
screens. In order to maximise transformation efficiency, bait and library plasmid were 
transformed into Y 190 sequentially, with initial selection being for tryptophan alone. In
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view of the results of the autoactivation analysis, 25 mM 3-AT was used, as the addition 
of excessive 3-AT may compromise the detection of weak, but real interactions. 
Screens were performed using a mouse embryo library (E 9 1/2 and 10/2) cloned into 
the Notl site yeast two hybrid vector pVP16 (Figure 3.12). Murine homologues of WT1 
are expressed at this stage of development, so theoretically, prospective interaction 
candidates should be similarly expressed. The library had been generated by random 
hexamer-primed cDNA synthesis of E9.5/10.5 CD1 embryo polyA+ RNA, followed by 
size selection with a preference for insert sizes in the range of 350-700 nucleotides 
(Hollenberg et al, 1995). The rationale for short cDNAs was to minimise bias towards 
C-terminal sequences, separate protein interaction domains from inhibitory regions 
contained within the full length polypeptide, to reduce the toxicity sometimes seen with 
full-length foreign proteins expressed in the yeast, and to facilitate more rapid analysis 
by sequencing. However, the disadvantage of small inserts is that more clones must be 
screened, large domains may be missed and shorter protein fragments may have 
interaction specificities irrelevant to the parental native protein, thus increasing the 
frequency of false positives. A theoretical library of two million independent clones 
was screened, and since pVP16 has a wild type leucine gene, this was used as the 
metabolic selection marker for AD plasmid selection.
Figure 3.12 Map of the pVP16 vector used for subcloning of the E9.5/10.5 cDNA 
library used for yeast two hybrid screening. The red arrow indicates the cloning site.
bU1
pVP16
8.10 Kb
ADH
BcoBlSP6 M  Kpnl Npg -----
TOCATCCCCOOOTACOTAOCTCAATTCCOCCCCCTACATAaAT«3AAaCIAOCTOCAATTC
Transformation efficiency was assessed by plating a 1:10,000 dilution of the library 
transformation on -Trp, -Leu and +His plates. Good transformation efficiencies of 
approximately 3.7 x 106 cotransformants/pg of DNA for the +KTS isoform, and 2.9 x
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106 cotransformants/pg for the -KTS isoform were obtained for each of the two screens 
performed. Interacting clones were initially selected for by growth on minimal medium 
-Trp, -Leu, -H is + 25 mM 3AT. A total of fourteen colonies were picked for the +KTS 
isoform and six for the -KTS isoform. Of these, six +KTS colonies and four -KTS 
isoforms also resulted in activation of the lacZ reporter gene on p-Gal assay. These 
were recovered into HB101, followed by analysis of insert size by Notl digest (Figure 
3.13). Inserts were subsequently PCR amplified using vector specific flanking primers, 
and sequenced. BLAST analysis of the sequences of captured clones is shown in Figure 
3.14, and the results summarised in Table 3.4. Of note, the first library screen produced 
a better result for the -KTS isoform (despite comparable transformation efficiencies), 
with four colonies resulting in activation of both reporters as opposed to one, whereas 
the second screen produced a better result for the + KTS isoform, with six colonies 
activating both reporters as opposed to none in the first screen. None of the interactors 
were detected in both screens.
Figure 3.13 N ot! digests of clones selected through His and lacZ  repo rter gene activation 
analysed on a 1.5% agarose gel. The num bers represent each clone; enzyme digest was 
perform ed in triplicate
-  + KTS
-  -KTS
-  - KTS 
w t- 1 0 2
wt-1202 wt-123 wt-12
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Figure 3 .1 4  Results of BLAST searches of the sequences of putative interactors 
identified through yeast two hybrid screening of a E 9.5/10.5 day VP16 whole 
mouse embryo library, using murine WT1 + and -  KTS GAL4 fusions
A) Results of BLAST searches of yeast two hybrid screen with +KTS isoform 
(http://www.ncbi.nlm.nih.gov/blast)
(i) Edr protein (AJ006464)
Three of six clones (Clones 2, 9 and 11) were identified as EDR protein (AJ006464). EDR protein has 
two putative ORF’s, but no protein translations are present as yet in databases. Consequently, protein 
database searches were inconclusive.
Clone 2 nucleotide sequence:
1 c g c a t g t c c a  t c c g t a t a t g  c a t c a g c a t c  t g c a t c a g c a  t c t g c a t c a g  t t t c t g c a t c
61  c a g a t c c g c a  t c a g t a t c c g  c a t c c g g a t c  c g c a t t a t c a  t c a t c a t c a g  c a g g c g g a t a
1 2 1  t g c a g c a c c a  a c t g c a g c a g  t a t c t a t a t c  a g t a t t t g t a  t t a c c a c c t g  t a t c c g g t t
BLAST search of clone 2 nucleotide sequence detected Edr protein.
>g i | 1 6 9 4 5 3 2 1 | e m b | A J 0 0 6 4 6 4 . 1 | M M A J 6 4 6 4  Mus m u s c u l u s  mRNA f o r  E d r  p r o t e i n  
L e n g t h  = 5 1 6 6 ;  C D ' s  4 3 3 . . 3 3 5 8  
S c o r e  = 3 5 5  b i t s  ( 1 7 9 ) ,  E x p e c t  = 9 e - 9 6
I d e n t i t i e s  = 1 7 9 / 1 7 9  (10 0%)
S t r a n d  = P l u s  /  P l u s
Query: 1 cgcatgtccatccgtatatgcatcagcatctgcatcagcatctgcatcagtttctgcatc 60
I I I I I I I I I  I I I I I I I I I I I I I I I I I I I I  I I I I I  I I I I !  I I I I I  I I I I  I I I I  I I  I I I I I I
Sbjct: 1943 cgcatgtccatccgtatatgcatcagcatctgcatcagcatctgcatcagtttctgcatc 2002 
Query: 61 cagatccgcatcagtatccgcatccggatccgcattatcatcatcatcagcaggcggata 120
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
Sbjct: 2003 cagatccgcatcagtatccgcatccggatccgcattatcatcatcatcagcaggcggata 2062 
Query: 121 tgcagcaccaactgcagcagtatctatatcagtatttgtattaccacctgtatccggtt 179
l l l l l l l l l l l l i l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
Sbjct: 2063 tgcagcaccaactgcagcagtatctatatcagtatttgtattaccacctgtatccggtt 2121
Clone 9 nucleotide sequence:
1 c a g c t c c a t t  g t c c t c a a c t  c t g a t t a c t g  c c g a c t t c g c  t g c c g g a t g c  c c g c a c a g a t
61  a c c t t c t a a c  t t a c t g t t t a  c a g t g c c a c a  a c c g a a t t t g  c a t c c g t a t c  t a c t t c a t c a
1 2 1  t g t g c a t c c g  c a t g t c a t c g  c a t a t g c a t c  a g c a t c t g c a  t c a g c a t c t c  g a t c a g t t c t
1 8 1  g c a t c a g a t c  g a t a g t a t c g  a t c g a t c g a t  a t a t a t a t a c  g a c g g a a t t c
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BLAST search of clone 9 nucleotide sequence detected Edr protein.
>g i [ 1 6 9 4 5 3 2 1 | e m b | A J 0 0 6 4 6 4 . 1 |MMAJ6464  Mus m u s c u l u s  mRNA f o r  E d r  p r o t e i n  
L e n g t h  = 5 1 6 6 ;  C D ' s  4 3 3 . . 3 3 5 8 .
S c o r e  = 2 2 6  b i t s  ( 1 1 4 ) ,  E x p e c t  = 7 e - 5 7
I d e n t i t i e s  = 1 6 4 / 1 7 8  ( 9 2 % ) ,  G a p s  = 2 / 1 7 8  (1%)
S t r a n d  = P l u s  /  P l u s
Query: 3 gctccattgtcctcaactctgattactgccgacttcgctgccggatgcccgcacagatac 62
l l l l l l l l l l l  l l l l l l l l l l l l l l l l l l l l l l  l l l l l l l l l l l  M I N I M I
Sbjct: 1817 gctccattgtcttcaactctgattactgccgactctgctgccggatgtttgcacagatac 1876 
Query: 63 cttctaacttactgtttacagtgccacaaccgaatttgcatccgtatctacttcatcatg 122
! l 1 1 1 1 1 1 1 1 1 1 1 1 1 I I 1 1 1 1  l l l l l l l l l l l  I I  l l l l l l l l l l l l l l l l l l l l l l l
Sbjct: 1877 cttctaacttactgtttacagcgccacaaccgagttcgcatccgtatctacttcatcatg 1936 
Query: 123 tgcatccgcatgt-cat-cgcatatgcatcagcatctgcatcagcatctcgatcagtt 178
l l l l l l l l l l l l l  I I I  I I  l l l l l l l l l l l l l l l l l l l l l l l l l l l l  l l l l l l l
Sbjct: 1937 tgcatccgcatgtccatccgtatatgcatcagcatctgcatcagcatctgcatcagtt 1994
Clone 11 nucleotide sequence:
1 c a c g c a t g t c  c a t c c g c a t a  t g c a t c a g c a  t c t g c a t c a g  c a t c t g c a t c  a g t t t c t g c a
61 t c c a g a t c c g  a t c a g t a t c c  g c a t c c g g a t  c c g c a t t a t c  a t c a t c a t c a  g c a g g c g g a t
1 2 1  a t g c a g c a c c  a a c t g c a g c a  g t a t c t a t a t  c a g t a t t t g a  t t a c c a t c t g  t a t c g g t t a t
1 8 1  g c a c a c c a t g  t c t a g a t c a g  c a t g a g a c t c  t c g a t g a g t a  t c t c g a c t a t  a g t a t c t c g a
2 4 1  c t a g t a t c t g  c a t c a g t t c t  g c a t a c a
BLAST search of clone 11 nucleotide sequence detected Edr protein.
>g i | 1 6 9 4 5 3 2 1 | e m b | A J 0 0 6 4 6 4 . l | M M A J 6 4 6 4  Mus  m u s c u l u s  mRNA f o r  E d r  p r o t e i n  
L e n g t h  = 5 1 6 6 ; C D ' s  4 3 3 . . 3 3 5 8
S c o r e  = 3 0 3  b i t s  ( 1 5 3 ) ,  E x p e c t  = 4 e - 8 0
I d e n t i t i e s  = 1 8 0 / 1 8 5  ( 9 7 % ) ,  G a p s  = 3 / 1 8 5  (1%)
S t r a n d  = P l u s  /  P l u s
Query: 3 cgcatgtccatccgcatatgcatcagcatctgcatcagcatctgcatcagtttctgcatc
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II
62
Sbjct: 1943
II 1 II 1 II 1 II 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
cgcatgtccatccgtatatgcatcagcatctgcatcagcatctgcatcagtttctgcatc 2002
Query: 63 cagatccg-atcagtatccgcatccggatccgcattatcatcatcatcagcaggcggata 
1 1 1 1 1 1 1 1 1 1 1111 1111 1 1 1 1 1 1 II 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
121
Sbjct: 2003
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
cagatccgcatcagtatccgcatccggatccgcattatcatcatcatcagcaggcggata 2062
Query: 122 tgcagcaccaactgcagcagtatctatatcagtatttg-attaccatctgtat-cggtta 
1 1 1 1 1 1 1 1 11 1 1 1 1 1 1 1 1 1 1 11 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 lllllll 1 1 1 1 1 1 1 1 1 1 1 1
179
Sbjct: 2063
1 1 1 1 1 1 1 1 11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 lllllll 1 1 1 1 1 1 1 1 1 1 1 1 
tgcagcaccaactgcagcagtatctatatcagtatttgtattaccacctgtatccggtta 212
Query: 180 tgcac 184 
1 1 1 1 1
Sbjct: 2123
1 1 1 1 1
tgcac 2127
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BLAST searching of protein databases: various uncharacterised ORF’s detected; for
example, clone 2 :-
> g i | 2 2 0 5 7  8 | d b j ]B A A 0 0 4 4 7 . 1 [  (DO0 5 7 0 )  o p e n  r e a d i n g  f r a m e  ( 2 5 1  AA) [Mus 
m u s c u l u s ] L e n g t h  = 2 5 0
S c o r e  = 3 2 . 5  b i t s  ( 6 9 ) ,  E x p e c t  = 0 . 0 7 3
I d e n t i t i e s  = 2 0 / 5 4  ( 3 7 % ) ,  P o s i t i v e s  = 2 8 / 5 4  ( 5 1 % ) ,  G a p s  = 2 3 / 5 4  (42%)
Query: 7 CISI CISICISF-CIQIRISIRIRIRIIIIISRRICSTNCSSIYISI--CI 54
C+SI C+SIC+S+ C+ I +SI I C S+Y+SI Cl
Sbjct: 115 CLSIMSVCLSICLSYVCLSIYLSI -1---------------- CLSVYLSIYLCI 151
Sequence alignment of clones 2,9 and 11 using CLUSTAL W (1.81)
c lone 11 -------------------C ACGCATGTC C ATCCGCATATGCATC AG - CATCTGC ATCAGC
c 1 one_2  GC ATGTCCATC CGTATATGCATC AG - CATCTGC ATCAGC
clone_9 CAGCTCCATTGTCCTCAACTCTGATTACTGCCGACTTCGCTGCCGGATGCCCGCACAGAT
★ ★ ★  ★ ★ ★ * ★★★★
c lone 11 ATCTGCATCAGTTTCTGCATCCAGATCCG-ATCAGTATCCGCATCCGGATCCGCATTATC
clone_2 ATCTGCATCAGTTTCTGCATCCAGATCCGCATCAGTATCCGCATCCGGATCCGCATTATC
clone 9 ACCTTC-TAACTTACTGTTTACAGTGCCACAACCGAATTTGCATCCGTATCTACTTCATC
★ ★ ★ ★ ★ ★ ★★ ★★★ ★ ★★★ ★★ ★ * ★ ★★ ★★★★★★★ ★★★ ★ ★ ★★★
c lone 11 ATCATCATCAGCAGG CGGATATGCAGCACCAACTGCAGCAGTATCTATATCAGTAT
clone_2 ATCATCATCAGCAGG CGGATATGCAGCACCAACTGCAGCAGTATCTATATCAGTAT
clone_9 ATGTGCATCCGCATGTCATCGCATATGCATCAGCATCTGCATCAGCATCTCGATCAGT-T
★ ★ ★★★★ ★★★ ★ ★★ ★★★★★★★ ★★ ★★ ★★★★ ★★★★★★ ★
c lone 11 TTG - ATTA- - CC ATCTGTATC - GGTTATGC ACACCATGTCTAGATCAGCATGAGACTCTC
clone 2 TTGTATTA--CCACCTGTATCCGGTT------------------------------------
clone_9 CTGCATCAGATCGATAGTATC-GATCGATCGATATATATATACGACGGAATTC-------
★ ★ ★ ★ ★  ★ ★★★★★★★
clone 11 GATGAGTATCTCGACTATAGTATCTCGACTAGTATCTGCATCAGTTCTGCATACA
clone_2 ----------------------------------------------------------
clone_9 ----------------------------------------------------------
Consensus key
* - single, fully conserved residue 
- no consensus
Alignment of clones 2, 9 and 11 suggested that a series of overlapping sequences had 
been identified. The occasional lack of match between clone 9, and clones 2 and 11
reflects sequence quality. Alignment of clones would normally have been made using
predicted protein sequences, but this was not possible in view of the lack of a reliable
protein translation for the Edr gene in the databases.
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(ii) Angiomotin (AF461135)
One of six clones detected (clone 4) = Angiomotin (AF461135)
Clone 4 nucleotide sequence:
1 c a c c t g c t a c  t g t t t c t c c a  a c t g c t c c a c  t g c t a c t g c t  g c t g t t g c t g  c a g c t a c t a c
61  t g c t g c t a t c  a c t g c t g c t g  c t g c t g c t g c  c a c t a c t g c t  a t t c a g g c c g  c t c a g c t a c t
1 2 1  t c g g c t c c g g  t t c c a t c t c a  g c t t c g a t t c  c g g c t c a g c a  a c g g c t c a g g  c t t c t g c t c g
1 8 1  a t c g a c t c a g  c a t c a a c t c a g t c g a c t g a c  t c t a g t c a g t  c c t c
BLAST search of clone 4 nucleotide sequence detected angiomotin (AF461135):
>g i [ 1 8 4 7 9 1 3 6 l g b | A F 4 6 1 1 3 5 . 1 | Mus m u s c u l u s  a n g i o m o t i n  mRNA, c o m p l e t e  c d s  
L e n g t h  = 2 8 3 7 ;  C D ' s  1 0 7 . . 2 7 8 2  
S c o r e  = 2 8 0  b i t s  ( 1 4 1 ) ,  E x p e c t  = 5 e - 7 3
I d e n t i t i e s  = 1 7 5 / 1 8 1  ( 9 6 % ) ,  G a p s  = 4 / 1 8 1  (2%)
S t r a n d  = P l u s  /  P l u s
Query: 3 cctgctactgtttctccaactgct-ccactgctactgctgctgttgctgcagctactact 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
61
Sbjct: 2339
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
cctgctactgtttctccaactgctgccactgctactgctgctgttgctgcagctactact 2398
Query: 62 gctgctatcactgctgctgctgctgctgccactactgctattcaggccgct-cagctact 
1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 III 1 1 1 1 1 1 1 1
120
Sbjct: 2399
1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 III 1 1 1 1 1 1 1 1 
gctgctatcactgctgctgctgctgctgccactactgctattcaggttgctccagctact 2458
Query: 121 tcggctccggttccatct-cagcttcgattccggct-cagcaacggctcaggcttctgct 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
178
Sbjct: 2459
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 I 1 1 1 1 1 1 
tcggctccggttccatctccagcttcgattccggctccagcaacggctcaggcttctgct 2518
Query: 179 c 179 I
Sbjct: 2519
1
c 2519
Clone 4 Protein sequence:
TCYCFSNCSTATAAVAAATTAAITAAAAAATTAIQAAQLLRLRFHLSFDSGSATAQASARSTQHQLSRLTL
VSP
BLAST search with clone 4 protein sequence:
>g i 118 47  9 1 3 7 | g b 1A A L 7 3 4 3 6 . 1 [ A F 4 6 1 1 3 5 _ 1  ( A F 4 6 1 1 3 5 )  a n g i o m o t i n  [Mus 
m u s c u l u s ]  L e n g t h  = 8 9 1  
S c o r e  = 7 7 . 8  b i t s  ( 1 7 6 ) ,  E x p e c t  = 2 e - 1 5
I d e n t i t i e s  = 3 7 / 6 7  ( 5 5 % ) ,  P o s i t i v e s  = 3 9 / 6 7  ( 5 7 % ) ,  G a p s  = 2 4 / 6 7  (35%)
Query: 10 TATAAVAAATTAAITAAAAAATTAIQAAQLLRLRFHLSFDSGS------------ ATAQA 57
TATAAVAAATTAAITAAAAAATT AIQ A + S ATAQA
Sbjct: 754 TATAAVAAATTAAITAAAAAATTAIQVAP ATSAPVPSPASIPAPATAQA 802
Query: 58 SARS-TQ 63 
SA + TQ 
Sbjct: 803 SAPTPTQ 809
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(iii) False positives: clones 5 and 7
Two of the six clones detected were false positives, as database searching with the nucleotide 
sequence revealed prey sequences in the opposite orientation, and protein database searching 
was unable to isolate a significant match.
Clone 5 nucleotide sequence:
1 c a g c c a g g g g  c c a a g t g t c a  c t t g c t g c t g  c t g c t g c t g c  t g c t g c t g c t  g c t g c t g c t g
61  c t g c t g c t t t  g c t g c t g c t g  t t g t t g c t g c  g c t g c t g c g  a g a t a a t a a a  a g t t c g a t t c
1 2 1  t g g t t c a a a g  a g g c c c c a t c  t g c t g t t g c t  g a a g c t g c a g  c t g t t g t t g c  t g g t g c a g c t
1 8 1  g c t c g c t c g a  a g t g c a t g c g  t c g t g t t g t t  g c t g c t g c t
BLAST search of clone 5 nucleotide sequence detected:
>g i | 6 7 5 4 1 6 7 | r e f | N M _ 0 1 0 4 0 8 . 1 | Mus m u s c u l u s  h y p e r p o l a r i z a t i o n - a c t i v a t e d ,  
c y c l i c  n u c l e o t i d e - g a t e d  K+ 1 ( H c n l ) ,  mRNA L e n g t h  = 3 3 0 5  
S c o r e  = 1 1 1  b i t s  ( 5 6 ) ,  E x p e c t  = 3 e - 2 2  
I d e n t i t i e s  = 6 6 / 6 8  ( 9 7 % ) ,  G a p s  = 1 / 6 8  (1%)
S t r a n d  = P l u s  /  M i n u s
Query: 23 tgctgctgctgctgctgctgctgctgctgctgctgctgctgctgct-ttgctgctgctgt 81
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I  I I I I I I  I I I I I I I I I I l l l l l l l l l l l l
Sbjct: 2328 tgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgctgt 2269 
Query: 82 tgttgctg 89
M I N I M
Sbjct: 2268 tgttgctg 2261
Clone 7 nucleotide sequence:
1 c a c c g c a t t c  t g g c g t t g c t  g t t g c t g c t g  c t g c t g t t g c  t g c t g t t g t t  g t t g c t g c t g
61  c t g c t g c t g t  t g t t g c t g c t  g c t g c t g c t g  c t g c t g c a g g  g a c t a g g y g g  y a c g g c c c a c
1 2 1  g g t a t c t c g c  a a a c t a g t a c  g s g g a a a a a g  t g t c g c a c a  g c g t g t g a a c  t g c t g g a g g c
1 8 1  t g g t a g c a g a  g a a a t a t a t a  a t t a t c a t a t  c
BLAST search of clone 7 nucleotide sequence detected:
>g i | 1 6 7 1 6 5 6 6 | r e f | N M _ 0 5 3 2 4 2 . 1 | Mus m u s c u l u s  f o r k h e a d  b o x  P2 ( F o x p 2 ) ,  
mRNA L e n g t h  = 2 1 4 5
S c o r e  = 1 2 0  b i t s  ( 6 0 ) ,  E x p e c t  = 5 e - 2 5
I d e n t i t i e s  = 7 7 / 8 2  ( 9 3 % ) ,  G a p s  = 3 / 8 2  (3%)
S t r a n d  = P l u s  /  M i n u s
Query: 15 gttgctgttgctgctgctg ctgttgctgctgttgttgttgctgctgctgctgctgtt 71
I I I I  I I I  I I I  I I  I I I  I I I I I I I  I I I I  I I I I I I I I I I  I I I  I I  I I I I I I I I I I I I I I
Sbjct: 571 gttgctgttgctgctgctgttgctgctgctgctgttgctgttgctgctgctgctgctgtt 512 
Query: 72 gttgctgctgctgctgctgctg 93
I I I  I I I I I  I I I I I  I I I I  I I I I  I
Sbjct: 511 gttgctgctgctgctgctgctg 490
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Protein BLAST searches with clone 5 and 7 protein sequence did not detect any 
significant matches within the databases.
B) Results of BLAST searches of yeast two hybrid screen with -KTS isoform 
(http://www.ncbi.nlm.nih.gov/blast)
(i) AICARFT/IMPCHASE: GENE “ATIC”
One of four clones was identified as 5-aminoimidazole-4-carboxamide ribonucleotide 
formyltransferase/IMP cyclohydrolase, the AICARFT/IMPCHASE or “ATIC” gene.
Clone WT1 -  12 nucleotide sequence:
1 a t a t g c a a g a  g c g a a g a g g a  c g t g a t a g g a t  g t c t t c a t t t  g g t g a t t t t g  t t g g c a t t g
61  t c t g a c g a t t  t g t g a t a t c c  c a a g t g g c a a a  a a t t a t c t c c  a g a g a a g t g t  e g g
BLAST search of clone WT1 -12 nucleotide sequence detected the AICARFT/ 
IMPCH-ase or ATIC gene:
>g i [ 1 2 8 4 8 5 8 9  1d b j | A K 0 1 2 0 7 4 . 1 |A K 0 1 2 0 7 4  Mus m u s c u l u s  10  d a y s  e m b r y o  w h o l e  
b o d y  cDNA, RIKEN f u l l - l e n g t h  e n r i c h e d  l i b r a r y ,  c l o n e : 2 6 1 0 5 0 9 C 2 4 : 5 -  
a m i n o i m i d a z o l e - 4 - c a r b o x a m i d e  r i b o n u c l e o t i d e  f o r m y l t r a n s f e r a s e / I M P  
c y c l o h y d r o l a s e ,  f u l l  i n s e r t  s e q u e n c e  ( L e n g t h  = 2 5 4 7 ;  (CDS 1 . . 1 7 1 3 )
S c o r e  = 1 3 1  b i t s  ( 6 6 ) ,  E x p e c t  = l e - 2 8
I d e n t i t i e s  = 1 0 6 / 1 1 4  ( 9 2 % ) ,  G a p s  = 4 / 1 1 4  (3%)
S t r a n d  = P l u s  /  P l u s
Query: 1 atatgcaagagcgaagaggacgtgataggatgtcttcatttggtgattttgttggcattg 60
1 1 1 1 1 I I 1 1 1 1 1  l l l l l l l  l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l  M M
Sbjct: 943 atatgcaagagc-aagaggagctgataggatgtcttcatttggtgattttgtt-gcattg 1000 
Query: 61 tctgacgatttgtgatatcccaagtggcaaaaattatctccagagaagtgtcgg 114
l l l l l l  M I N I M I  1 1 1 1 I I  I 1 1 1 I I 1 1 1 1 1 1 1 1 1 I I I I 1 1 I I 1 1 I I 1 1
Sbjct: 1001 tctgac-atttgtgatgtcccaact-gcaaaaattatctccagagaagtgtcgg 1052
Clone WT1 -1 2  protein sequence:
MQERRGRDRMS SFGDFVGIVRFVISQVAKIISREVS
Protein BLAST search:
>g i | 1 8 5 5 3 5 1 4 | r e f | X P _ 0 5 5 2 5 7 . 3 | ( X M _ 0 5 5 2 5 7 )  5 - a m i n o i m i d a z o l e - 4 -
c a r b o x a m i d e  r i b o n u c l e o t i d e  f o r m y l t r a n s f e r a s e / I M P  c y c l o h y d r o l a s e  [Homo 
s a p i e n s ] L e n g t h  = 5 1 1
S c o r e  = 5 7 . 5  b i t s  ( 1 2 8 ) ,  E x p e c t  = l e - 0 8
I d e n t i t i e s  = 2 3 / 3 8  ( 6 0 % ) ,  P o s i t i v e s  = 2 4 / 3 8  ( 6 2 % ) ,  G a p s  = 1 1 / 3 8  (28%)
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Q u e r y :  5 RGRDRMSSFGDFVGIV*RFVISQV A K IIS R E V S  37
RG DRMSSFGDFV +S V AK IIS R E VS
S b j c t :  3 0 6  RGADRMSSFGDFV------------ ALSDVCDVPTAKIISREVS 3 3 7
(ii)Unknown proteins.
Three of the four clones were compatible with as yet uncharacterised proteins.
Clone WT-123 nucleotide sequence:
1 a t g a t a a a t g  a g a a t t g t g t  g t c c c t g g c c  g a a g t t c c a g  g c t c c t c a g c
51  t g g g g g g g c t  g g g c a a g a g t  t g t a c c c c t t  t c t t g g a a a g  g g g a c t a c c c
1 0 1  g a g a g a a a t g  a a c a c a g g g t  t c a c c g g g t t  t
BLAST search with nucleotide sequence:
>g i [ 7 2 6 2 7 1 3 | g b l A C 0 0 7 8 4 4 . 3 2 \ Mus m u s c u l u s  c h r o m o s o m e  6 c l o n e  c t 7 - 5 4 1 1 2 2  
s t r a i n  1 2 9 / S v  ES c e l l  l i n e  C J 7 , c o m p l e t e  s e q u e n c e .  L e n g t h  = 1 5 2 3 1 6  
S c o r e  = 3 6 . 2  b i t s  ( 1 8 ) ,  E x p e c t  = 0 . 3 9  
I d e n t i t i e s  = 2 1 / 2 2  (95%)
S t r a n d  = P l u s  /  P l u s
Q u e r y :  58  g c t g g g c a a g a g t t g t a c c c c t  79
i i i immi i i im mi
S b j c t :  6 1 2 7 4  g c t g g g c a a g a g t t g t a t c c c t  6 1 2 9 5  
Protein BLAST database searching: no significant matches.
Clone WT 1202 nucleotide sequence:
1 t a g c a t c g t a  t g a g a c c a t g  t c t a g a a a t g  a c a t a t g t t t  c t t a c g t c a a
51  t g g t c c g a t g  g t c c a g a a g c  c c a t g g c a c c  c a t g c g c t c c  a c g c c g a g a a
1 0 1  c c a a t g c g c t  c c a t g g t c t g  g c c c a t g c g c  t c a a t a c t g g  a g g c c a t g t g
1 5 1  g t c a a g c c t a  g t g g g c c c a t  g c g c t c g a t g  c t g g a g c c c a  t g c g c t c a a c
2 0 1  t g a g c c c a t g  c g g t c c a t g a  c c a g g c c c a t  g c g c t c a
BLAST search with nucleotide sequence:
>g i 1 1 3 5 4 3 1 8 0 l g b [ B C 0 0 5 7 5 8 . 1 1 BC 0 0 5 7 5 8  Mus m u s c u l u s ,  c l o n e  IMAGE:3 6 0 1 0 6 7 ,  
mRNA, p a r t i a l  c d s  L e n g t h  = 1 4 3 9
S c o r e  = 2 9 3  b i t s  ( 1 4 8 ) ,  E x p e c t  = 4 e - 7 7
I d e n t i t i e s  = 1 6 2 / 1 6 4  ( 9 8 % ) ,  G a p s  = 2 / 1 6 4  (1%)
S t r a n d  = P l u s  /  M i n u s
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Query: 75 ggcacccatgcgctccacgccgagaaccaatgcgctccatggtctggcccatgcgctcaa 134
1 1 1 1 1 1 1 1 1 I I 1 1 1 1 1 1 I I 1 1  M  I I I I I  M  M  I I I I I  M  I I  M  I I I I  M  I I I I  M  I M
Sbjct: 433 ggcacccatgcgctccacgcc-agaaccaatgcgctccatggtctggcccatgcgctcaa 375 
Query: 135 tactggaggccatgtggtcaag-cctagtgggcccatgcgctcgatgctggagcccatgc 193
l l l l l l l l l l l l l l l l l l l l l l  M  M  M  1 1 1 ! 1 1 1 1 1 1 1 1 1 1 1 1 ! ! !  1 1 1  M  11 M  M  !
Sbjct: 374 tactggaggccatgtggtcaaggcctagtgggcccatgcgctcgatgctggagcccatgc 315 
Query: 194 gctcaactgagcccatgcggtccatgaccaggcccatgcgctca 237
l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l
Sbjct: 314 gctcaactgagcccatgcggtccatgaccaggcccatgcgctca 271
Clone WT1 -1202 protein sequence:
ASYETMSRNDICFLRQWSDGPEAHGTHALHAENQCAPWSGPCAQYWRPCGQA 
Protein BLAST database searching: no significant matches.
Clone WT -102 nucleotide sequence:
BLAST search with nucleotide sequence:
>gi|1 7 0 2  8 4 4 0 | g b | B C 0 1 7 5 3 9 . 1 | B C 0 1 7 5 3 9  Mus m u s c u l u s ,  S i m i l a r  t o  RIKEN cDNA 
2 6 1 0 0 2 3 M 2 1  g e n e ,  c l o n e  IMAGE: 4 5 1 1 1 5 5 ,  mRNA ( L e n g t h  = 2 4 4 0 )
S c o r e  = 1 4 5  b i t s  ( 7 3 ) ,  E x p e c t  = 2 e - 3 2  
I d e n t i t i e s  = 8 0 / 8 1  ( 9 8 %) ,  G a p s  = 1 / 8 1  (1%)
S t r a n d  = P l u s  /  M i n u s
Query: 161 ggcacccatgcgctccacgccgagaaccaatgcgctccatggtctggcccatgcgctcaa 220
l l l l l l l l l l l l l l l l l l l l l  I I  M l  I I  M  M  I I I  M  I I I I I  M M  I I  M M  I I  M  M M
Sbjct: 1353 ggcacccatgcgctccacgcc-agaaccaatgcgctccatggtctggcccatgcgctcaa 1295 
Query: 221 tactggaggccatgtggtcaa 241
l l l l l l l l l l l l l l l l l l l l l
Sbjct: 1294 tactggaggccatgtggtcaa 1274
Clone WT 102 protein sequence:
HRMRPCLEMTYVCTSMVRWSRSPWHPCAPRREPMRSMVWPMRSILEAMWS 
Protein BLAST database searching: no significant matches.
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Table 3.4 Summary of yeast two hybrid analysis using -  and + KTS WT1 GAL4 
fusion proteins
Details of library screens + KTS KTS
Transformation efficiency j 3.6 - 3.7 x 10s 2 J 7 2 3 x 1 <?.
Number of histidine
pos i t ives
Number of histidine and 
iaeZ positives
N u m b e r  of known 
i n t e r a c t o r s
4: colonies 2,9,11 = Edr 
protein; colony 4 = 
angiomotin
14
6
| ' iTcoiOT^wTT-ii
aicarft/impch-ase
6
4
Number of unknown 3
interactors j
Number of likely false j
positives (including colonies j 10 j 2
failing  to activate LacZ | j
reporter) j  j
3.5.7 Confirmatory yeast analysis
Once positive clones had been identified, the WT1 bait plasmids and captured clones 
were retransformed into Y190 to establish that the interactions were reproducible. The 
GAL4 BD WT1 fusions were also transformed against empty pVP16 vector, to confirm 
that the interaction was not a result of spurious binding to the library vector. 
Interactions between +KTS WT1 and both Edr protein and angiomotin were found to be 
reproducible, as was the interaction between -K TS WT1 and 5~aminoimidazole-4- 
carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC). Interaction 
between the WT1 bait proteins and empty pVP16 vector were not detected.
3.5.8 Further analysis o f  positives
Further confirmation by biochemical methods of the WT1 protein-protein interactions 
detected in the yeast was not performed. The poorly characterised nature of the clones 
detected, and the lack of an obvious relevance to the pathogenesis of renal disease 
meant that these experiments would fall outside the overall remit of the project.
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3.6 Discussion
3,6.1 The nephropathic phenotypes associated with DDS and FS are genetically 
heterogeneous
Although more than sixty germline WT1 gene mutations (both familial and de novo) 
have now been described in DDS, these were found to be absent in all cases of isolated 
DMS and FSGS examined during this study. The infrequent occurrence of WT1 
mutations in isolated FSGS was subsequently confirmed in a study of 37 children with 
non-familial primary steroid-resistant nephrotic syndrome (Denamur et al, 2000). In 
contrast, three groups reported a minority of cases with isolated DMS and WT1 gene 
mutations. Jeanpierre et al (1998b) detected mutations in exons 8  and 9 of the WT1 gene 
in 4 out of 10 patients with DMS, but no other features of DDS. Three of these four 
patients were female. One mutation was a novel 1147 T to C (F383L) in exon 9. Two 
others, 1186 G to A (D396N) in exon 9 and 1129 C to T (H377Y) in exon 8 , had been 
previously detected in DDS. The fourth, an intron 9 (+4 C to T) mutation, is more 
commonly associated with FS (Barbaux et al, 1997, Klamt et al, 1998, Kikuchi et al,
1998), a condition not generally associated with either Wilms’ tumour or gonadal 
abnormalities in cases with a 46 XX karyotype. In addition, all cases in which mutations 
were detected underwent nephrectomy in early life. Since nephropathy may precede 
onset of Wilms tumour by a number of years, and cases of DDS with a normal 46XX 
karyotype are also not generally associated with abnormal genitalia, this may have 
resulted in an incomplete diagnosis of DDS. Schumacher et al (1998) also studied a 
broad spectrum of patients with early onset nephrotic syndrome for WT1 gene 
mutations. Two of four patients with isolated DMS had WT1 mutations, one a novel 
1135 G to T (G379C) mutation exon 8 , and the other the 1180 C to T (R394W) mutation 
characteristically associated with DDS. Both patients were female, and additionally had 
bilateral nephrectomies by the age of two years. More recently, Ito et al (2001) detected 
WT1 mutations in two of seven cases with isolated DMS. One case was male, with DMS 
and an R312Q mutation in exon 7, but no documented genital abnormalities or Wilms’ 
tumour and again, early nephrectomy. The other case had a 46XX in association with 
nephropathy and an intronic +4 C to T mutation, with a phenotype compatible with a 
diagnosis of FS.
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Despite the observed differences in the outcome of each mutation screen, all confirmed 
the genetic heterogeneity of DMS and FSGS despite the uniform appearance in renal 
histology seen. These studies also illustrate the inherent difficulty in differentiating these 
relatively similar phenotypes on the basis of clinical criteria. Although a small subset of 
cases of isolated DMS are likely to arise as a result of WT1 gene mutations, the results 
presented here suggest that when a larger, more generalised population of cases with 
isolated DMS is examined, WT1 gene mutations are infrequent. The occasional 
detection of mutations in isolated DMS lends support to the existence of a subgroup of 
incomplete DDS where nephropathy may be the only defining feature, and indicates that 
the remit of this disease should be broadened to include these cases. This phenomenon 
appears more common in females with isolated DMS, which affirms the less critical role 
of WT1 in female gonadal development suggested by other experimental data 
(Nachtigal et al, 1998; Hammes et al, 2001), and correlates with the observation that 
individuals with a 46XX karyotype and the related syndrome, FS, do not have any 
obvious gonadal abnormalities (Klamt et al, 1998; Demmer et al, 1999). Although 
karyotype analysis remains the most important first line investigation, the presence of 
characteristic WT1 gene mutations may indicate an increased Wilms’ tumour risk. WT1 
mutation analysis of exons 7 to 9 should therefore be considered in selected individuals, 
particularly 46 XX individuals who may not demonstrate any other diagnostic clues for 
an underlying diagnosis of DDS. In addition, there is evidence that WT1 mutations in 
DDS may be hereditary (Coppes et al, 1992; Denamur et al, 1999), which underscores 
the importance of WT1 analysis in this group.
In view of the phenotypic overlap with DDS, the lack of WT1 mutations in isolated 
DMS and FSGS was disappointing. Subsequent linkage studies of two Turkish families 
with autosomal recessive DMS excluded the WT1 gene locus (Ozen S, personal 
communication), and the association of familial FSGS with at least three other genes 
(e.g.Winn et al, 1999; Boute et al, 2000; Kaplan et al, 2000) has provided further 
evidence for the genetic heterogeneity of these conditions. It had been hoped that as in 
DDS (Jeanpierre et al, 1998a), genotype-phenotype correlation would provide some 
indication of the role that WT1 plays in the pathogenesis of nephrotic syndrome. The 
minority of cases of DMS in whom WT1 gene mutations were present is likely to 
represent a subset of DDS, although whether this group has an increased Wilms’ tumour
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risk cannot be quantified. Factors that determine which aspects of the DDS phenotype 
are expressed may be related to the genetic background of an individual, or coincidental 
abnormalities in related genes, possibly resulting in genetic epistasis.
In DDS, the mutations characteristically leave the WT1 protein intact, but result in the 
disruption or inactivation of DNA binding its zinc fingers (Little et al, 1995). Nearly half 
of all cases have missense mutations affecting a crucial arginine residue in zinc finger 
3 (Arg394) and, collectively, missense mutations in zinc fingers 2 and 3 (encoded for by 
exons 8  and 9) account for more than 80% of DDS mutations. (Coppes et al, 1994). It is 
now recognised that these mutations affect amino acids crucial for the stability of DNA 
binding of the zinc fingers (Little et al, 1995; Borel et al, 1996), and may also change its 
ability to bind RNA. As these mutations were only detected in one allele of the WT1 
gene, it was initially thought that DDS mutations act in a dominant manner. However in 
some DDS cases, WT1 mutations located either within or upstream of the zinc finger 
region result in truncated non-functional proteins. In this situation, a more likely 
mechanism is that these mutant proteins behave in a dominant-negative fashion, and 
interfere with the function of the wild type protein produced from the remaining allele 
(Little et al, 1993; Reddy et al, 1995; Little, 1997). Effective WT1 concentrations in 
cells are probably reduced to below 50% because the WT1 proteins tend to dimerise, 
resulting in abundant non-functional homodimers and heterodimers of mutant WT1 
protein (Moffett et al, 1995). Further support for a dominant negative effect comes from 
gene-targeting experiments. Heterozygosity for a targeted murine WT1 allele, 
W77(tmT396), which truncated the third zinc finger at codon 396, induced mesangial 
sclerosis characteristic of DDS in adult heterozygous and chimeric mice. Male genital 
defects also were evident, and there was a single case of Wilms tumour in which the 
transcript of the non targeted allele showed an exon 9 skipping event, implying a causal 
link between WT1 dysfunction and Wilms’ tumorigenesis in mice (Patek et al, 1999). 
Interestingly, expression from the mutant allele accounted for only 5% of the total 
amount of WT1 protein, suggesting that even small amounts of mutant protein can have 
devastating effects on urogenital development.
To date, all WT1 gene mutations detected in cases of isolated DMS overlap with those 
characteristically associated with the complete form of DDS, making genotype-
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phenotype correlation of little value. It is likely that a large proportion of isolated DMS 
and FSGS cases result from abnormalities of other glomerular genes, possibly either 
upstream or downstream of WT1, and thus able to partially mimic the effects of WT1 
mutations seen in DDS. These remain unidentified, although there is some preliminary 
evidence that expression of Pax2, a transcription factor regulated by WT1 in vitro, 
(Ryan et al, 1995) is abnormal in some cases of DDS and isolated DMS (Yang et al,
1999). In addition, it is tempting to speculate that mutations may be present in a 
recently identified downstream target of WT1, podocalyxin (Palmer et al, 2001). 
Podocalyxin is a major structural membrane protein in podocytes, and strongly 
implicated in the maintenance of the slit diaphrgam as null mice exhibit profound 
defects in kidney development and die within 24 hours of birth from renal failure 
(Doyonnas et al, 2001). Although podocytes are present in the glomeruli of the 
podocalyxin (-/-) mice, they fail to form foot processes and slit diaphragms. Binding of 
WT1 to conserved elements within the podocalyxin gene promoter results in potent 
transcriptional activation, and the expression pattern of podocalyxin in the developing 
kidney mirrors that of WT1 itself, providing further evidence for a potential interactive 
role for these genes, perhaps in the specific activation of a glomerular differentiation 
program in renal precursors. Other candidates are a novel adaptor protein CD2AP, 
originally cloned in T cells, where it orchestrates receptor patterning and cytoskeletal 
polarity in T-cell contacts (Dustin et al, 1998). CD2AP also plays a role in glomerular 
filtration, as CD2AP null mice develop a congenital nephrotic syndrome consistent with 
DMS (Shih et al, 1999), and in addition, CD2AP interacts with the key slit diaphragm 
protein nephrin, linking it to the actin cytoskeleton (Shih et al, 2001; Yuan at al, 2002). 
Recent screening of cases of isolated DMS for CD2AP mutations has detected two base 
changes within the interaction domain between CD2AP and nephrin, which appear to 
diminish the ability of CD2AP’s to bind nephrin, a key player in slit diaphragm function 
(Gopa G, Koziell A, unpublished data). Although these changes have not been detected 
in normal controls, their significance still requires verification.
3.6.2 Defective alternative splicing o f  WT1 leads to a reversal in the normal +/- KTS 
isoform ratio and causes Frasier syndrome
The detection of specific WT1 mutations in all four cases of FS provided clear evidence 
that this condition is caused by heterozygous mutations of the second alternative splice
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donor site in exon 9. Although two different mutations were detected in this series, the 
phenotypic consequences were indistinguishable. Twenty additional FS cases with 
intronic WT1 mutations are now present in the literature (Barbaux et al, 1997; Kikuchi 
et al, 1998; Klamt et al, 1998; Okuhara et al, 1999; Demmer et al 1999; Buzi et al, 
2 0 0 1 ), and if mutation data for all twenty-four cases is merged, there is a striking bias in 
their distribution. Twenty-two cases have either a + 4 C to T or a +5 G to A substitution, 
whereas the remaining two have mutations at +2 and + 6  respectively (Kikuchi et al,
1998). The mutation hot spot observed in the majority of FS cases may result from the 
5-methylcytosine at the +4/+5 CpG di-nucleotide being especially susceptible to 
deamination. An association between WT1 exon 9 mutations and FS has also been 
described (Kohsaka et al, 1999), although on closer examination the clinical phenotype 
and genotype are more suggestive of a diagnosis of incomplete DDS, than FS.
Figure 3.15 Location of WT1 gene mutations in FS
-KTS
+KTS
CATACAGGTAAAACAAgtgcgtaactt.......................... gtcaacagGTGAAAAGCCC
ST
Exon 9
gto a
tto c c to t
Kbjt
•  sites most frequently affected
The presence of alternative splice site mutations in FS highlights the importance of a 
precisely balanced expression of WT1 isoforms for correct function, and suggested that 
the + and -  KTS splice variants are likely to play distinct biological roles within the 
kidney and gonad. The +5 G to A mutation detected in many cases had previously been 
shown to abolish alternative splicing in transient transfections using minigene constructs 
(Bruening et al, 1992). Although these experiments have not been repeated for other FS
151
splice site mutations, computer prediction programmes suggest a similar disruption of 
alternative splicing through loss of the second alternative splice site (Figure 3.5). 
Importantly, the analysis of gonadoblastoma tissue from case DG confirmed the in vitro 
and in silico findings by demonstrating an altered +/- KTS isoform ratio in vivo. 
Patients with FS therefore have one normal copy of WT1 and one that can only produce 
the KTS negative isoform. This allele loss leads to cells that cannot produce the + KTS 
isoform of WT1, but still have large amounts of the - KTS isoform, resulting in a 
relative deficiency of the usually more abundant + KTS isoform. The WT1 proteins 
produced are theoretically otherwise normal with normal binding abilities, which 
appears to have a significant impact on the predisposition to Wilms’ tumour, not 
normally associated with FS despite the existence of one case report (Barbosa et al,
1999). Of note three patients reported with diffuse mesangial sclerosis and WT1 intron 
9 mutations usually associated with FS, also did not develop Wilms’ tumour (Barbosa et 
al, 1999). This suggests that disruption of the isoform ratio is insufficient for tumour 
production, which is supported by in vitro observations that the tumorigenicity of the 
G401 Wilms’ tumour cell line in nude mice can be suppressed by both + and - KTS 
isoforms to the same extent (McMaster et al, 1995).
Understanding of the molecular mechanisms underlying FS and DDS nephropathy were 
recently advanced by the generation of specific mouse strains in which either the -KTS 
or +KTS isoforms were specifically removed (Hammes et al, 2001), and these confirm 
that these splice variants are likely to have distinct functions during sex determination 
and nephron formation. Heterozygous mice with a reduction of +KTS levels developed 
glomerulosclerosis within the first three months of life, and a female phenotype 
regardless of karyotype, thus representing a murine model of FS. The kidney phenotype 
was perhaps more pronounced than in humans, in that most of the glomeruli showed 
DMS rather than FSGS, reminiscent of the histology more commonly associated with 
DDS. Of note, DMS nephropathy has been described in association with the intron 9 
mutations characteristically detected in FS (Denamur et al, 1999; Ito et al, 2001). The 
finding of DMS in +KTS deficient mice strengthens the hypothesis that the DDS 
phenotype in man is caused by a reduction of functional WT1 due to dominant negative 
mutations, and underlines the importance of the +KTS isoform in podocyte homeostasis. 
In contrast, mice with a reduction of the -KTS isoform had hypo-dysplastic kidneys and
152
streak gonads in both XY and XX animals. This reduction in the size of the kidneys and 
gonads may have resulted from an increase in renal and gonadal apoptosis, indicating 
that -KTS variants are critical for the survival of embryonic tissue. In addition, an 
almost complete absence of synaptopodin and a-integrin expression suggests that -KTS 
isoforms are required for an early differentiation step of the presumptive podocyte layer 
into the visceral epithelium.
FS mutations also have a significant impact on gonadogenesis in individuals with a 46 
XY karyotype, but it remains unclear how these exert their effects at a molecular level 
as in vitro and in vivo data conflict. Initial work by Nachtigal et al (1998) suggested that 
steroidogenic factor 1 (SF1) participates in sexual development by regulating expression 
of the polypeptide hormone Mullerian inhibiting substance (MIS). In the normal 
situation, (-KTS) WT1 isoforms associate and synergise with SF1 to promote expression 
of the gene encoding MIS, whereas DAX1, a gene thought to direct ovarian 
development, antagonises this synergy. In contrast, if WT1 mutations characteristically 
seen in DDS are introduced, the resultant WT1 protein and SF1 fail to associate and 
synergise, functional opposition of the DAX1 gene no longer occurs, and testis 
development fails. Thus, the severity of the genital phenotype is dependent on the degree 
to which WT1/SF1 binding is disrupted. Because different mutations might be expected 
to have different effects on the synergistic action of the protein cascade, this might 
explain why such a wide variety of genital phenotypes are seen in patients with DDS and 
a 46 XY karyotype. Interestingly, because an intact WT1 gene is not an absolute 
requisite for female gonadal development, individuals with DDS or FS and a 46 XX 
karyotype usually have no gonadal abnormality. However, WT1 -KTS isoforms are also 
able to activate the Daxl promoter, at least in vitro (Kim et al, 1999), so the situation is 
complex. A further in vitro target for WT1 appears to be SRY, an important component 
of the male sexual differentiation pathway. Again, these experiments suggested that SRY 
activation was only achieved by -KTS variants (Shimamura et al, 1997; Hossain 2001). 
In contrast, data from the in vivo experiments in + and -  KTS knockout mice shows the 
opposite. Here, absence of +KTS variants lead to reduction of SRY expression levels 
and absence of Sox 9 and MIS activation, whereas -KTS isoforms did not appear to 
regulate SRY, and were instead required for the survival of the gonadal primordium
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(Hammes et al, 2001). In keeping with human FS, the effects of mutations were only 
seen in XY mice, as XX animals had normal female gonads.
The clinical overlap between FS and DDS, and the association of both conditions with 
mutations of the WT1 gene opened up a debate as to whether these form part of a 
spectrum, or different disorders caused by mutations of the same gene. Although 
historically, specific clinical characteristics apply to FS and DDS, genetic analysis has 
produced an increasingly complex picture. Mutations commonly associated with DDS 
have not been reported in FS patients. However, there are now three reports of the two 
most common intronic splicing mutations associated with FS, +4 C to T and +5 G to A, 
occurring in patients with DMS and a phenotype compatible with DDS, although not 
associated with Wilms’ tumour. Two had +4 C to T substitutions (Jeanpierre et al, 
1998b; Denamur et al, 1999) and one a +5 G to A substitution (Jeanpierre et al, 1998b). 
Furthermore, 46XX individuals with FS and intronic WT1 mutations do not have 
gonadal abnormalities (Klamt et al, 1999; Demmer et al, 1999), and there is increasing 
evidence that mutations may occasionally be transmitted to offspring, which may 
develop DDS. For example, vertical transmission of the +5 G to A WT1 mutation was 
reported from a mother with a normal 46XX karyotype, normal renal function and 
FSGS, to her phenotypically female child who subsequently developed nephrotic 
syndrome (Denamur et al, 1999). On further investigation, the child had a 46 XY 
karyotype and DMS, features suggestive of DDS. Quantification of WT1 +KTS/-KTS 
isoforms by semi-quantitative RT-PCR showed reversal of the ratio in both the index 
case and her mother, as reported in FS. There was no clear explanation for the difference 
in observed phenotype, as neither mosaicism in the index case's mother, nor additional 
WT1 mutations in the index case were detected. As mentioned previously, phenotype 
may depend on the genetic background of the individual, for example, polymorphisms 
in WT1 target genes, which might result in different activation levels by WT1 mutants, 
subtly altering the effects of mutations. These findings clearly identify a subset of cases 
sharing the clinical and genetic characteristics of both disorders, where the pathogenetic 
mechanisms and the projected clinical course are not clear cut, and although 
characteristic mutations suggestive of FS or DDS may be present, strict classification on 
the basis of clinical and genetic criteria is likely to be misleading. These findings 
provide further evidence that DDS and FS form two ends of an overlapping spectrum,
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and the nephropathy seen in both can result from disruption of the normally precisely 
balanced expression of WT1 isoforms.
3.6.3 Yeast two hybrid analysis
In view of the differing functions + and -  KTS isoforms are likely to play in vivo, an 
approach to try and establish their roles in renal and gonadal development was to 
determine which protein-protein interactions each isoform might participate in. 
Alteration of protein-protein interactions is known to contribute to many diseases, and 
the detection of WT1 mutations resulting in an altered protein isoform ratio suggested 
that disrupted protein binding might also contribute to disease pathogenesis within the 
FS/DDS spectrum.
Protein-protein interactions are intrinsic to virtually every cellular process, and their 
analysis is often able to provide important information about gene function. A number 
of tools are available, such as biochemical approaches, which in general involve 
physical methods such as protein affinity chromatography, affinity blotting, co- 
immunoprecipitation and cross-linking. Alternatively, protein probing using a labelled 
protein to screen an expression library is another well recognised technique. However, 
since all combinations of protein-protein interaction are assayed, including those that 
might never occur in vivo, the possibility of identifying artifactual partners is a major 
disadvantage. A second drawback derives from the use of a bacterial host, where not all 
post-translational modifications, such as phosphorylation, needed for the interaction 
might occur. A more recent technique known as the “two hybrid” or “interaction trap”, 
enables the identification of interacting partners in vivo using yeast genetic machinery. 
As mentioned previously, the two hybrid technique exploits the modular properties of 
GAL4 and other transcription factors, and that the DNA binding domain of GAL4 is 
unable to activate transcription unless associated with an activation domain. This use of 
the different functional modules of a transcription factor to study protein-protein 
interactions was first proposed by Fields and Song (1989), using SNF1 fused to the 
binding domain and SNF4 fused to the activation domain of GAL4. Expression of both 
chimeras and subsequent interaction of SNF1 and SNF4 was required for reconstitution 
of the transcription factor, and thus induction of reporter gene expression. These intial
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experiments confirmed that a transcriptional read-out could be used to study 
interactions between proteins not involved in the transcription process.
The yeast two hybrid has some clear advantages over classical biochemical and genetic 
approaches. Firstly, it embodies an in vivo technique using the yeast host as a live test 
tube, which is able to mimic more closely the cellular processes seen in higher 
eukaryotes than most in vitro approaches or techniques based on bacterial expression. 
An important feature is the minimal requirements to initiate a screen. In effect, only the 
cDNA is needed, in contrast to the large quantities of purified proteins or good quality 
antibodies often needed in other approaches. Since the genetic reporter strategy results 
in significant amplification, weak and transient interactions are more readily detected, 
although there is clearly a trade-off between the detection of weak interactions and the 
number of false positives encountered when performing a screening procedure. An 
additional feature of yeast two hybrid screening is that the identification of an 
interacting protein is concurrent with the cloning of the corresponding gene. This may 
give important functional information about the bait protein, such that this technique 
has been instrumental in the resolution of the molecular details of many signalling 
cascades (Tapon et al, 1998; Geijsen et al, 1999; Georgakopoulos et al, 2001).
There are, however, a number of drawbacks. Since the read-out of the yeast two hybrid 
makes use of a transcription event, one of the most crucial initial experiments is to 
establish whether the protein of interest is able to initiate transcription independently, 
resulting in autoactivation. This is often circumventable by the use of deletion 
constructs with the autoactivation domains removed, or by manipulation of the 
sensitivity of the reporters by the use of metabolic antagonists such as 3-aminotriazole, 
an inhibitor of histidine synthesis. Fortunately neither of the WT1 constructs used for 
yeast two hybrid assay demonstrated any appreciable autoactivation, and were therefore 
suitable for use in this system. An obvious criticism is also the use of artificially made 
fusion proteins, which might change the conformation of the bait and/or prey with a 
consequent change in protein function. The possibility of identifying artifactual partners 
as a result is a typical disadvantage, although an empirical way of excluding this is 
reciprocal transfer of the proteins i.e. switching around from DNA binding domain 
fusions to activating domain fusions, which should not affect the protein-protein
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interaction. In addition, some interactions depend on post translational modifications 
that do not occur in the yeast. Finally, all library screens require as good as possible 
representation of cDNA’s, and ideally, over a million independent clones should be 
screened.
Both Gal4 DNA binding domain -  murine +KTS and -KTS WT1 fusion proteins were 
used independently as bait for yeast two hybrid screening of a E9.5/10.5 day mouse 
embryo cDNA library. Full length proteins were used to maximise the chance of the 
constructs adopting the correct protein conformation within the yeast cells. Previous 
experience with the combination of a pAS binding domain vector, pVP16 embryo 
library and the Y190 yeast strain suggested an average of 20 to 30 positive clones might 
be expected. This meant that despite good transformation efficiencies, a greatly sub- 
optimal result was obtained as after dual selection for both the histidine and lacZ 
reporters, only 6  positive clones were detected after two screens for the +KTS isoform, 
and 4 positive clones for the -KTS isoform. Since the pVP16 library screened was of 
good quality and other screens had indicated that it was representative, it is unlikely that 
an insufficient number of clones were screened. The pASl vector contains a full length 
ADH promoter and is able, at least theoretically, to induce strong expression of a hybrid 
protein. However, this did not appear to be the case in these experiments as neither the 
+ or -KTS isoforms could be detected on Western blot. This was a recurring problem 
with these particular constructs (Rachel Davies, MRC Unit Edinburgh, personal 
communication), and meant that even though expression was sufficient to allow self 
association of the WT1 proteins, weaker protein-protein interactions may not have been 
able to occur. Full length WT1 proteins were used, and there remains a possibility that 
using shorter constructs may have improved the result, despite the additional risk of 
misconformation. In addition, the yeast strain used plays a key role. Y190 only has two 
reporters and a reputation for false positives, as it is not as sensitive or specific as newer 
strains e.g. PJ69. These have tightly controlled multiple reporters, which makes them 
more sensitive, but at the same time less prone to false positives. It is unlikely that WT1 
was toxic to the yeast, as self-association could be clearly demonstrated.
Two yeast two hybrid screens were performed and these identified two putative 
interactors for the +KTS isoform, and one for the -KTS isoform. All interactors initially
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represented unknown clones, which were gradually characterised with the 
improvements made in the databases resulting from the ongoing Human Genome 
Mapping project (http://www.ornl.gov/hgmis).
Three of the six protein-protein interactions detected for the +KTS isoform were with 
the predicted novel Edr (embryonal carcinoma differentiation regulated) protein 
(Shigemoto et al, 2001). The Edr gene is a novel developmentally regulated gene, 
originally identified through differential screening of an embryonal carcinoma cDNA 
library. It is present in whole mouse embryo RNA at all stages between E9.5 and E l6.5 
days gestation. Further analysis detected Edr in most foetal tissues including kidney, 
but in adult tissue low levels are only detected in brain and testis. Two overlapping 
open reading frames were identified, one encoding a 320 amino acid polypeptide 
containing a putative zinc finger binding domain of the CCHC subclass, whereas the 
second reading frame encoded a 631 amino acid polypeptide containing a consensus 
motif for an aspartyl protease catalytic site. Both motifs are also characteristic features 
of retroviral genes, and subsequent experiments showed that Edr is also likely to 
participate in ribosomal frameshifting, a mechanism that enables protein translation to 
occur from overlapping reading frames. This generally occurs in viral genomes, but is 
very rare amongst prokaryotic and eukaryotic cellular genes. Edr is the first mammalian 
gene to be identified that is capable of programmed translational recoding, which 
undoubtedly forms an important mechanism for regulating gene expression.
The putative detection of a protein-protein interaction between +KTS WT1 and Edr 
protein is of interest, in view of the possible role for +KTS isoforms in the regulation 
of RNA metabolism. All three clones appeared to be overlapping, lending support to the 
validity of the interaction, at least in yeast. Sequence quality was however relatively 
poor. At the time, the best way of plasmid rescue was considered transformation into 
HB101 bacteria, as these bacteria are unable to grow on a leucine deficient medium, 
forming additional selection for the activation domain plasmid. However, DNA 
prepared from HB101 bacteria can be difficult to sequence, and since sequence quality 
was relatively poor, this accounted for the surprising lack of a 1 0 0 % match between the 
captured clones. This interaction remains speculative as no further confirmatory tests
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were undertaken due the poorly characterised nature of Edr protein, a lack of an obvious 
link with renal disease, and the time constraints of the project.
One of the six clones detected using the +KTS isoform encoded an in frame fragment of 
angiomotin (Troyanovsky et al, 1902). This is a novel angiostatin-binding protein, 
which may regulate endothelial cell migration and tube formation. Angiomotin is 
expressed on Northern blot in most tissues examined, including the kidney. However it 
is unlikely to represent a true positive, as intracellular localisation studies indicate that it 
co-localises with F-actin and is therefore cytoplasmic, whereas WT1 is nuclear. This 
limits the biological significance of the interaction, which might have occured in the 
relatively artificial context of a library screen, but in reality the sub-cellular localisation 
of these two interactors means that they never meet in vivo. The remaining two clones 
were also false positives, as both nucleotide sequences were in the opposite orientation 
and thus encoded nonsense proteins.
Yeast two hybrid analysis using the -KTS isoform was even less successful. Only one 
potential interactor was detected, aminoimidazole carboxamide ribonucleotide 
transformylase/inosine monophosphate cyclohydrolase (ATIC), a bifunctional enzyme 
catalysing the last two steps in the de novo purine biosynthetic nucleotide pathway (Rayl 
et al, 1996). In view of the role of WT1 in oncogenesis, this may have represented a 
biologically significant positive. Since only one clone was detected, and there was no 
apparent link to human nephrotic disease, further confirmatory experiments were not 
undertaken.
Subsequently, a number of groups have now been successful in identifying WT1 protein 
binding partners using the yeast two hybrid, although none give particular clues about 
renal development or podocyte function. Of particular significance, are SF1, which 
provided further insight into the role of WT1 protein in sex determination (Nachtigal et 
al, 1998), and WTAP (Little et al, 2000), a nuclear protein, which like WT1 localizes 
throughout the nucleoplasm as well as in speckles and partially co-localizes with 
splicing factors. In addition, the detection of protein-protein interaction with U2AF65, a 
constitutive splicing protein (Davies et al, 1998), provided further evidence for a role in 
RNA metabolism. However, the main sine qua non of protein-protein interaction 
analysis is the differentiation between informative biological interactions, and non-
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significant or false interactions, i.e. those unable to occur in nature due to expression at 
different times or in different locations. Of the interactions detected using the + and — 
KTS isoforms of WT1, the best candidate for true biological significance was Edr 
protein. However, a degree of pragmatism must be adopted when assessing the validity 
of yeast two hybrid results, and the evidence that Edr protein was a true interactor was 
insufficient to justify further follow-up.
Yeast two hybrid analysis of the WT1 isoforms could easily have been improved on, but 
unfortunately time constraint did not allow experiments to be optimised. Repeating the 
screens using improved yeast strains, more refined reporter systems and a kidney cDNA 
library may have resulted in a more successful outcome. A number of alternative 
binding domain vectors are now available, which result in better expression of the bait 
protein within the yeast allowing the detection of weaker, though potentially significant 
interactions. Another strategy might have been to screen using constructs deleted for the 
DNA binding domain, which might minimise false positives. However, since all areas of 
the WT1 protein have been implicated in protein-protein interactions, this could have 
potentially resulted in false negative results. In addition there is a significant risk of the 
bait protein adopting an incorrect conformation thus opening up spurious sites and 
closing biologically significant ones. Multiple reporter yeast strains may well have made 
a difference in the number of positive clones detected. Since each reporter gene is under 
the control of a different promoter, sensitivity can be increased without increasing the 
number of false positives. However, this was not a viable option, so the project moved 
on to two other genes with critical roles in glomerular filtration, NPHS1 encoding 
nephrin and NPHS2 encoding podocin. Results of NPHS1 and NPHS2 analysis are 
described in Chapter 4.
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CHAPTER 4: Molecular analysis of the NPHS1 and NPHS2 genes in 
congenital and early onset nephrotic syndrome
4.1 Background
Finnish type congenital nephrotic syndrome (CNF) is the most common congenital 
nephrotic syndrome. However, in early life, isolated nephrotic syndromes associated 
with FSGS and DMS as the renal histology also form a significant component of the 
overall pathology. CNF is characteristically a disease confined to the kidney, and 
diagnosis is based on time of onset, clinical features at time of presentation and renal 
histology. The same diagnostic criteria apply to FSGS and DMS, although in some 
cases these types of nephrotic syndromes may be associated with extra-renal 
manifestations, as described in Chapter 3. Inheritance of nephrotic syndromes in early 
life purely affecting the kidney is usually considered to be autosomal recessive, although 
apparently sporadic cases without a clear family history are also common.
The molecular basis underlying the loss of glomerular permselectivity seen in nephrotic 
syndrome characterised by CNF, FSGS or DMS renal histology was investigated. A 
mutational analysis strategy was adopted to analyse the involvement of two novel renal 
glomerular genes, NPHS1 and NPHS2. These two genes were chosen for study as both 
are exclusively expressed within the podocyte layer of the renal glomerulus, and initial 
data had established a link with human disease. Mutations of the NPHS1 gene had been 
detected in CNF cases of Finnish origin (Kestila et al, 1998), whereas NPHS2 gene 
mutations were detected in a form of autosomal recessive familial FSGS (SRN1), with 
an onset between 3 months and five years (Boute et al, 2000). The initial focus was to 
test the hypothesis that NPHS1 gene mutations were also responsible for cases of CNF 
without Finnish ancestry (section 4.2 and 4.3). Outside Finland, CNF generally follows 
a similar clinical course, although anecdotal reports of milder phenotypes including 
spontaneous resolution of proteinuria have been documented (e.g. Haws et al 1992), 
originally thought to be suggestive of genetic heterogeneity. An extension of the initial 
hypothesis was to determine whether NPHS1 mutations also caused these milder 
phenotypes. In addition, other types of congenital nephrotic syndrome, namely those
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characterised by FSGS renal histology, and selected cases of DMS, in which WT1 gene 
mutations had not been detected were also analysed (section 4.4 and section 4.5). The 
results led to further experiments to test whether NPHS2 gene mutations were present in 
cases of CNF without NPHS1 gene mutations, and whether they contributed to the 
variable severity of clinical phenotype occasionally seen in CNF (section 4.6). The role 
of NPHS2 mutations in a possible phenotypic switch from CNF to congenital FSGS was 
explored, and the extent of the overlap between NPHS1 and NPHS2 mutations in CNF 
examined (section 4.7). Five cases with early onset FSGS compatible with SRN1, and 
two cases of early onset DMS were also screened for NPHS2 mutations (section 4.8). 
Finally, electromobility shift assays were performed to explore the significance of the 
promoter mutation detected in two non-Finnish CNF patients (section 4.9). The NPHS1 
and NPHS2 mutations detected during this study were mapped to establish whether 
mutations targeted specific areas of each gene, thereby providing an indication of areas 
of particular functional importance. In addition, genotype-phenotype correlations were 
made to confirm whether a functional interrelationship between NPHS1 and NPHS2 was 
present. The results are discussed in section 4.9.
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4.2 Patient selection and control material
Fifty-four affected individuals with congenital and early onset nephrotic syndrome were 
studied in total. Selection of cases for the study was based on clinical presentation, 
family history, laboratory findings and renal pathology. Causes of secondary nephrotic 
syndrome such as pre-natal infection were excluded, and only cases with pure renal 
involvement studied. Patients originated from the United Kingdom, Malta, Turkey, 
Middle East, Pakistan, Bangladesh, India and South Africa. Forty-one cases had CNF, 
although mutational analysis was only possible in thirty-seven, four congenital FSGS, 
five early onset FSGS compatible with a diagnosis of SRN1, two congenital DMS and 
two early onset DMS. The clinical details of each case entered into the study are listed 
in Appendix I. In order to maximise the ethnic diversity of the control group, fifty 
European and North American, sixty-one Asian and twenty-two Maltese were 
examined. The study had ethical approval from the Institute of Child Health Research 
Ethics committee (number 99MM05) and informed consent was obtained in all cases. 
Diagnosis of congenital nephrotic syndrome required a clinical history of prematurity, 
placental weight >25% of infant birth weight, and onset of proteinuria/ nephrotic 
syndrome between birth and three months of age. By definition, cases of CNF had 
normal renal function and were normotensive at presentation. Cases of congenital FSGS 
followed a similar pattern to CNF, but the two cases of congenital DMS both presented 
with hypertension and renal compromise within the neonatal period in conjunction with 
a severe nephrotic syndrome. Diagnosis of early onset nephrotic syndrome was made if 
onset was between three and thirty-six months of age. Cases had a mean onset of 18 
months and the presence of characteristic features on renal biopsy was used to refine the 
diagnosis to FSGS or DMS. The salient clinical features used for diagnosis are listed in 
Table 4.1, and all cases studied were characterised on the basis of these criteria.
Although it is generally considered that nephrotic syndrome in early life follows an 
autosomal recessive pattern of inheritance, many of the cases studied were sporadic, 
with only one individual affected per family. Thirteen of the forty-one CNF cases had a 
positive family history of an affected a sibling or first-degree relative. Consanguinity 
between parents was identified in nineteen cases, five of which also had a positive 
family history. Two of the four cases of congenital FSGS and both cases of congenital
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DMS studied had affected siblings. Within the early onset group, three of the five cases 
with SRNl-like disease and none of the DMS patients had a family history.
The majority of the cases studied developed a severe nephrotic syndrome with 
progression to end stage renal failure within five years, irrespective of whether 
presentation was at birth or subsequently. However nine CNF patients originating from 
Malta, India, Bangladesh, South Africa and the United Kingdom did not follow a typical 
course and went on to develop an unexpectedly mild phenotype. Initial presentation was 
identical to those patients who subsequently developed severe CNF, and cases were 
indistinguishable on clinical and histological grounds until 2-3 years of age. At this 
point, resolution of proteinuria rather than progression into chronic renal failure was 
seen. Proteinuria partially resolved in five cases (1, 26, 91, 92 and 94; clinical details 
listed in Appendix I) with preservation of renal function, and four cases (15, 90, 91 and 
96) went into spontaneous remission. This was also not consistently associated with any 
particular treatment, for example the majority of cases that went on to develop severe 
CNF disease received anti-proteinuric agents, whereas cases 90 and 92 with mild CNF 
did not. This suggested that the lack of progression of nephrotic disease was not simply 
related to differing treatment strategies. The mild phenotype was not observed in 
conjunction with congenital FSGS or early onset FSGS or DMS, where all cases 
developed severe nephrotic syndrome.
Clinical findings were confirmed by renal biopsy or post-mortem analysis in fifty of the 
fifty-four patients studied, and a histopathological diagnosis set based on accepted 
criteria for the diagnosis of CNF, FSGS and DMS as listed in Table 4.2. Biopsies of 
patients with a diagnosis of congenital FSGS were independently examined at two 
centres. These showed early focal segmental changes in 50% of the glomeruli in three 
cases, and an initial histological appearance of minimal change at five months in one 
case, which developed into FSGS by the second biopsy at 18 months. Renal histology 
was not examined in four cases, however all originated from Malta, and two had a 
family history of CNF in a sibling or first cousin.
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Table 4.1 Diagnostic criteria used to ascertain cases
Congenital nephrotic syndrome 
Clinical features
(i) Prenatal
• Elevated a-fetoprotein (AFP) during pregnancy
• Prematurity
• Low birth weight
• Placental weight > 25% of infant birth weight
• Onset between birth and three months of age
(ii) Features at presentation
• Proteinuria at birth
• Oedema/nephrotic syndrome at birth
• Male: female ratio 1:1
• Autosomal recessive inheritance or sporadic
(iii) Clinical features distinguishing between CNF, FSGS and DMS
• CNF cases: generally normal renal function and normo-tension
• DMS cases: renal insufficiency and hypertension +/- abnormalities in extra- 
renal systems. AFP not uniformly elevated and generally normal placental size
• Congenital FSGS: features resemble CNF or DMS
Early Onset Nephrotic Syndrome
• Onset of nephrotic syndrome between 6 and 36 months
• Normal gestational history
• occasional response to steroid therapy
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Table 4.2 Histological Criteria used to establish underlying renal pathology
CNF
Early Features
• glomeruli normal +/- mesangial hypercellularity
• proximal tubular dilatation
Late Features
• enlarged sclerotic glomeruli with marked microcystic dilation of the tubules
• tubular atrophy and interstitial fibrosis
FSGS
• presence of areas of both focal and segmental glomerular sclerosis
• focal and segmental tuft collapse
• +/- segmental hyalinosis, +/-glomerular deposits of IgM/C3
DMS
Early Features
• increased mesangial matrix, no mesangial hypercellularity
• extensive tubular dilatation
Late Features
• most glomeruli with condensed sclerotic tufts +/- collar epithelial cells
• dilated Bowman’s capsule and tubules
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4.3 The NPHS1 gene is a suitable candidate for non-Finnish CNF
Haplotype analysis of Finnish and non-Finnish CNF families (Manniko et al, 1995, 
Fuchshuber et al, 1996; Manniko et al, 1996; Manniko et al, 1997) suggested Finnish 
and many non-Finnish CNF patients shared the same disease locus. Subsequent 
detection of NPHS1 gene mutations in the majority of Finnish cases of CNF (Kestila et 
al, 1998) implied that mutations might also be responsible for non-Finnish CNF. 
However, linkage analysis in the majority of non-Finnish CNF cases is not feasible, as 
many cases lack clear autosomal recessive inheritance. Furthermore, the CNF phenotype 
within the non-Finnish population is more variable, both in severity of clinical 
presentation and histological appearance. In view of these discrepancies, the first 
question to answer prior to embarking on mutation screening was whether NPHS1 was 
an appropriate candidate gene for the cases of non-Finnish CNF to be studied.
To test this, a partial haplotype analysis was performed on selected families using the 
three polymorphic markers D19S608, D19S609 and D19S610, originally developed to 
fine map the critical region of NPHSJ gene (Mannikko et al, 1995, Olsen et al, 1996). 
The NPHS1 gene lies immediately distal to D19S609, and overlaps marker D19S610 as 
shown in Figure 4.1. D19S608 is located approximately lOOkb proximal to D19S610. A 
particular emphasis was placed on D19S608 and D19S610. D19S610 was thought likely 
to be intragenic, and also showed the most significant linkage disequilibrium, with an 
allelic association of 84% at least within the Finnish population (Manniko et al, 1995). 
Two major haplotype classes were present in Finnish CNF, both sharing allele 6  of 
D19S610, although this was subsequently linked to both Fin major and Fin minor 
mutations rather than a single mutation (Kestila et al, 1998). However, subsequent 
haplotype analysis of non-Finnish CNF observed the strongest linkage disequilibrium to 
be with D19S608 in the population tested (Mannikko et al, 1996). Four main haplotype 
classes were present, and in many cases the alleles found were the same as in Finnish 
CNF families. This suggested that NPHS1 was also the causative gene in non-Finnish 
CNF. In view of the clinical variability of non-Finnish CNF, allelic association was first 
tested in as many of the non-Finnish CNF families selected for study as possible. A 
premise was set that the presence of allelic association would corroborate a link between 
NPHS1 and non-Finnish CNF, substantiating mutational screening in these cases.
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Figure 4.1 Location of polymorphic m arkers used to establish allelic association 
with the NPHS1 locus on chromosome 19ql3.1.
P13.3
pl3.2
pl3.1
P12
ql2
ql3.1
ql3.2
ql3.3
ql3.4
Genetic
Distance
(cM)
D19S213
D19S416
D19S208
D19S191
D19S224
D19S220
Physical
Distance
(kB)
D19S208
D19S609 •
D19S610 •
920
D19S608 •
D19S224
Key
• polymorphic markers used to ascertain likelihood that NPHS1 was a candidate 
gene for non-Finnish CNF
168
Partial haplotype analysis o f  selected CNF fam ilies. The two groups considered likely 
to be informative were families originating from Malta and those with demonstrable 
consanguinity. The Maltese are known to represent a genetically homogeneous 
population, and the incidence of congenital nephrotic syndrome is surprisingly high. The 
carrier frequency was found to be 1 in 20 normal Maltese controls. Consanguineous 
families originated from the Indian sub-continent, the Middle East and Turkey. None of 
the Maltese or Asian families examined had demonstrable Finnish ancestry. Affected 
individuals had a clinical diagnosis of CNF, confirmed by histological diagnosis on 
renal biopsy or post-mortem in the majority of cases. Seven had a family history of CNF 
in a sibling or first-degree relative. The family trees for the Maltese and consanguineous 
families are shown in Appendix II.
Partial haplotype analysis was performed on eight Maltese, two Turkish, nine Asian and 
two Middle Eastern families. Clinical details are shown in Table 4.3. Polymorphic 
markers D19S608, D19S609 and D19S610 were analysed using standard methodology 
as described in the methods section in Chapter 2, section 2.3.11. PCR amplification of 
each repeat was performed using genomic DNA from the Maltese and consanguineous 
families, and the products obtained visualised on a 2 % agarose gel as shown on the 
representative gels in Figure 4.2. PCR products were then analysed on an ABI PRISM™ 
377 DNA Automated Sequencer using ABI PRISM™ GeneScan™ Analysis software. 
Representative traces obtained for D19S608, D19S609 and D19S610 are shown in 
Figures 4.3 a, b, and c. All Maltese cases were homozygous for the same 122 base pair 
allele for marker D19S608, 118 base pair allele for marker D19S609, and 216 base pair 
allele for marker D19S610 suggestive of linkage disequilibrium for the NPHS1 gene. 
All parents tested were heterozygous, sharing one 216 base pair allele in combination 
with 210, 212 and 220 in approximately equal incidence. The majority of 
consanguineous families were also homozygous for different alleles of D19S608, 
D19S609 and D19S610. Marker D19S610 was considered particularity valuable, as it 
was intragenic and located at the 5’ end of the NPHS1 gene. The results for this marker 
are shown in Table 4.3, in conjunction with the clinical details of the cases tested.
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Figure 4.2 Representative gels to demonstrate PCR products for polymorphic 
m arkers DS19608, DS19S609 and D19S610
216 bp 
122 bp
1Kb 81 82 83 84 85 B 11 50 64
la d d e r------------- 1-----------------------  1----
D19S610 D19S608
216 bp 
(D19S610)
122 bp
1Kb B 26 50 62 63 64 11 
ladder |
D19S609
so a  4* H
mm
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Figure 4.3 (a) Genescan trace representative of D19S608 analysis of probands in 
Maltese and consanguineous families
Allele size: 122
i
120
*
Figure 4.3 (b) Genescan trace representative of D19S609 of probands in 
Maltese and consanguineous families
Allele size: 118
i
120  J___
Figure 4.3 (c) Genescan trace representative of D19S610 analysis in four Asian 
families.
Allele size: 212
4-
210
■
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Figure 4.3 (d) Representative trace of D19S610 analysis of Maltese families: traces 
showing partial haplotype analysis of case 91 and parents
Allele size (bp)
•i' 4’ >1”
A
2 1 0
216
J L
Case 91: homozygous
214
Mother: heterozygous
210
Father: heterozygous
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Table 4.3 Clinical details and partial haplotype analysis of Maltese and consanguineous 
families tested for allelic association with markers D19S608, D19S609 and D19S610
Case Sex Family
History
9
Features at 
presentation
Alb Histo
Clinical status and Haplotype
Alb Creat Outcome Allele size (bp) 
608 609 610
A) Maltese families
81 M no 11 CNF - * Tx 122 120 216
82 F yes:83 13 CNF - - Dx 122 120 216
83 M yes:82 8 CNF - - DIED 122 120 216
84 M no 11 - - - SP 122 120 216
90 F no 12 CNF 34 35 R 122 120 216
91 F no 15 - 29 35 MP 122 120 216
92 F yes - 34 50 MP 122 120 216
93 F no 13 - 39 42 R 122 120 216
94 M yes 13 - 29 40 MP 122 120 216
B) Asian families
7 F no 6 CNF - - DIED 120 114 210
10 M no 5 CNF - - Dx 122 114 214
20 M no 8 CNF - - 7 122 114 218
26 F yes 4 CNF 35 40 MP 128 118 212
62 F no 11
CNF - - 7 140 120 212
63 F no 10 CNF - - 7 130 120 214
64 M no 15 CNF - - 7 128 118 212
80 M no 6 CNF - - DIED 128 118 212
85 M no 8 CNF - - DIED 128 118 212
C) Turkish families
8 F no - CNF - - DIED - 212
15 M no - CNF - - Dx - 210/214
D) Middle East
11 M yes 6 CNF - - DIED - 218
50 M yes 7 CNF - - Tx - 212
Key Alb = albumin concentration (mg/dL); Creat = plasma creatinine (pM/L); Histo. = histology;
SP = severe proteinuria; MP = mild proteinuria; Tx = transplant; Dx = dialysis ? = outcome unknown
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Partial haplotype analysis for both the intragenic marker D19S610, and markers 
D19S608 and D19S609 located within the critical region for NPHS1 consistently 
demonstrated allelic association in the non-Finnish CNF cases analysed (Table 4.3). 
These results were suggestive of linkage to the NPHS1 region on chromosome 19q 13.1 
for the majority of the non-Finnish CNF families tested. Furthermore, the results 
indicated a likely founder effect in the Maltese CNF population, making it probable that 
these cases would carry the same NPHS1 mutation. On this basis, it was concluded that 
NPHS1 was an appropriate candidate gene for non-Finnish CNF in these families, and 
mutational analysis of affected individuals was appropriate.
4.4 Mutations of the NPHS1 gene are present in the majority of non- 
Finnish CNF cases, including those with unusually mild phenotypes
Mutational analysis of the NPHS1 gene was undertaken to identify whether mutations of 
the NPHS1 gene were present in a population of non-Finnish individuals with CNF. 
Although milder phenotypes have been documented, the majority of non-Finnish CNF 
cases emulate the classically severe clinical phenotype seen in Finland, and renal 
histology typically represents the mesangial hypercellularity and microcystic dilatation 
of the proximal renal tubules seen in Finnish cases. Thirty-seven cases of CNF 
underwent mutational analysis, of which twenty-eight had classically severe, and nine 
atypically mild disease. The mild and severe groups were clinically indistinguishable for 
the first two to three years of life.
NPHS1 exons 1-29, adjacent introns and the promoter region were analysed by PCR 
amplification and sequencing of DNA from affected individuals. Any mutations 
detected were confirmed by restriction enzyme digest, parental analysis and absence in 
normal controls. Twenty-one different mutations were detected throughout the NPHS1 
gene in 29 of 37 CNF cases analysed. All occurred in a homozygous or compound 
heterozygous manner and affected exons 4, 6 , 7, 9, 10, 11, 14, 17, 18, 23, 24, 26, 27, 
intronic splicing regions and the promoter, and all parents available for analysis were 
carriers. Isolated heterozygous mutations were not found in association with a CNF 
phenotype. This indicated that NPHS1 mutations were responsible for the majority of
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CNF cases with no demonstrable Finnish ancestry. The same homozygous exon 27 
nonsense mutation (R1160X, Figure 4.4.19) was detected in all thirteen cases 
originating from Malta, confirming the founder effect suggested by partial haplotype 
analysis in section 4.3. R1160X was also detected in CNF cases of Asian origin, but the 
association with different alleles suggested a different founder in this population. Only 
parental DNA was available for mutation screening from Maltese CNF cases 8 6 , 87, 8 8  
and 89 (Table 4.5). However, the detection of heterozygous R1160X mutations in both 
parents in conjunction with a typical clinical history and a positive family history in all 
four provided strong evidence that homozygous R1160X mutations were also 
responsible for their disease. Importantly, the R1160X mutation was associated with 
mild CNF in six of the twelve cases analysed, five of which were female. This was seen 
in both the Maltese and Asian populations, which suggested that the discrepant 
phenotype seen was influenced by gender but not ethnic origin. The clinical details of 
each case with an R1160X mutation are also given in Table 4.5. Heterozygous R1160X 
changes were associated with a normal phenotype, and were present in all Maltese 
parents, the phenotypically normal sister of case 81, and in 1 of 44 Maltese control 
chromosomes. Of note, R1160X was the only NPHS1 mutation to be associated with 
mild disease, and all other NPHS1 mutations resulted in a consistently severe CNF 
phenotype, regardless of location or predicted effect on the protein. An nt 2335-1 
(G-»A) exon 18 splicing mutation was the commonest mutation in patients of English 
origin (Figures 4.4.14 A, B, C and D). We also document the first occurrence of Fin 
minor (R1109X) (Figure 4.18) outside Finland, in a Turkish patient with no 
demonstrable Finnish ancestry. Nine mutations remain novel (denoted by an * in Table 
4.4), whereas the remainder have now also been reported by other groups (Lenkkeri, et 
al, 1999; Aya et al, 2000; Beltcheva et al, 2001). The mutations detected in non-Finnish 
CNF are listed in Table 4.4 and representative sequencing analysis traces for each 
mutation shown in Figure 4.4. NPHS1 mutations were not detected in eight CNF cases, 
five of which had severe and three of which had atypically mild nephrotic disease. Table 
4 . 6  illustrates the common polymorphisms detected in patients and normal controls, and 
Table 4.7, those mutations altering restriction enzyme sites.
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Table 4.4 NPHS1 mutations in non-Finnish CNF patients (excluding R1160X)
Case Origin Exon Nucleotide Effect on Effect on Mutation
Change coding protein status
sequence
Frameshift Mutations
5 England 6 nt 650 (delAG) frameshift truncation comp het
50 Middle 10* nt 1291 (ins A) frameshift truncation hom
East
4 England 24 nt3250(insG) frameshift truncation comp het
Non-frameshift mutations and insertions
6 Middle 4 nt514(del ACC) del Thr 172 del Thr hom
East
7 Pakistan 6 nt603(delCACC Tyr205, Pro206 del TPR, hom
C Arg207—>Ile205 ins I
CGG (ins TT)
Nonsense Mutations
8 Turkey 26 nt3325(C->T) R1109X truncation hom
(Fin minor)
Splicing mutations
73 England H a * ntl905(C->T) alternative aberrant comp het
splice donor site? splicing
25 England 18 nt2335-l(G—»A) exon 18-1(G-»A) splicing comp het
32 England 18 nt2335-l(G—»A) exon 18-1(G->A) splicing comp het
47 England 18 nt2335-l(G-»A) exon 18-1(G-»A) splicing comp het
65 England 18 nt2335-l(G->A) exon 18-1(G->A) splicing hom
2 England 23* nt2335-l(A-»T) exon 23 donor splicing comp het
4 England 27 nt3482(G—»T) exon 27 donor splicing comp het
5 England 27 nt3482(G-»T) exon 27 donor splicing comp het
Missense mutations
9 England/ 7* nt791(C—»G) P264R Arg268->Pro comp het
India.
47 England 7 nt808(G—»T) G270C Gly270-»Cys comp het
10 India 9 ntl099(C—»T) R367C Arg367—>Cys hom
9 England/ 11* ntl337(T—>A) I446N Ile446 —>Asn comp het
India
11 Middle 11 nt 1379(G—»A) R460Q Arg460->Glu hom
East 14
25 England 14* ntl868(G—»T) C623F Cys623->Phe comp het
20 India 17 ntl927(T-»C) L643P Leu643-»Pro hom
2 England 18 nt2227(C—»T) R743C Arg743->Cys comp het
62 India nt2404(C—>T) R802W Arg802->Trp hom
Promoter mutations
32 England P* nt-340(G-»C) _ comp het
from ATG
73 England P* nt-340(G-»C) - - comp het
from ATG
KEY: del = deletion; ins = insertion; hom = homozygote; comp het = compound
heterozygote; nt = nucleotide; * = novel mutation
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Table 4.5 Clinical details of patients with homozygous R1160X (nt 3478 C->T) NPHS1
mutations
Case Origin Sex Family
History
?•
Features a t 
presentation 
Alb Renal 
histology
Clinical status/outcome 
a t time of study
A) Maltese and Asian fam ilies: severe phenotype (n=6)
80 India M no 6 CNF died aged 6  months, 
diagnosis confirmed on 
postmortem
81 Malta M no 1 1 CNF renal transplant aged 18 
months, 1 2  yeasr alive and 
well
82 Malta F yes:83 13 CNF dialysis aged 4 years, failed 
transplant
83 Malta M yes: 82 8 CNF died post transplant aged 6  
months
84 Malta M no 1 1 - severe nephrotic syndrome 
at 15 months
85 India M no 8 CNF died aged 1 month, diagnosis 
confirmed on postmortem
B) Maltese and Asian families mild phenotype (n=6)
90 Malta F no 1 2 CNF aged 11 years; alb 34, 
creat 35; R; Nt
91 Malta F no 15 aged 5 years; alb 29, creat 
35; MP; Nt
92 Malta F yes: 8 6 - “ aged 19 years; alb 34, creat 
50; MP; Nt
93 Malta F no 13 “ aged 5 years; alb 39, creat 
42; R; Nt
94 Malta M yes 13 “ aged 8  years; alb 29, creat 
40; MP; Nt
26 India F yes 4 CNF aged 7 years; alb 35, creat 
40; MP; Nt
C) Patients with a clinical diagnosis o f  classically severe CNF, mutations status 
not determined, but both parents heterozygous fo r  R1160X (n=4)
8 6 Malta M yes:92 CNF died aged 3 months
87 Malta M yes: 88
-------
- CNF died aged 5 years
8 8 Malta M yes :87 - - died aged 2  months
89 Malta M yes: 94 CNF died aged 2 1  months
KEY: alb=albumin; creat=creatinine; MP=mild proteinuria; R=remission; Nt= normotension
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fTable 4.6 NPHS1 polymorphisms detected in patients and controls
Nucleotide Change Exon/intron Effect on coding 
sequence
nt349(g—»a) exon 3 E117K"
ntl407(c—»t) exon 1 1 P440P
d elcaa-3 0  nt 1933 intron 14 intronic deletion"
nt 2289 (c—»t) exon 17 V763V
nt3230(a—>g) exon 24 N1077S-
: nt3403 +36 (c—H) intron 24 intronic base change
nt3404+89(c->t) intron 24 intronic base change
nt3315(g->a) exon 26 S1106S
Key: ■ = very common in all ethnic groups examined
Table 4.7 Restriction enzyme sites altered by NPHS1 mutations in CNF
Mutation Altered restriction enzyme 
site (- removal; + addition)
nt603 del CACCCC ins (TT) - Nci I, Sac I
nt514 (del ACC) - BseM II
nt2335-l (A —► T) -P fl MI
nt3482(G—*T) - Mae III, Bsa JI, Tsp 451
nt791(C->G) - Tse I
nt808(G-»T) - Dde I
nt 3478 (C—»T) - Ava I
nt340(G—»C) + Sty I
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Figure 4.4 Representative ABI sequence analysis traces of mutations in
non-Finnish CNF
Figure 4.4.1 A) N P H S 1  P rom oter G ->  C m issense m utation  5’ to 3’
4-
A G  G C C A  A G  C T G  G G A  
?7B____________  280
C) N orm al contro l 5 ’ to 3 ’
I
A G G C C N A G G T G G G  A 
  270
Figure 4.4.2 A) N P H S 1  exon 4 n t 514 (del ACC, T h r 172) homozygous m utation 3’ to 5’
___________ I ___________
CTCAG G AG AATG ATG TC AG G TG 
50 60
C) N orm al control 3 ’ to 5’
C T C A G G  A G  A ATG G T G  A T G  T C AG G T 
30 40 50
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Figure 4.4.3 A) NPHS1 exon 6 nt 603 homozygous del CACCCGG(ins TT) 5’ to 3’
I
G G G  T G  A T T A G C T C A G  A T A A T A G G  
160 170
C) N orm al control 5 ’ to 3 ’
I
G G G  T G  A C A C C C C G G  A G C T G A G  A T  
150 1« 170
Figure 4.4.4 A) N P H S 1  exon 6 nt 650 heterozygous del AG
G G C A T C T C N N A N C T C T G T C N T G N C C G  
90_______________ 100_____________
B) N orm al control 5 ’ to 3
I
’ to 3 ’
1 8 0
Figure 4.4.5 A) NPHS1 exon 7 nt 791(C—>G) P264R heterozygous mutation 3’to 5’
I
B) N orm al control 3 ’to 5 ’
 i _______
G G G C C A C G C A C G G C A G C T C C A A  
lae___________ lie
Figure 4.4.6 A) N P H S 1  exon 7 n t 808 (G -»T ) G270C heterozygous m utation 5 ’to 3’
______________ I
C G T  G G C C C  G A G G G T G T  A A T C C C  
410___________________420__________________
B) N orm al control 5 ’to 3’
________________I __________
C G T T G C C C  N A G G G G G T A A  T C C C  
440 450________
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Figure 4.4.7 A) NPHS1 exon 9 nt 1099(C —>T) R367C homozygous mutation 3’ to 5’
4
A AC C C G CGG GC A ACTGG 
120
B) N orm al contro l 3’ to 5 ’
I
A ACC C G CGG G CG ACTG G 
100 110
Figure 4.4.8 A) N P H S 1  exon 10 n t 1291(ins A) homozygous m utation 5’ to 3 ’
I
G G A G A C C T T C A A G  A A A G T C G C T C A T C C  
150 160 170
B) N orm al control 5’ to 3 ’
I
G G  A G  A C C T  T C A  A G  A A G T C G C T C A  T C  C 
140  150
A
160
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Figure 4.4.9 A) NPHS1 exon 11 nt 1379(G —>A) I446N heterozygous mutation 3’ to 5’
I
G G G G G  A C C C T C A T T C C A C A G  
130 140
B) N orm al control 3 ’ to 5 ’
____________ 4
T G G G G G  A C C C T C A A T C C A C A G  
130 140
Figure 4.4.10 A) N P H S 1  exon 11 nt 1337(G —>A) R460Q homozygous m utation 3’ to 5’
I
C C T C  A C C T G G G T C C C A  
100 118
B) N orm al contro l 3 ’ to 5 ’
I
CC T C  A C C C G G G  TCCC A 
100 110
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Figure 4.4.11 A) NPHS1 exon 14 ntl868 (G—>T) C623F heterozygous mutation 5’ to 3’
i
C C A G C G C G T G  A C C T G C C G C G C C C  
L5 0  1 6 0  1 7 8
B) N orm al control 5’ to 3’
I
C C A G C G  C G T G  A C C T G C C G C G C C C  
1 6 0  1 7 0  1 8 0
Figure 4.4.12 A) N P H S 1  exon 14 n t 1928 (T->C) L643P (? Splicing) homozygous m utation 
5’ to 3’ I
C G T  A C  C G  T G  T  A T G  T G 
210
B) N orm al control including +8 bases of splice donor site 5’ to 3’.
I
T G  T  A T G  T G  
2 3 0
C G  T A C T G  
220 _____
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Figure 4.4.13 A) NPHS1 exon 14 ntl904(C-»T) alternative donor splice site mutation
5’ to 3’
4
B) N orm al control 5 ’ to 3 ’
A A A C C G T G A G C T C C T T C T A T C G C C  
188 190 200
Figure 4.4.13 A) Exon 17 nt2227(C -»T) R743C heterozygous m utation 5’ to 3’
4
C C C A C C A T C N G T C C C C T C  C 
50 60
a. N orm al control 5’ to 3 ’
4
C C C A C C A T C  C G T G C C C T C C
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Figure 4.4.14 A) NPHS1 exon 18 nt2335-l(G—»A) homozygous splicing mutation 5’ to 3’
1
G G  C C T C  C  A  A G  G G A G  
50 60
B) N orm al con tro l 5 ’ to  3 ’
>1
G G C C T C  C  A G  G G A G  
50
C) Exon 18 n t2335 -l(G -»A ) heterozygous splicing m utation  5’ to 3 ’
I
G G C C T C C A A G G  A G  
5 0 ______
1
D) N orm al con tro l 5 ’ to 3 ’
G  G C C T C C  A G G G  A G  
58
1 8 6
Figure 4.4.15 A) Exon 18 nt2404(C—>T) R802W homozygous mutation 5’ to 3’
I
GGGG CGCCTG TGG ATTC 
120
B) N o rm al co n tro l 5 ’ to  3 ’
_____________I
G G G G  C G C C T G C G G  AT TC 
130 140
Figure 4.4.16 A) N P H S1  exon 23 nt3164(A-»T) heterozygous splicing m utation 5’ to 3’
i
C C A C C  T  T C T G  G C A  AG 
100
B) Norm al control 5’ to 3’
I
C C  A C C T  T C A G  G C A A G  
100
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Figure 4.4.17 A) NPHS1 exon 24 nt3250 (insG) 5’ to 3’
I
C C T C C T G  T G  T C G  N G N G N C  N N C N N  T H G  N N G  
14® 150 160
B) Normal control 5 ’ to 3’
C C T C C T G  T G  T C G G G C G G G T C C T C  T G G C A G  
140 150 160
Figure 4.4.18 A) N P H S1  exon 26 nt3325(C->T) R1109X (Fin minor) 3’ to 5’
T T C C T G  A C T C A G T C C T C  T T C T G  A 
140 150
B) Normal control 3’ to 5’
I
T T C C T N A C T C G G T C C T C T T C N G A i  
140 150
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Figure 4.4.19 A) NPHS1 exon 27 nt3478(C->T) homozygous R1160X mutation 5’ to 3’
C T  T A  T  T  C C T G  A G  G T G  
 _________ 150
B) Norm al control 5 ’ to 3’
i
C T T A T T C C C G  A G  G T G  
128 138
Figure 4.4.20 A) N P H S 1  exon 27 n t 3482 (G -> T) splice donor m utation 5’ to 3’
I
A T T C C C G  A G N T G  A G  T  T A  
  150___
B) Norm al control 5’ to 3’
I
A T  T C  C C G  A G  G T G  AG T T  
130
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Bioinformatics. Ten of the NPHS1 mutations detected were predicted to result in 
frameshifts, non-frameshift insertions and deletions, nonsense and splicing mutations, 
nine in missense mutations, and one in a putative promoter change. Computer prediction 
programmes were used to provide corroborative evidence of the predicted effect of these 
on the translated nephrin protein. Computer predictions are only able to provide 
hypothetical projections, which must be substantiated by experimental data. However, 
an indication of the possible effect is given and this may reduce the number of 
functional assays required to establish the physiological effect of the mutation.
NPHS1 frameshifts, non-frameshift insertions/deletions and nonsense mutations in 
CNF. The effect of these was assessed using SMART (Simple Modular Architecture 
Research Tool) analysis (http://smart.embl-heidelberg.de/smart/show motifs.pl), which 
estimates the size and domain structure of a protein sequence (Schultz et al, 1998, 
2000). SMART analysis predicted that three of the four frameshift mutations (cases 4, 5, 
and 50) would result in truncated proteins, whereas both non-frameshift deletions would 
produce proteins structurally almost identical to wild type nephrin (Figure 4.5). Nephrin 
expression was detected in the glomeruli of case 7 (nt 603 (del CACCCCGG, ins TT) 
NPHS1 mutation), despite severe changes of end stage renal failure (Figure 4.6 A). Both 
nonsense mutations were predicted to produce truncated proteins 1109 and 1160 amino 
acids in length respectively, which retained the transmembrane domain, but had a 
shortened cytosolic tail. Glomerular nephrin expression was normal in all R1160X cases 
examined (represented in Figure 4.6 B), regardless of disease severity. In contrast, 
R1109X resulted in loss of glomerular nephrin expression (Patraaka etal, 2000).
NPHS1 Splicing mutations in CNF. These were analysed using a combination of 
Neural network, which is able to predict the validity of a putative splice acceptor or 
splice donor site (Ogura et al, 1997) (http://www.fruitflv.org/seq tools/splice.html) and 
SMART analysis. These computer prediction programmes suggested that the splicing 
mutations detected during this study would either result in putative splice site activation, 
which might result in an alteration in isoform ratio or similar mechanism (case 73), or 
truncated nephrin proteins through read-through into intronic sequence and the 
generation of premature stop codons (cases 25, 32, 47, 65, 2, 4, and 5). The result of 
computer predication analysis are shown in Figure 4.7 (A to D).
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Figure 4.5 SMART (http://smart.em bl-heidelberg.de/smart/show motifs.pl) analysis to dem onstrate the effects of fram eshift 
and nonsense m utations on translated m utant nephrin protein sequence in comparison to wild type nephrin.
(i) Motifs detected in wild type nephrin protein.
(ii) Case 7: nt 613 (del T, P, R, ins I) to show domains within the m utant sequence truncated at 1237 residues
Key: Transmembrane segments as predicted by the TMHMM2 program (Mi), coiled coil regions determined by the Coils2 program ( ") and
Segments of low compositional complexity, determined by the SEG program ( """). Ig represents immunoglobulin domain, Igc2 C2 type Ig 
domain and FN3 a fibronectin motif.
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(ii) Case 5 : frameshift nt 661(delAG) domain predition within within mutant sequence of 250 residues
(iv) Case 50: truncation nt 1291(insA) domain predition within within m utant sequence of 446 residues
(v) Case 4 nt 3250(insG)) domain predition within within m utant sequence of 1092 residues
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(vi) Case 8 R1109X: domain predition within mutant sequence truncated at 1109 residues
(v) Cases carrying R1160X (nt3478 C—>T): domain predition within mutant sequence truncated at 1160 residues.
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4.6 (A) Im m unoperoxidase staining of nephrin expression associated with homozygous nt 
603 (del CA CCCCG G  ins TT) (X40). Despite end stage disease, nephrin 
expression is still seen in podocytes (brown pattern). An antibody raised against an 
unknown in tracellu lar epitope was used.
Nephrin
expression
(B) Nephrin expression associated with R1160X. This is seen in podocytes and 
follows the linear d istribution of the GFB (immunoperoxidase; x40)
Nephrin
expression
(C) Norm al linear nephrin expression, which follows the GFB 
(im m unoperoxidase; x40)
Nephrin
expression
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Figure 4.7 Analysis by Neural network (http://www.fruitfly.org/ seq_tools/ 
splice.html) to predict effects of NPHS1 splicing mutations.
A. (i) Exon 14 wild type NPHS1 (sequence 1)
1 AGCCCTGGCTTGACCCCGGTTCCACAGGCTGGAGGGCGTGGCCGCCCCAC 
51 CCCGGAGAGCCCCATTCAAAGGCTCCGCCGCCGCCAGGAGCGTCCTTCTG 
101 CAAGTGTCATCCCGCGATCATGGCCAGCGCGTGACCTGCCGCGCCCACAG 
151 CGCCGAGCTCCGCGAAACCGTGAG C TCCTTCTATCGCCTCAACGTACTGT 
201 GTatgtgccccggcctgaa
Donor splice site predictions for sequence lw ith donor score cut-off 0.10 
(exon/intron boundary shown in larger font):
S tart End Score Exon Intron
164 178 0.57 cgaaacc gt gag|tc
195 209 0.29 gtactgt gt atgtgc
(ii) Exon 14 ntl905(C —»T) m utant (sequence 2) at detected in case 73
1 AGCCCTGGCTTGACCCCGGTTCCACAGGCTGGAGGGCGTGGCCGCCCCAC 
51 CCCGGAGAGCCCCATTCAAAGGCTCCGCCGCCGCCAGGAGCGTCCTTCTG 
101 CAAGTGTCATCCCGCGATCATGGCCAGCGCGTGACCTGCCGCGCCCACAG 
151 CGCCGAGCTCCGCGA AACCGTGAG T TCCTTCTATCGCCTCAACGTACTGT 
201 GTatgtgccccggcctgaa
Donor splice site predictions for sequence 2 with donor score cut-off 0.10 
(exon/intron boundary shown in larger font):
S tart End Score Exon Intron
164 178 0.98 cgaaacc gt gag|tc
195 209 0.29 gtactgt gt atgtgc
If the earlier splice donor site represents a true alternative splice site, the mutation may 
result in preferential splicing at this location, potentially disrupting the normal isoform 
ratio with less isoforms containing the extra 9 amino acids SFYRLNVLY normally 
present.
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B. (i) Exon 18 wild type NPHS1 (sequence 1)
1 ggccaattctggactcttgggcctcca G GGAGAAGATGAGGAGGACCAGG 
51 CCTGGATGACATGGAGAAGATATCCAGGGGACCAACGGGGCGCCTGCGGAT 
101 TC ACC ATGCC AAACTGGCCC AGGCTGGCGCTTACCAGTGCATTGTGGAC AAT 
151 GGGGTGGCGCCTCC AGCACGACGGCTGCTCCGTCTTGTTGTCAGAT
Exon 18 m utant NPHS1 (sequence 2) (Cases 25,32,47,65)
1 ggccaattctggactcttgggcctcca A GGAGAAGATGAGGAGGACCAGG 
51 CCTGG ATG AC ATGGAGAAGATATCCAGGGGACCAACGGGGCGCCTGCGGAT 
101 TC ACC ATGCC AAACTGGCCC AGGCTGGCGCTTACCAGTGCATTGTGGAC A AT 
151 GGGGTGGCGCCTCC AGCACGACGGCTGCTCCGTCTTGTTGTCAGAT
(ii) Acceptor site predictions for Sequence 1:
Start End Score Intron Exon
8 48 0.29 tctggactcttgggcctcc ag GAGAAGATGAGGAGGACCA
Acceptor site predictions for Sequence 2
No site. This removes the exon 18 splice acceptor and a truncated 825 residue protein 
results on the assumption that read through into intron 17 occurs, with the addition of 
141 bases to exon 17 and termination at a premature stop codon:
Exon 17 —> normal termination at E R | l
1 -  TCCCCAAGCCTCTGCCTTCCACCAGAT GCTCCCACCATCCGTGCCCTCCAGGACCCCACT - 60
| P T I R A L Q D P T  
61 - GAGGTGAACGTCGGGGGTTCTGTGGACATAGTCTGCACTGTCGATGCCAATCCCATCCTC - 120 
E V N V G G S V D I V C T V D A N P I L  
121 - CCGGGCATGTTCAACTGGGAGAGACTGGTGAGGATCCAGCCTTTGGTGAATAGAGGTGGG - 180
p g m f n w e r | v r i q p l v n r g g
181 - GTCAAGGGGTTGTGGTTTCTTGACTGTGAGTTCCTTGGGAGTGGGGACCACATACATCTG - 240 
V K G L W F L D C E F L G S G D H I H L  
241 - TATG ACCCTTAT AACTAT ATACTCGCC AGGGC ATGCTCCC AG A ATG AAT AACTGTTGGTG - 300 
Y D P Y N Y I L A R A C S Q N E l
SMART (http://smart.embl-heidelberg.de/smait/show motifs.pl) analysis to 
demonstrate the effects of aberrant exon 18 splicing. The mutant protein is truncated.
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C. (v) Exon 23 wild type NPHS1 (sequence 1)
1 CCACCCCCCAGGTCTCCACCAGCCTTCTGGAGAACCTGAAGACCAGCTGC 
51 CCACAGAGCCACCTTCA GGC aagtcctcagtcccctgatccctc
(vi) Exon 23 splicing m utation nt 3164(A-»T) (sequence 2) (case 2)
1 CCACCCCCCAGGTCTCCACCAGCCTTCTGGAGAACCTGAAGACCAGCTGC 
51 CCACAGAGCCACCTTCT GGC aagtcctcagtcccctgatccctc
Splice site prediciton programmes were uninformative, but an assumption was made that 
this mutation disrupted the splice donor site, resulting in read through into intron 23, as 
follows:
Exon 23 -> ( normal termination at G)
1 -  CCACCCCCCAGGTCTCCACCAGCCTTCTGGAGAACCTGAAGACCAGCTGCCCACAGAGCC -  60
| H Q P S G E P E D Q L P T E P  
6 1  -  ACCTTCAGGCAAGTCCTCAGTCCCCTGATCCCTCCCGGCTCCCCTGAGAATGGAACCTCC -  1 2 0  
P S | K S S V P *
SMART ('http://smart.embl-heidelberg.de/smart/show motifs.pl) analysis to 
demonstrate the effects of aberrant exon 23 splicing. The mutant protein is truncated.
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D. (vii) Exon 27 wild type NPHS1  sequence (sequence 1).
1 TTGTTTTGCGTGTGGGGAACAGGTCAGCACAACAGAGGCAGAGCCGTATT 
51 ACCGCTCCCTGAGGGACTTCAGCCCCCAGCTGCCCCCGACGCAGGAGGAA 
101 AGGTGTCTTATTCCCGAG G tgaccatgcttggcctaaaggtt
(viii) Exon 27 nt 3482 (g to t) splicing m utation (sequence 2) (Cases 4 and 5)
1 TTGTTTTGCGTGTGGGGAACAGGTCAGCACAACAGAGGCAGAGCCGTATT 
51 ACCGCTCCCTGAGGGACTTCAGCCCCCAGCTGCCCCCGACGCAGGAGGAA 
101 AGGTGTCTTATTCCCG AG T tgaccatgcttggcctaaaggtt
Donor site predictions for wild type NPHS1 sequence (sequence 1):
Start End Score Exon Intron
16 30 0.91 ggaacag g t cagcac
110 124 0.46 tcccgag g t gaccat
Donor site predictions for m utant NPHS1 sequence (sequence 2):
S tart End Score Exon Intron
16 30 0.91 ggaacag I t  cagcac
110 124 0.46 tcccgag ( t  gaccat
Mutation destroys true donor site, and a truncated 1182 residue protein results:
Exon 27 (normally concludes at | l  160) —>
1 - TGTTTTGCGTGTGGGG A AC AGGTC AGC AC AAC AG AGGC AG AGCCGT ATT ACCGCTCCCTG - 60
| S T T E A E P Y Y R S L  
61 - AGGGACTTCAGCCCCCAGCTGCCCCCGACGCAGGAGGAGGTGTCTTATTCCCGAGTTGAG - 120 
- R D F S P Q L P P T Q E E V S Y S l V E  
121 - TTAGGACCATGTCAGGATTCCCTCACTCAGAGGTACCCCCGACGCCTGGACTGGGTGCCT - 180 
- L G P C Q D S L T Q R Y P R R L D W V P  
181-TGA
I
SMART (http://smart.ernbl-heidelberg.de/srnart/show motifs.pl) analysis to 
demonstrate the effects of aberrant exon 27 splicing. The mutant protein is truncated.
?NPHS1 Missense mutations in CNF . The validity of base substitutions is notoriously 
difficult to interpret, even in the presence of sufficient numbers of controls of the correct 
ethnic background. Although all missense changes detected within this series resulted in 
non-conservative amino acid substitutions with the potential to significantly affect 
protein function, mutational analysis data was supported by the use of a computer 
prediction by SIFT analysis (http://www.blocks.fhcrc.org/~pauline/SIFT.htmri (Ng and 
Henikoff 2001). This tool uses sequence homology to predict whether a substitution is 
able to affect protein function, by sorting intolerant from tolerant substitutions based on 
protein homology and species conservation. Deleterious substitutions score < 0.05, and 
the median sequence information should be < 3.25 for reasonable accuracy, as this 
indicates that sequence diversity is adequate for analysis of whether a substitution is 
deleterious or tolerated. The median sequence information was 3.05 for nephrin 
indicating significance, with 6  sequences represented at this position during PSI-PHI- 
BLAST (http://www.ncbi.nlm.nih.gov/BLAST). The results for SIFT analysis of 
missense mutations detected within this study are shown below in Table 4.8.
Table 4.8 Predicted effect of NPHS1 missense mutations on the nephrin protein 
combined with SIFT analysis
Amino
acid
change
Immuno­
globulin (Ig) 
Domain
Nature of the 
change
Putative impact 
on protein
SIFT analysis
P264R Ig-3 Aromatic to basic - Tolerated 
(score: 0.15)
G270C Ig-3 Small to SH group ?novel 
disulphide bridge
Deleterious 
(score 0 .0 0 )
R367C Ig-4 Basic to SH group ?novel 
disulphide bridge
Deleterious 
(score 0.05)
I446N Ig-5 Neutral to basic Deleterious 
(score 0 .0 0 )
R460Q Ig-5 Basic to acidic “ Tolerated 
(score: 0.06)
C623F Ig- 6 SH group to 
aromatic
? loss 
disulphide bridge
Deleterious 
(score 0 .0 0 )
L643P Ig- 6 Neutral to 
aromatic
Deleterious 
(score 0 .0 1 )
R743C Ig-7 Basic to SH group ?novel 
disulphide bridge
Deleterious 
(score 0 .0 2 )
R802W Ig-7 Basic to aromatic Tolerated 
(score: 0.07)
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4.5 Mutations of the NPHS1 gene are present in congenital FSGS, but 
not congenital DMS or early onset FSGS
All four congenital FSGS cases analysed had NPHS1 mutations. One patient a 
homozygous nt2335-l (G—>A) exon 18 splicing mutation also identified in connection 
with CNF (cases 25, 32, 47, 65; Figure 4.4.14), two siblings had heterozygous N188I 
missense mutations (Figure 4.8.1), also detected in one maternal allele, but absent in 122 
Asian, 100 Caucasian and 40 Maltese control chromosomes, and the remaining patient a 
heterozygous intronic mutation ntl930+ ll(c-»a), predicted to result in activation of a 
cryptic splice site, detected in one maternal allele but absent in 2 2 2  control 
chromosomes (Figure 4.8.2) These changes were not detected in conjunction with other 
homozygous or compound heterozygous NPHS1 mutations. NPHS1 mutations were not 
detected in two cases of autosomal recessive congenital DMS or in five cases of early 
onset FSGS. The results are summarised in as shown in Table 4.10.
4.6 Mutations of the NPHS2 gene are present in cases of CNF lacking 
NPHS1 mutations, but not congenital DMS
NPHS1 mutations were not detected in eight CNF cases (five severe and three atypically 
mild). However, homozygous NPHS2 mutations were detected in two of the cases with 
severe CNF lacking NPHS1 mutations (Table 4.9 and 4.10). One mutation was a novel 
homozygous frameshift nt (465/6) ins T in exon 4 (Figure 4.8.5), and the other R138Q, 
a homozygous missense mutation in exon 3 (Figure 4.8.3, Table 4.9). NPHS2 mutations 
were absent in CNF cases with homozygous R1160X mutations, virtually excluding 
concurrent mutations in NPHS2 as a cause for the discordant phenotype observed. 
NPHS2 mutations were not detected in congenital DMS. Both mutations lay within the 
PHB domain, which lies within the stomatin signature and is thought to play a crucial 
role in protein function. Computer predication for the frameshift mutations by SMART 
analysis (http://smart.embl-heidelberg.de/smart/show motifs.pl) suggested that this 
resulted in a truncated protein of 185 amino acid residues (Figure 4.9 iii), and SIFT 
analysis (http://www.blocks.fhcrc.org/~pauline/SIFT.html) predicted the R138Q 
substitution to be deleterious with a score of 0.00, (median sequence score 3.21).
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4.7 Mutations of the NPHS2 gene are present in congenital FSGS
NPHS2 mutations were detected in all four cases of congenital FSGS (Table 4.8). One 
was a novel homozygous nt436delA frameshift in exon 3 (Figure 4.8.4) affecting two 
siblings, one a heterozygous R229Q missense mutation in exon 5 (Figure 4.8.6) not 
present in 1 2 0  control chromosomes and previously detected as a homozygous event in 
association with adult onset FSGS (Tsukaguchi et al, 2000), and one the homozygous 
R138Q missense mutation in exon 3, previously described in connection with SRN1 
(Figure 4.8.3). All mutations were located within the PHB domain. SMART analysis of 
the frameshift mutation indicated that this was likely to result in a truncated protein of 
179 residues (Figure 4.9 ii). SIFT analysis gave the R229Q mutation a marginal score 
of 0.06.
To clarify the extent of the NPHS1/NPHS2 mutation phenotype overlap, cases with pre­
determined homozygous and compound heterozygous NPHS1 mutations and CNF 
(Table 4.4) were also screened for NPHS2 mutations. Only two heterozygous R229Q 
NPHS2 missense mutations were detected, in cases 25 and 32. Both had heterozygous 
nt2335-l (G->A) exon 18 splicing mutations in conjunction with an exon 14 C623F 
missense mutation (case 25), and a promoter mutation (case 32) in the remaining allele. 
Of note, NPHS2 mutations were not identified in case 65, who had the same 
homozygous nt2335-l (G-»A) exon 18 splicing mutation detected in congenital FSGS 
(case 49). This may represent a further overlap in the NPHS1/NPHS2 mutation 
spectrum. Alternatively, cases 25 and 32 were bom at 35 weeks gestation and had renal 
biopsies in the immediate post-natal period rather than at three months. Features were 
relatively non-specific, and it may have been too early for FSGS to be apparent.
Table 4.9 Predicted effects of NPHS2 missense mutations on podocin combined 
with SIFT analysis
Amino
acid
change
Location Nature of the 
change
Putative impact 
on protein
SIFT analysis
R138Q PHB domain Basic to acidic -
........
Deleterious 
(score 0 .0 0 )
R229Q PHB domain Basic to acidic Tolerated 
(score 0.06)
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Table 4.10 NPHS1 and NPHS2 mutation phenotype in CNF lacking NPHS1 mutations and congenital FSGS (n=6)
Case details NPHS1 mutation NPHS2 mutation
Patient [ Origin
1
Family
history?
Exon Nucleotide 1 Effect on 
(nt) protein 
change |
Mutation
Status
Exon Nucleotide
(nt)
change
Effect on 
protein
Mutation
Status
(A) CNF (n=2)
54 UK no 3 nt 413 
(G-+A)
R138Q hom
15 Turkey no 4 nt (465/5) 
insT
frameshift/
truncation
hom
(B) Congenital FSGS (n=4)
39 UK no 18 nt 2335-1 
(G-*A)
Abnormal
splicing
hom 5 nt 623 
(G—>A)
R229Q het
23,24 India Yes;
siblings
5 nt 563 
(A—>T)
N188I* het 3 nt (436) del 
A*
Frameshift/
trunction
hom
49 UK no 14 N t1929+13 
(gccccgg ► 
gcccagg
Cryptic splice 
site 
activation? *
het 3 nt 413 
(G—>A)
R138Q hom
KEY: hom = homozygous mutation; het = heterozygous mutation; * = novel mutation
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Figure 4.8 Representative sequencing traces for NPHS1 and NPHS2 mutations 
associated with congenital FSGS, and NPHS2 mutations detected in CNF cases 
lacking NPHS1 mutations
Figure 4.8.1 A) NPHS1 exon 5 nt563 (A->T) N188I heterozygous splicing mutation 5’ to 3’
i
CA A ACG T G ATCG AGG G 
80
B) Normal control 5’ to 3’
i
CAAACGTG A AC G AGG G 
80 90
Figure 4.8.2 A) NPHS1 intron 14 nt 1929 +13 (G->A) cryptic splicing mutation 5’ to 3’
T G  C C C C  M G  C C  T G  
220 ________
A A  A G  
 230
C T G  T G  T A T G  
210
B) Normal control sequence 5’ to 3’
I
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Figure 4.8.3 A) NPHS2 exon 3 nt 413 R138Q homozygous mutation 5’ to 3’
I
ATATTCCAAC TG G G ACATCTG 
80 90
B) Normal control sequence 5’ to 3’
A T A T T C  C G A C T G G G  A C A T C T G  
80 90
Figure 4.8.4 A) N P H S 2  exon 3 nt436(del A) homozygous fram eshift m utation 5’ to 3 ’
I
B) Norm al control sequence 5 ’ to 3’
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Figure 4.8.5 A) NPHS2 exon 4 nt465/6 (ins T) homozygous frameshift mutation 5’ to 3’
i
B) Normal control sequence 5’ to 3 ’
Figure 4.8.6 A) N P H S2  exon 5 nt623(G->A) R229Q heterozygous m utation 5’ to 3’
•I’
T A G C A C A T C A A T C C C T C A C T G  
170 180
B) Norm al control 5’ to 3’
T  A G  C A C A T C G  A T C C C T C  A C T G  
190 200
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F ig u re  4.9 S M A R T  (h ttp ://sm a r t.e m b l-h e id e lb e rg .d e /sm a r t/sh o w  m otifs.p l) 
ana lysis  to  d e m o n s tra te  th e  effec ts  o f  f ra m e s h if t  m u ta tio n s  in  N P H S 2  o n  tra n s la te d  
m u ta n t podocin  p ro te in  seq u en ce  in  c o m p a riso n  to  w ild  ty p e  p odocin
(i) Wild type podocin (383 amino acids) to show location of PHB domain 
(amino acids 123-282)
1 123 282 383
(ii) Frameshift nt (436) del A to show mutant protein with a query sequence 
of 179 residues
(iii) Frameshift nt(465/6) ins T to show mutant protein 
with a query sequence of 185 residues
Key: T ransm em brane segments as predicted by the T M H M M 2  program  (tfB), segments of 
low compositional complexity, determ ined by the S E G  program  ( ). PHB represents
PHB domain.
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4.8 Early onset FSGS is genetically heterogeneous and mutations of the 
NPHS2 gene are not present in early onset DMS
Five cases of early onset FSGS were analysed for NPHS2 mutations. Despite the 
phenotypic similarity to SRN1, only one mutation was detected, a heterozygous R138Q 
missense mutation in a patient with autosomal recessive FSGS compatible with SRN1, 
documented previously (Boute et al, 2000), and used as a positive control. Again, no 
mutation was detected in the other allele. NPHS2 mutations were not detected in two 
cases of sporadic early onset DMS. This suggests that early onset FSGS/SRN1 is likely 
to represent a genetically heterogeneous entity. The lack of a concomitant NPHS1I 
NPHS2 overlap in early onset FSGS suggested hat this phenomenon may be specific to 
congenital FSGS.
4.9 The promoter mutation results in diminished DNA -  protein 
binding on electromobility shift assay
Electromobility shift assay (EMSA) was used to validate the putative G —» C promoter 
mutation detected -340 base pairs of the ATG initiation codon. This change was only 
detected in two patients, 32 and 73, and was present in combination with exon 18 and 
exon 14 splicing mutations respectively in the other allele (Table 4.4). The only other 
change detected in cases 32 and 73 was E117K, a known common polymorphism in 
exon 3. The G —» C base change was not detected in 100 ethnically matched control 
chromosomes, which provided further corroborative evidence that this may constitute a 
pathological change rather than a silent polymorphism. No other sequence variants were 
detected within 1 kb of the putative promoter upstream of the initial ATG.
Although the base change was located two base pairs 3’ from a putative NF-1 binding 
site (see below), it did not itself lie directly within an obvious transcription factor 
consensus binding sequence. EMSA experiments were performed to determine the 
effect of the mutation on the ability of this area of the promoter to bind whole mouse 
kidney nuclear extract. Wild type and mutant thirty base pair oligonucleotides (-362 to -  
332 from the intial ATG start codon) were generated as described in Chapter 2, section
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2.3.14.4. These encompassed the putative mutation and an additional 15 base pairs of 
promoter sequence both upstream and downstream of this base change. Preliminary 
results indicated greatly diminished protein-DNA complex formation with the mutant 
oligonucleotide relative to the wild type, as well as successful competition of the 
binding by the wild-type but not mutant DNA (Figure 4.11), or an unrelated probe 
“INS”, from the HBLXA-9 promoter, suggesting that the base change resulted in 
diminished binding of an unknown nuclear protein. This was not due to secondary 
structure formation, and was reproducible under a variety of experimental conditions 
(data not shown). These results could be reproduced by whole mouse liver nuclear 
extract, suggesting that the DNA binding protein was not kidney specific (Figure 4.12). 
In view of the proximity of the mutation to the NF1 consensus sequence site, further 
competition experiments were carried out to determine whether the mutation resulted in 
disruption of NF1 binding. However, it was not possible to compete out protein-DNA 
binding to the NF1 consensus binding sequence by the wild type NPHS1 promoter 
oligonucleotide, or vice versa under a variety of experimental conditions (representative 
gel shown in Figure 4.13), which virtually excluded NF1 as a candidate transcription 
factor. These observations provided preliminary data for further investigation of the 
transcriptional regulation of the NPHS1 promoter. The following NPHS1 promoter 
sequence depits the site of the G to C base change with respect to the intial ATG, as 
well as the location of the putative NF1 site:
AGAGAGAGAGACAGAGAGAGAGGAAGAGACAGAGACAAAAGGAGAGAGAACGGCTTAGA 
C A AGG AG AG A A AG ATGG A A AGAT A A AG AG ACTGGGCGC AGTGGCTC ACGCCTGT A
C (-340 from ATG; -184 from AG)
E BOX NF1 site
I _______
atH I — — - ■ H ^ ^ M a tg g c ttg a a g g a a a g a g tc tg
AGATC,AACCTGG(XAACATAGTGAGACCCCGTCTCTAAAAAAAAAAAAAAGAAAAAAAAA
AGAAAAAAGAAAAAAAAGTTTTTTTAAAGAGACAGAGAAAGAGACTCAGAGATTGAGACT
GAGAGCAAGACAGAGAGAGATACTCACAGGGAAGAGGGGAAGAGGAAAACGAGAAAGGG
AGGAGAGTAACGGAAAGAGATAAAAAAGAAAAGCAGGTGGCAGAGACACACAGAGAGGG
ACCCAGAGAAAGCCAGACAGACGCAGGTGGCTGGCAGCGGGCGCTGTGGGGGTCACAGTAG
ggggacctgtgH I gc c ctgg gg acgacg ctcag ggcttctctcctgctcctg gg gctg ctg
ACTGAA
Interestingly, an E box binding Helix-loop-helix transcription factors is also located 
within the near vicinity, although the significance is unknown.
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Figure 4.10 Diminished binding of whole kidney nuclear ex tract to N PH S1  m utant 
prom oter sequence in com parison to wild type
INS competition 
NPHS1 competition 
NPHS1 probe 
Kidney nuclear extract
Unknown protein/ 
NPHS1 complex
Figure 4.11 Diminished binding of whole liver nuclear extract to N PH S1  m utan t 
prom oter sequence in com parison to wild type
NPHS1 probe 
Kidney nuclear extract 
Liver nuclear extract
wt
+
mt
+
wt mt
Unknown protein/ 
NPHS1 complex
Free probe
Key: wt = wild type N P H S1  oligonucleotide; mt = m utant N PH S1  oligonucleotide; INS 
unrelated probe using sequence from  HBLXA-9 prom oter
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Figure 4.12 NF1 transcription factor binding to the NPHS1 promoter is unlikely to 
be affected by the -340 (G —> C) base pair substitution.
NF1 probe wt mt wt mt wt mt wt -
NPHS1 probe - - - - - - - w t w t
Competition NF1 - - wt wt wt
Competition NPHS1 wt - -
Kidney nuclear extract - - + + + + +  + +
Complex
Unbound
probe
Key: wt = wild type N P H S1  oligonucleotide; mt = m utan t N PH S1  oligonucleotide.
Competition reactions were carried  out with cold probe versus radiolabelled probe.
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4.9 Discussion
The results of this study confirm the pivotal roles the NPHS1 and NPHS2 genes play in 
renal glomerular filtration and more importantly, provide the first direct evidence of a 
potential functional relationship between them within the podocyte. A number of key 
conclusions about the roles of these genes within glomerular filtration and the 
pathogenesis of nephrotic syndrome in early life are made, as discussed below.
4.9.1 Glomerular filtration is critically dependant on normal function o f  the NPHS1 
gene
NPHS1 mutations are responsible for the majority of cases of non-Finnish CNF, despite 
the variability in phenotype seen. In the main, NPHS1 mutations cause severe CNF in 
non-Finnish patients, regardless of location or predicted effect on the nephrin protein. 
Moreover, NPHS1 mutations are distributed throughout the gene, emphasising a 
functional requirement for both extracellular and intracellular domains. Compilation of 
our results with those in the literature (Kestila et al, 1998; Lenkkeri et al, 1999, Aya et 
al, 2000, Patraaka et al, 2000, Beltcheva et al 2001, Koziell et al, 2002), results in a 
total of fifty-nine unique NPHS1 mutations detected in CNF and congenital FSGS 
patients to date, of which two lie within the promoter region. Figure 4.13(A) illustrates 
the distribution of mutations detected within this study, and Figure 4.13(B) summarises 
the distribution of the fifty-seven mutations detected within the coding region, and 
within donor and acceptor consensus splicing sequences, lying just immediately outside 
the coding regions. These appear to cluster in immunoglobulin domains two, four and 
seven, which gives a focus as to where to commence diagnostic tests. To date, 
approximately 40% of NPHS1 mutations are nonsense, frameshift and splicing 
mutations predicted to result in a non-functional truncated nephrin protein, likely to be 
unstable and therefore not expressed at the cell membrane. Lack of glomerular nephrin 
expression has been demonstrated for both Fin major (nt 121 del2) and Fin minor 
(R1109X), which would support this hypothesis (Patraaka et al, 2000). A further 5% of 
mutations are non-frameshift deletions and insertions, resulting in the deletion or 
insertion of amino acids, but predicted to result in a protein not dissimilar to wild type 
nephrin. The remainder are missense mutations, which account for just over half of all
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Figure 4.13 (A) D istribution of the unique N P H S 1  m utations within the coding sequence 
detected in CNF within this series (n=19;Table 4.4) showing locations and gene “hot spots”
  1------------------------------
Exons: 1-23 24 25-29
I /  \
Extracellular Domain Transmembrane Cytosolic
Domain Tail
KEY
[3j 1 number of unique mutations
|5] mutation "hot spots” in current series
Figure 4.13 (B) D istribution of all unique N P H S 1  m utations detected within the coding sequence 
(n=57) to date showing m utation “ hot-spots” and location of the m utations detected 
in congenital FSGS within this study
JN
Exons:
KEY
0
 1---------------------------
1-23
I
Extracellular Domain
24 25-29
/  \
Transmembrane Cytosolic 
Domain Tail
/ 11 number of unique mutations detected
mutation "hot spots" based on current study and literature 
missense mutation "hotspots" 
location of NPHS1 mutations in congenital FSGS
2 1 2
mutations detected and so far, are all located within the extracellular region. Of note, 
with the exception of one cytosolic nonsense mutation, all NPHS1 mutations caused a 
severe CNF phenotype in non-Finnish patients, regardless of location or predicted effect 
on the nephrin protein. These findings suggest that disease pathogenesis cannot be 
simply related to a lack of nephrin, and dysfunction of an expressed nephrin protein is 
also able to result in severe glomerular protein leak. Furthermore, the lack of 
compensation by other slit diaphragm proteins when nephrin is absent, both in human 
disease and in NPHS1 null mice (Putaala et al, 2001), or when it malfunctions by more 
subtle mechanisms, underscores the critical role nephrin plays within the glomerular 
filtration barrier.
Of note, over two thirds of the mutations found within immunoglobulin domain “hot 
spots” are missense, or result in non-frameshift deletion or insertion of one or more 
amino acids, suggesting that these areas are of particular functional importance, 
potentially for ligand binding or for maintaining the proposed homophilic interaction 
within nephrin molecules expressed by adjacent podocytes. The missense mutations 
detected during this study all resulted in non-conservative amino acid substitutions, 
which were not detected in normal controls. In addition, 81% were also predicted to be 
deleterious by SIFT analysis (http://www.blocks.fhcrc.org/~pauline/SIFT.html). Many 
of the missense mutations targeted charged residues such as arginine, and hydrophobic 
amino acids such as leucine and isoleucine, resulting in changes in charge and 
hydrophobicity likely to produce significant alterations in protein conformation. Others 
targeted cysteine residues, introducing the potential for disruption or novel formation of 
di-sulphide bridges.
As yet there is no satisfactory in vitro system in which it is possible to study the 
mechanisms through which missense mutations exert their effects in vivo. However, 
preliminary in vitro evidence suggests that nephrin is a highly flexible protein, easily 
able to change conformation in vivo (Zhang et al, 2001). Further data suggests that some 
missense mutations may result in misfolding of the nephrin protein, with the mutants 
becoming trapped in the endoplasmic reticulum, and failing to express at the plasma 
membrane (Liu et al, 2001). However, these trafficking experiments are only a guide, as 
COS-7 cells, which are non-polarised fibroblasts were used for experiments. This is an
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entirely different situation to that seen in podocytes, which are polarised epithelial cells. 
On this basis, the effect of some missense mutations may be similar to that seen with 
Fin major and Fin minor mutations, and other nonsense and frameshift mutations 
predicted to create defective, unstable nonsense proteins failing to express. Equally, 
some mutations do not affect glomerular nephrin expression, so an unexplored area 
remains location of ligand binding to the extracellular domains, which again might 
become disrupted by the introduction of a point mutation, or an amino acid change. In 
addition, these observations provide evidence for a more diverse role for nephrin within 
the podocyte than simply a structural component of the slit diaphragm, as might be 
suggested from initial studies of the Finnish CNF population. The cytosolic tail is rich in 
serine, threonine and tyrosine residues suggesting that nephrin is likely to become 
phosphorylated and thus participate in signal transduction from the extracellular to the 
intra cellular compartments. This is supported by preliminary in vitro observations that 
nephrin is able to activate the MAPK pathway (Huber et al, 2001) and that it may form 
a complex with other key podocyte proteins, for example CD2AP and podocin within 
lipid rafts ((Schwartz et al, 2001, Simmons et al, 2001), structures known to play a 
major role in cellular signalling. An additional disease mechanism for the glomerular 
protein leak in association with NPHS1 mutations may therefore be a failure of 
transduction of key extracellular signals to the podocyte intracellular machinery, 
resulting in dysfunction of the actin cytoskeleton, foot process effacement and 
proteinuria.
4.9.2 The clinical and genetic heterogeneity o f  the CNF phenotype
Mutational analysis of non-Finnish cases of CNF detected a variety of different NPHS1 
mutations located throughout both the extracellular and intracellular regions of the gene. 
Furthermore, mutations were not detected in all cases, even those with a typical clinical 
CNF phenotype. This is a different situation to that found in the Finnish population, 
where mutations have been detected in >98% of cases, the majority being Fin Major. 
Fin major and Fin minor mutations are very rare in non-Scandinavian populations, 
suggesting that the wide variety of different mutations detected in non-Finns are likely 
to be de novo events, especially when the ethnic diversity of the test populations is taken 
into account. Some populations may exhibit a founder effect, such as that detected
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!within our series in Malta for R1160X, which facilitates the planning of diagnostic tests. 
Intriguingly, one Turkish CNF patient originating from Anatolia had a homozygous Fin 
minor mutation (R1109X), hitherto only detected in a small subset of Finnish patients. 
The apparent ethnic diversity of these populations implied an independent event rather 
migratory influence, as Fin minor has been not detected in other Turkish patients. 
However examination of the genetic ancestry of the Finns, and Turks from Anatolia, 
reveals a significant contribution of Central Asian genes to both groups (Di Benedetto et 
al, 2001), and population admixture between Hungarians, Slavs, Finns, Turks and 
Iranians (Guglielmino et al, 2000) advocating the possibility of a common ancestor.
The majority of NPHS1 mutations were associated with typically severe CNF disease 
regardless of mutation type and gene location. However, a specific nonsense mutation 
located in exon 27, R1160X, resulted in an unexpectedly mild phenotype in 
approximately 50% of cases, formally expanding the CNF clinical spectrum to include 
mild disease. There are numerous anecdotal reports in the literature of mild congenital 
nephrotic syndrome phenotypes, occasionally thought to be the result of a response to 
anti-proteinuric drugs (Patrakka et al, 2000; Guez et al, 1998). Interestingly, recent data 
suggests a link between anti-proteinuric drugs and rescue of the down-regulated NPHS1 
mRNA and diminished glomerular nephrin expression seen as a result of progressive 
renal injury in rats with Passive Heyman Nephritis through angiotensin II blockade 
(Benigni et al, 2001). However, the use of anti-proteinuric agents is commonplace in the 
management of congenital nephrotic syndrome in humans (Heaton et al, 1999), often 
slowing the rate of clinical deterioration, but rarely correlating with a favourable long­
term outcome. These cannot provide an explanation, as two of the mildly affected CNF 
cases described in this series did not receive anti-proteinuric drugs during the course of 
their illness.
The reason for the discordant phenotype remains elusive, and does not appear to be 
population specific as cases originated from Malta, Bangladesh and Gujerat, India. 
However, there appears to be a significant gender contribution to disease expression, 
since the majority of severely affected individuals are male and those mildly affected, 
female (Table 4.5). This is true both inter- and intra-family; for example patients 8 6  
(male, severely affected) and 92 (female, mildly affected) were siblings, and patient 26
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who has mild disease whereas her five brothers died in infancy from severe CNF. In 
addition, this mutation was originally reported in a female with mild disease (Lenkkeri 
et al, 1999; Guez et al, 1998). The apparent influence on phenotype by gender in non X- 
linked conditions is rare, but has been described with a classic example being autosomal 
recessive limb-girdle muscular dystrophy (Zatz et al, 2000), where strategies such as 
mutation screening of related genes, investigation of modifier loci in murine models and 
detection of protein partners have been used to identify modifiers, as yet with no 
success. A role for oestrogen in the modulation of cellular activity and thus phenotype 
has also been documented, but remains poorly characterised. There is however, 
increasing evidence that complex regulatory mechanisms exist by which oestrogen may 
alter cell function, and that this hormone has important physiological roles beyond those 
related to gonadal function. Obviously the gender impact can be positive or negative, 
and may reflect the effects of several gonadal steroids on the varied pathways for 
inflammation, cell migration or proliferation that mediate different disease models. The 
potential effect of oestrogens in renal disease has been explored through in vitro studies 
in glomerular mesangial cells. Initial studies showed that oestrogen increases AP-1 
transcription factor activity that in turn inhibits type I collagen gene activation (Silbiger 
et al, 1999). Subsequent studies showed that selective inhibition of oestrogen receptor- 
beta suppresses type I and type IV collagen synthesis, suggesting that this can also 
mediate the effects of oestrogen on collagen synthesis (Neugarten et al, 2000). On this 
basis, it has been suggested that because accumulation of glomerular extracellular 
matrix after renal injury is a precursor to the development of glomerular sclerosis and 
progressive loss of renal function, the ability of estrogens to potentially inhibit 
fibrogenic cytokine-stimulated collagen IV synthesis may contribute to the anecdotal 
protective effect of female gender on the progression of renal disease. However, the 
mechanism of action of oestrogens within the glomerulus is likely to be complex. There 
is also preliminary data that oestradiol may attenuate glomerulosclerosis by inducing 
nitric oxide synthesis via an oestrogen receptor-dependent mechanism, and also through 
its metabolites, 2 -hydroxyestradiol and 2 -methoxyestradiol, which inhibit glomerular 
mesangial cell proliferation independent of oestrogen receptors (Xiao et al, 2001). It is 
tempting to speculate that the apparent effect of gender on the progression of nephrotic 
disease in CNF may be related to an effect of oestrogens on podocyte function. This 
might occur through a direct effect on oestrogen response elements within the NPHS1
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promoter, or through receptors on the cell surface. Equally, an indirect effect may be 
mediated through other transcription factors. Alternatively, differential effects on 
phenotype may be modulated by separate effects on mesangial or endothelial cells, 
known to cooperate with podocytes in glomerular filtration barrier function.
At a molecular level, the R1160X mutation results in truncation of the nephrin protein 
downstream of the last amino acid residue in exon 27. In contrast to Fin minor (exon 26) 
(Patraaka et al, 2000), glomerular nephrin expression appears normal in all patients, 
regardless of severity in clinical phenotype (Figure 4.6). This suggests that the nephrin 
protein reaches the cell membrane and remains normally distributed within the cell. 
These two mutations are only 51 amino acids apart, which perhaps makes the lack of 
nephrin expression in association with R1109X surprising. Potential explanations are 
that motifs critical for membrane targeting are preserved in R1160X, but are absent in 
the R1109X truncation, or that a binding site for a protein required for nephrin 
trafficking is present in the intervening 51 amino acids. Alternatively, a critical amount 
of the cytosolic tail may be required for protein stability. The presence of the R1160X 
mutant protein at the membrane provides further evidence that nephrin dysfunction may 
occur through the lack of binding of intracellular protein partners, such as adapter 
molecules, which normally link it to the actin cytoskeleton, or other molecular pathways 
critical for podocyte function. Evidence presented to date suggests that both podocin 
(Huber et al, 2001) and CD2AP (Shih et al, 2001) bind to this region. Of note, other 
exon 27 mutations, even when situated in the immediate vicinity of R1160X, result in a 
severe CNF phenotype, but all three cases in which this mutation has been described so 
far, are male.
Although the variable phenotype associated with the R1160X mutation appeared to be 
influenced by gender, another possibility remains that this was the result of co­
inheritance of a particular allele of an unrelated gene. In view of the key role NPHS2 
also plays in glomerular filtration, a hypothesis that concurrent NPHS2 mutations were 
responsible for the variable phenotype seen in association with R1160X was tested. In 
addition, CNF cases lacking NPHS1 mutations were also screened for NPHS2 mutations 
to determine whether there was a phenotypic overlap. The absence of NPHS2 mutations 
in the R1160X group excluded the NPHS2 gene as a modulator of CNF phenotype, at
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least in these individuals. However, two of the five typically severe CNF patients 
lacking NPHS1 mutations had homozygous NPHS2 mutations (Table 4.10). One was a 
novel frameshift mutation in exon 4, and the other was a missense mutation R138Q, 
previously been detected in association with SRN1 (Boute et al, 2000) and located in a 
mutation “hot spot” within the predicted location of the PHB domain of the NPHS2 
gene. These findings support the genetic heterogeneity of CNF, which is further 
endorsed by the lack of mutations in the remaining three patients with typically severe 
disease. There remains the possibility that mutations were not detected as they lie in 
intronic regions not screened, or in regulatory regions upstream of the nephrin promoter. 
Equally, causative mutations may be present in other glomerular genes with clearly 
demonstrable links to nephrotic disease such as NEPH1, which encodes a novel slit 
diaphragm protein homologous to nephrin (Donoviel et al, 2001).
The ability of NPHS1 and NPHS2 mutations to result in the same clinical phenotype 
provided the first evidence of a link between the two genes. However, the argument 
remains that CNF and SRN1 may represent the same disease, or that the two CNF cases 
were simply misdiagnosed. The differences between the two disorders are subtle; both 
exhibit autosomal recessive inheritance, although CNF presents by definition as a 
congenital nephrotic syndrome, whereas SRN1 presents after three months of age. The 
histological features in CNF may be non-specific, and focal sclerotic changes can 
appear, but are a late feature and tend to affect glomeruli in a global rather than a 
segmental distribution. Global sclerosis is considered to be a non-specific sign of 
glomerular injury, rather than an indicator of the underlying disease pathogenesis. In 
SRN 1, focal segmental changes are detected early on and the only other histology that 
has been documented is minimal change, which subsequently develops into the classical 
appearance of FSGS. The clinical presentation and renal histology of the cases with 
NPHS2 mutations was typical of CNF, and it is therefore perhaps more likely that SRN 1 
and CNF form an overlapping spectrum of disorders. The important conclusion that can 
be made by the detection of NPHS2 mutations in CNF is that this condition is 
genetically heterogeneous, so both NPHS1 and NPHS2 genes require screening for 
diagnostic purposes, and that molecular diagnosis is able to provide a more accurate 
indication of phenotype than one based on clinical criteria.
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4.9.3 NPHS1 and NPHS2 mutations are not responsible fo r  congenital or early onset 
DMS, or all cases o f  SRN1-like disease
NPHS1 and NPHS2 mutations were not detected in any of the cases of DMS or early 
onset FSGS compatible with SRN 1-like nephrosis analysed, except for one FSGS case 
known to carry a heterozygous R138Q NPHS2 mutation. This was perhaps surprising, 
as NPHS2 mutations have been reported in apparently sporadic FSGS (Frishberg et al, 
2002). However, closer examination of the cases screened revealed the same R138X 
nonsense mutation in the majority of affected individuals, suggestive of a founder effect 
and autosomal recessive inheritance. This underlines the profound genetic heterogeneity 
of FSGS, and it is likely that many causative genes will be detected, potentially all able 
to lead to podocyte damage and the histological appearance of FSGS. Although the 
number of cases studied was small, the lack NPHS1 and NPHS2 gene mutations in DMS 
make them unlikely candidates for this disease. However, this result needs to be 
interpreted with caution as in common with FSGS, DMS is a genetically heterogeneous 
disease.
4.9.4 Di-genic inheritance results in congenital FSGS
Mutational analysis of patients with congenital FSGS was also performed. This is a rare 
entity, which is traditionally made distinct from CNF on histopathological grounds, and 
follows a similar albeit more severe clinical course. We detected the co-existence of 
NPHS1 and NPHS2 mutations in all congenital FSGS patients tested (Table 4.10), 
providing further corroborative evidence for a functional relationship between these two 
genes. Mutation hits were required in three out four alleles to produce the congenital 
FSGS phenotype, as parents who were compound heterozygotes for the respective 
NPHS1 and NPHS2 mutations were phenotypically normal. One NPHS1 mutation was a 
homozygous exon 18 nt2335-l (G—>A) NPHS1 splice acceptor mutation previously 
detected in CNF, and the remaining two NPHS1 mutations were a novel missense 
mutation N 1881, and a C—> A mutation predicted to introduce a cryptic splice site 11 
base pairs downstream of the exon 14 splice donor site, an area already predicted to 
participate in alternative splicing (http://genome.cbs.dtu.dk/services/NetGene2/). 
Neither change was detected in control chromosomes or in conjunction with other
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NPHS1 mutations. Although detailed functional studies have not been performed, the 
N188I mutation could potentially disrupt an N-glycosylation site, a mechanism that has 
been shown, at least in transfected cells, to play a crucial role in the correct localisation 
of nephrin to the plasma membrane (Yan et al, 2 0 0 1 ), whereas the effects of cryptic 
splice site activation are well described (Krawczak et al, 1998; Ars et al, 2000; Bruce et 
al, 2001; Pagani et al, 2002; reviewed in O’Neill et al, 1998,). The C-» A mutation 
located within intron 14 appears to introduce a splice acceptor site. The predicted result 
would be inclusion of intronic sequence, possibly with the introduction of a novel exon 
through the activation of potential cryptic donor splice site sequences within intron 14. 
However, confirmatory experiments using RT-PCR or hybrid minigene constructs were 
not possible within the time frame of this project. Cryptic splice site activation has been 
also described in another immunoglobulin superfamily member, the mouse polymeric 
immunoglobulin receptor (Bruce et al, 1999). Here, the activated cryptic splice sites 
were located in the junction between two Ig domain boundaries. Exon 14 is predicted to 
encode the beginning of a putative spacer molecule, lying between the Ig 6  and Ig 7 
domains of extracellular nephrin, and could also encompass a protein domain boundary.
The NPHS1 mutations in congenital FSGS were associated with a heterozygous R229Q 
NPHS2 missense mutation, previously detected as a homozygous change in adult onset 
FSGS (Tsukaguchi et al, 2000), a novel homozygous frameshift in NPHS2 exon 3 and a 
homozygous R138Q NPHS2 mutation, previously detected in association with both 
CNF and SRN1 (Table 4.11). The changes were absent in normal controls, and located 
within the PBH/SPFH domain, an area likely to be crucial for correct podocin function. 
Evidence from C.elegans suggests that one of the roles of the SPFH domain confers an 
ability to homo-oligomerise and form core components of membrane associated 
proteolytic complexes (Tavemakis et al, 1999), clearly potentially important functions 
of podocin. An unanswered question remains the significance of the R229Q mutation, 
as this has now been detected as a heterozygous change within some series at a 
frequency of between 1 and 3 % of normal control chromosomes (Antignac, personal 
communication; Karle et al, 2002). In this study, the change was detected at a lesser 
frequency of 1 in 222 normal chromosomes, or an incidence of approximately in 0.5%. 
Of note, R229Q has not been detected as a homozygous event in controls to date, and if 
all published and unpublished data available data is complied, this encompasses a total
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of approximately 600 normal chromosomes. As seen in section 4.6, this mutation is 
tolerated, but only receives a marginal score of 0.06 on SIFT analysis (deleterious 
scores are <0.05). In addition, it has been detected in SRN1 in conjunction with a 
heterozygous mutation in the other NPHS2 allele, with no other apparent NPHS2 
mutation within the same individual (Karle et al, 2002). As mentioned previously, a 
homozygous R229Q has also been found in association with adult onset FSGS, but was 
not detected in association with apparently sporadic FSGS in Arab-Israeli children 
(Frishberg et al, 2002). However, in the absence of an in vitro model able to mimic the 
effects of missense mutations in vivo, it remains difficult to confirm the true 
pathogenicity experimentally.
These findings provide evidence for a di-genic inheritance of NPHS1 and NPHS2 
mutations resulting in a tri-allelic hit able to modify disease phenotype from CNF to one 
of congenital FSGS. This suggests the additional disease allele appears to act as a 
modifier of disease expression, and could represent a form of genetic epistasis. Di-genic 
inheritance resulting in three disease alleles may occur in autosomal recessive 
conditions, such as in the haemoglobinopathies, but generally there is no change in 
clinical phenotype, or this improves through the activation of compensatory 
mechanisms (Altay et al, 1997; Giordano et al, 1998; Kerkhoffs et al, 2000). In 
addition, trans-heterozygous mutations can affect the alleles of two different genes to 
produce an autosomal dominant phenotype, for example as with the PKD1 and PKD2 
genes in polycystic kidney disease; (Watnick et al, 2000; Pei et al, 2001), and for the 
RET proto-oncogene and neuroturin in Hirschsprung’s disease (Doray et al, 1998). 
However, in congenital FSGS, thought to have autosomal recessive inheritance, a tri- 
allelic hit is required either as a homozygous hit in NPHS1 together with a heterozygous 
hit in NPHS2, or vice versa for manifestation of disease. The importance of this third 
event is underscored by the finding that straightforward bi-allelic hit in either NPHS1 or 
NPHS2 results in CNF, and trans-heterozygote parents are phenotypically normal. 
Moreover, in view of the overlap in mutation phenotype between CNF and congenital 
FSGS, these disorders could be regarded as part of a spectrum, and the disease 
phenotype that develops may perhaps be partially determined by the genetic background 
of the patient, which could be explored further using transgenic strategies. The lack of 
mutations in the SRN 1-like group was surprising, but confirms the profound genetic
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diversity of FSGS despite in many cases the uniformity in clinical presentation and renal 
histology. No concurrent NPHS1 mutations were detected in the case with a 
heterozygous R138Q NPHS2 mutation and SRN1, which provides supporting evidence 
that the tri-allelic inheritance is a phenomenon specific to congenital rather than the later 
onset SRN 1 disease.
4.9.5 Analysis o f the -340 G to C base change suggests it is able to disrupt protein- 
DNA binding to the NPHS1 promoter
One of the base substitutions detected within this study lay -340 base pairs upstream of 
the initiation codon, and was not detected in 1 0 0  ethnically matched control 
chromosomes. However, this did not exclude the possibility of a rare polymorphism, as 
the mutation did not lie within a documented transcription factor consensus binding 
sequence. Electromobility shift assay (EMSA) was used to analyse whether this change 
was able to interfere with protein-DNA binding to the NPHS1 promoter. Preliminary 
EMSA analysis using wild type and mutated oligonucleotides showed diminished 
binding of kidney nuclear protein extract, suggesting that the mutation was functional 
and interfered with the binding of an unknown transcription factor. This did not appear 
to be kidney specific, as the mutated oligonucleotide was unable to bind liver nuclear 
protein extract to the same degree, and the EMSA experiments were reproducible in a 
variety of experimental conditions. Although the mutation lay immediately 3’ of a 
predicted NF1 site, this did not appear to be a suitable candidate on the basis of 
competition assays and the lack of a supershift. Further experiments are currently in 
progress to identify the transcription factor in question, which will provide an important 
insight into the transcriptional regulation of nephrin.
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4.9.6 Summary of findings
Genotype phenotype correlation of NPHS1Inephrin mutations indicates that the majority 
result in a severe congenital nephrotic syndrome, and that intact extracellular and 
cytosolic domains are required. Furthermore, immunoglobulin domains 2, 4 and 7, are 
likely to be particularly important for gene function and form a target for diagnostic 
tests. Moreover, a specific nonsense mutation within the cytosolic tail is associated with 
a variably severe clinical phenotype, apparently influenced by gender. This remains 
unexplained but might result from the co-inheritance of a disease allele in another gene, 
or compensation by a genetic or other determinant, such as through functional 
redundancy. NPHS1 and NPHS2 mutations can both result in the CNF phenotype, and 
identify a specific di-genic inheritance, resulting in three affected alleles able to modify 
the disease phenotype from CNF to congenital FSGS. These findings can be added to a 
growing body of data (Katsanis et al, 2001), which demonstrates that inheritance of 
different alleles at independent genetic loci may contribute to disease phenotype. In 
addition, the importance of a molecular diagnosis confirms observations made through 
the study of Denys Drash and Frasier syndromes (Chapter 3), that the clinical phenotype 
may not necessarily be indicative of the underlying molecular defect, or even whether 
different diseases are truly represented. The findings together with an overlap in 
mutation phenotype with other forms of FSGS clearly substantiate a wider functional 
role for nephrin and podocin reaching outside congenital nephrotic disease. This data 
also provided the first evidence for a functional inter-relationship between nephrin and 
podocin, underscoring the critical role these genes play in regulating glomerular protein 
filtration and in the pathogenesis of proteinuria. This apparent interplay provided the 
basis for a hypothesis that nephrin and podocin may form part of a multimeric complex 
activating or residing within intracellular pathways essential for podocyte function and 
slit diaphragm integrity, and that both genes are important mediators of the typical 
podocyte dysfunction seen universally in nephrotic disease. Preliminary data supporting 
this hypothesis is now emerging, through the identification of nephrin, podocin and 
CD2AP as potential binding partners within the podocyte (Schwartz et al, 2001; Shih et 
al, 2001). Finally, the presence of a functional mutation -340 base pairs upstream of the 
initiation codon, seemingly able to result in nephrotic disease, underlines the critical 
importance of the correct transcriptional regulation of the NPHS1 promoter.
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Concluding remarks and future directions
The aim of this study was to investigate the role of three glomerular genes WT1, NPHS1 
and NPHS2 in the pathogenesis of childhood nephrotic syndrome, through the 
mutational analysis of selected cases of inherited nephrotic syndrome and limited 
functional experiments. The work has contributed to the understanding of the basic 
processes of podocyte damage, although these remain poorly understood. The damage 
seen undoubtedly results from disruption of more than a single protein or pathway, 
making the basis of these diseases complex and difficult to define.
A number of the mutations detected in the NPHS1 and NPHS2 genes did not disrupt 
protein expression, suggesting that the loss of glomerular permselectivity is due to 
malfunction of the protein product within the podocyte rather than its absence. This has 
provided the basis for further experiments to determine intracellular protein binding 
partners for both proteins, which have suggested that nephrin has the potential to 
activate at least two different signalling pathways within the podocyte through 
interaction with proteins other than CD2AP (Shih et al, 2001). In addition, further 
studies of the NPHS1 promoter have identified potential candidate transcription factors 
that may bind the region of the mutation detected in this study. Data on the role of the 
WT1 gene in glomerular function remains confusing, but it is likely that it plays an 
important role in both glomerular development and podocyte homeostasis.
The common theme in all types of nephrotic syndrome is the appearance of gross 
morphological changes in podocyte phenotype, characterised predominantly by foot 
process fusion, and thought to be caused by disruption of the sub-membranous actin 
cytoskeleton. Since this structure forms the common link between the slit diaphragm and 
the podocyte foot process, it is tempting to speculate that indiscriminate damage of 
podocyte membrane proteins, and/or the disruption of their transcriptional control 
funnels into a final common pathway which by destabilising the actin cytoskeleton, 
induces foot process fusion, disruption of the GFB and proteinuria.
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APPENDIX I: Clinical Features of congenital and early onset nephrotic 
syndrome cases analysed for NPHS1 and NPHS2 mutations
Case Ethnic Origin I Sex 1 Family 
I I History?
Clinical
Presentation
Renal
histology
Outcome at 
time of 
study
Congenital CNF (n=41 patients)
1 England F no severe 
nephrotic 
syndrome 
from 2 weeks 
of life
CNF mild
proteinuria
2 England F no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF renal
transplant
4 England M no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF dialysis
5 England M no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF severe
proteinuria
6 Middle East M no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF dialysis
7 Pakistan F no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF deceased
8 Turkey F no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF deceased
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Case Ethnic Origin Sex Family
History?
Clinical
Presentation
Renal
histology
Outcome at 
time of 
study
9 England/India M no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF Dialysis
10 India M no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF Dialysis
11 Middle East F no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF severe
proteinuria
15 Turkey F no severe 
nephrotic 
syndrome 
from birth
CNF deceased
20 India M no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF Transplant
25 England F no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF Transplant
26 Bangladesh F yes prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF mild
proteinuria
32 England M yes prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF Transplant
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Case Ethnic Origin Sex Family
History?
Clinical
Presentation
Renal
histology
Outcome at 
time of 
study
47 England M yes prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF deceased
50 Middle East M yes prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF transplant
54 England M no severe 
nephrotic 
syndrome 
from birth
CNF transplant
62 India F no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF dialysis
63 India F no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF dialysis
64 Middle East M no severe 
nephrotic 
syndrome 
from 2 
months
CNF 9
65 England F no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF deceased
72 England F no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF dialysis
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Case Ethnic Origin Sex Family
History?
Clinical
Presentation
Renal
histology
Outcome at 
time of 
study
73 England M no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF transplant
80 India M no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF
with
tubular
atrophy
deceased
81 Malta M no prematurity; 
severe 
nephrotic 
syndrome 
from 2 
months
CNF transplant
82 Malta F yes:83 severe 
nephrotic 
syndrome 
from birth at 
term
CNF Dialysis;
failed
transplant
83 Malta M yes: 82 severe 
nephrotic 
syndrome 
from birth at 
term
CNF deceased
84 Malta M no severe 
nephrotic 
syndrome 
from birth
Severe
proteinuria
85 India M no prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF deceased
86 Malta M yes:92 Severe 
nephrotic 
syndrome 
from 12 days
deceased
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Case Ethnic
Origin
Sex Family
History?
Clinical
Presentation
Renal histology Outcome 
at time of 
study
87 Malta M yes:88 Prematurity; 
severe 
nephrotic 
syndrome 
from birth
CNF deceased
88 Malta M yes:87 Prematurity; 
severe 
nephrotic 
syndrome 
from birth
deceased
89 Malta M yes:94 severe 
nephrotic 
syndrome 
from 2 weeks 
of age
CNF deceased
90 Malta F no severe 
nephrotic 
syndrome 
from birth
remission
91 Malta F no severe 
nephrotic 
syndrome 
from birth
mild
proteinuria
92 Malta F yes:86 severe 
nephrotic 
syndrome 
from birth
mild
proteinuria
93 Malta F no severe 
nephrotic 
syndrome 
from birth at 
term
CNF remission
94 Malta M yes:89 severe 
nephrotic 
syndrome 
from birth at 
term
mild
proteinuria
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Case Ethnic
Origin
Sex Family
History?
Clinical
Presentation
Renal histology Outcome 
at time of 
study
96 South
Africa
M no severe 
nephrotic 
syndrome 
from birth at 
term
CNF remission
97 England F no nephrotic 
syndrome at 
?8 weeks
CNF Remission
Congenital FSGS (n=4patients)
23 India F yes:24 severe 
nephrotic 
syndrome 
from birth
dialysis
24 India M yes:23 severe 
nephrotic 
syndrome 
from birth
FSGS transplant
39 England M no severe 
nephrotic 
syndrome 
from birth
initial histology: 
minimal 
change; 
subsequently 
FSGS
transplant
49 England M no severe 
nephrotic 
syndrome 
from birth
FSGS transplant
Early onset FSGS
1 England F no severe 
nephrotic 
syndrome 
from 9 
months of 
age
FSGS dialysis
19 England F no severe 
nephrotic 
syndrome 
from 7 
months
FSGS transplant
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Case Ethnic
Origin
Sex Family
History?
Clinical
Presentation
Renal histology Outcome 
at time of 
study
21 Middle
East
F yes: 22 severe 
nephrotic 
syndrome 
from lyear
FSGS 9
22 Middle
East
F yes: 21 severe 
nephrotic 
syndrome 
from 8 
months
FSGS 9
99 England M yes severe 
nephrotic 
syndrome 
from 9 
months of 
age
FSGS transplant
Congenital DMS
16 England F yes severe 
nephrotic 
syndrome 
since birth
DMS transplant
40 India F yes severe 
nephrotic 
syndrome 
since birth
DMS dialysis
Early onset DMS
55 England M no onset of 
severe 
nephrotic 
syndrome at 
2 years
DMS dialysis
80 England M no onset of 
severe 
nephrotic 
syndrome at 
18 months
DMS dialysis
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APPENDIX II: Family trees of CNF families tested for allelic association to the 
NPHS1 locus (Parent were heterozygotes; affecteds homozygous as shown).
A) Families originating from the island of Malta 
Family 1: cases 82 and 83
o suicide
Still birth *
Family 2: case 81
C) i LI
Family 3: case 91
Family 4: case 86 and 82
•  m
Family 5: case 93
*
Family 6: case 94 and 89
o ■
94 89
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(B) Consanguineous families originating from the Bangladesh (26), Pakistan (7), 
India (10,20, 62, 63, 80), Turkey (8,15) and the Middle East (11,50)
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« i
t
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o I
c
t
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